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Abstract
Novel photoactive ruthenium(II) complexes were designed to incorporate existing
anti-tuberculosis drugs, isoniazid and nicotinamide, that could be released from the
ruthenium(II) cage by photoactivation with visible light.
Two sets of complexes were synthesised based on cis-[Ru(N-N')2(L)2][PF6]2 and cis-
[Ru(N-N')2(L)X][PF6], where N-N' is 2,2'-bipyridine (bpy) or 1,10-phenanthroline
(phen), L is isoniazid (INH) or nicotinamide (NA) and X is either Cl or I. Their
dynamic behaviour in solution was explored using NMR to probe the presence of
atropisomers. In the case of cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-
[Ru(bpy)2(NA)I][PF6] (2), the rotation of NA is hindered on the NMR timescale at
room temperature, behaviour that was surprisingly not observed for cis-
[Ru(bpy)2(NA)2][PF6]2 (5). The hindered rotation was explored by computational
methods (DFT) and revealed that hydrogen bonding between the halide and protons
of the NA ligand hindered the rotation.
The photochemical properties of the Ru(II) complexes were explored by UV-visible
spectroscopy and liquid chromatography. All cis-[Ru(N-N')2(L)2][PF6]2 complexes in
aqueous solution release one ligand, L, in under 1 min using a blue LED (λirr = 463
nm, 50 mW cm-2) to form the photoproduct cis-[Ru(N-N')2(L)(H2O)]2+. Continued
photoirradiation releases a second ligand, L, with the production of various Ru(II) and
Ru(III) aqua photoproducts (with both cis and trans geometry). Interestingly their
production was dependent on the power of the light source. Complementary
computational studies (DFT/TD-DFT) were utilised to understand structure-activity
relationships with respect to photoactivity. The results from the calculations suggest
that the number of key electronic transitions (notably 1MLCT) and the favourable
iv
leaving properties of the ligand, L, influence the rate of photorelease. In the latter case,
a stronger π-accepting leaving ligand shifts the dissociative 3MC state to lower energy,
thus promoting more efficient ligand release.
The photobiological properties of the Ru(II) complexes were explored by investigating
binding to biomolecules and screening their antibacterial activity in vitro. The
complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) binds to the nucleobase 9-ethylguanine (9-
EtG) after photoirradiation with a blue LED to produce cis-[Ru(bpy)2(INH)(9-EtG)]2+,
however reaction with the amino acid L-cysteine was not observed. A 96-array blue
LED (λirr = 465 nm, 20 mW cm-2) and 32-array multi-coloured LED (λirr = 465 nm,
520 nm, 589 nm and 625 nm, 5 mW cm-2) were designed in-house to screen the activity
of the complexes in vitro. Their design and construction is described in detail. When
tested against Mycobacterium smegmatis (a model for Mycobacterium tuberculosis),
complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6)
showed the greatest activity upon photoirradiation for 1 min with a blue LED, with at
least a 3x increase in potency when compared to the ligand alone, INH. Most
importantly the complexes are inactive in the dark, showing that the antibacterial
ligand is selectively released in vitro after photoirradiation.
The complex cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9), where MOPEP is 4-[2-(4-
methoxyphenyl)ethynyl]pyridine, was initially designed to study two-photon
activation via a femtosecond-pulsed laser. Surprisingly the complex was one-photon
active with 600 nm and 800 nm light, due to the MOPEP ligand extending and
increasing the intensity of the one-photon absorption band shoulder in the 600-800 nm
region.
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Chapter 1
Introduction
The aim of this chapter is to introduce the issue of bacterial infections and particularly
focus on the application of metals in medicine. Subsequent sections refer to
photoactivation of metal complexes for biological applications and their clinical
relevance. Throughout this chapter particular emphasis is placed on the applications
of ruthenium complexes.
1.1. Bacterial infections
Pathogenic bacteria can cause a variety of illnesses, for example Mycobacterium
tuberculosis is responsible for tuberculosis (TB), Escherichia coli and Staphylococcus
aureus can cause infections, while Streptococcus pneumonia can cause pneumonia. If
the disease is not treated with antibiotics / antibacterial agents it can be fatal.
An antibiotic can be described as an antibacterial agent that is produced by a
microorganism, while an antibacterial agent is any agent (either natural or synthetic)
that is harmful to bacteria. The first antibiotic was discovered in 1928 by Alexander
Fleming when he noticed that an agent, which he called penicillin, was produced by
the fungus Penicillicum and was able to inhibit the growth of Staphylococcus bacteria.
Between the 1940’s and 1960’s many new classes of antibiotics were discovered by
screening natural products for bacterial growth inhibition.1 However, only two new
major classes of antibiotics / antibacterials discovered in past 30 years are on the
market (discovery of lipopeptides in 1986 and diarylquinolines in 1997), resulting in
a large time gap in the discovery of new antibiotics / antibacterials.1-2 This is a problem
as the occurrence of bacterial resistance is increasing, which will be discussed in more
detail in Section 1.1.1. The most recent finding was made in early 2015 when a new
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class of antibiotic, Teixobactin, was discovered from a screen of uncultured bacteria
from soil samples (provisionally called Eleftheria terrae); Teixobactin showed
activity against S. aureus (including methicillin-resistant S. aureus, MRSA) and M.
tuberculosis.3
1.1.1. Bacterial resistance
Bacterial resistance has been a growing threat for several decades, with national data
showing that the proportion of E. coli, K. pseumoniae and S. aureus resistant to
commonly used antibacterial agents is > 50 % in many cases.4
There are four major mechanisms of action for antibacterial agents; 1) cell wall /
cytoplasmic membrane synthesis inhibition, 2) protein synthesis inhibition, 3) nucleic
acid synthesis inhibition, and 4) inhibition of metabolic pathways.5-6 Resistance to
such antibacterial agents is either intrinsic / natural (for example where a
microorganism does not naturally have a specific target for the drug) or acquired
(where the microorganism develops mechanisms in order circumvent the action of the
drug).7 The major clinically-relevant mechanisms of resistance are modification of the
target, decreased penetration of the drug, efflux of the drug, overproduction of the
target, enzymatic inactivation or modification of the drug and bypass pathways.2
One approach that may help to overcome resistance is by developing a therapeutic
agent that can inhibit or affect multiple targets.8 Furthermore metal-containing
antibacterial drugs could help overcome resistance by providing a metal-specific
mechanism of action, which cannot be attained by organic-based molecules.9
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1.1.2. Tuberculosis
Tuberculosis (TB) is a disease caused by the bacteria Mycobacterium tuberculosis. It
is still one of the world’s most deadly infectious diseases; c.a. 9 million people in 2013
developed TB globally (56% of the cases were in South-East Asia and Western
Pacific) with 1.5 million people dying from the disease.10
The bacteria are initially inhaled into the lung from droplets that have been expelled
from an infected person. Macrophages (cells forming part of the immune response that
destroys foreign microorganisms) engulf the bacteria containing it in a compartment
called a phagosome. In order to destroy the bacteria a lysosome fuses to the phagosome
to expose the bacteria to a destructive environment (for example low pH, reactive
oxygen species and lysosomal enzymes).11 If the macrophage fails to eradicate the
bacteria, the immune system tries to contain the bacteria by forming a granuloma
around the infected macrophages (known as the primary lesion) consisting of other
macrophages and immune cells. If the growth of the bacteria is inhibited by this
process it is known as latent TB, as it may be activated if the immune system becomes
weakened.12 The centre of the granuloma can become necrotic, causing cavities and
damaging the function of the lung. If the bacteria continually replicate and escape from
the primary lesion, they will spread to other parts of the lung to form secondary lesions
and extensive damage, see Figure 1.1.
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Figure 1.1. Primary and secondary lesions in tuberculosis (TB).
The main problem with Mycobacterium tuberculosis is that is it virulent. It has evolved
several survival strategies to survive in the hostile environment of a macrophage by
inhibiting phagasome-lysosome fusion, adapting to the limited nutritional
environment of the macrophage and increasing the resistance to toxic agents produced
by the host cell.13-14
Current treatment of TB involves a chemotherapy regime that lasts for > 6 months.
The first-line drugs isoniazid, pyrazinamide, ethambutol and rifampicin (Figure 1.2)
are given together for the first 2 months of treatment, then a combination of 2, 3 or 4
of these drugs is given for a further 4 to 5 months.15 Problems with this long treatment
include the development of resistance due to errors in the treatment regime and patient
failure to adhere to the regime, both of which make it difficult to control TB.16 Multi-
drug resistant tuberculosis (MDR-TB) occurs when M. tuberculosis is resistant to at
least isoniazid and rifampicin (i.e. first line drugs) and extensively-drug resistant
tuberculosis (XDR-TB) occurs when resistant to any of the second line drugs
(capreomycin, kanamycin and amikacin).17
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Figure 1.2. First line anti-tuberculosis drugs.
The target of isoniazid is an enoyl-acyl carrier protein reductase enzyme known as
InhA. InhA utilizes NADH (reduced nicotinamide adenine dinucleotide) to reduce the
trans double bond of a fatty acid chain that is attached to the protein.18 This is an
integral part of mycolic acid synthesis, which is required for the cell wall of M.
tubercuclosis. Isoniazid is a prodrug that is activated by a catalase-peroxidase enzyme
called KatG to produce an isonicotinic acyl radical, see Figure 1.3. This radical is
coupled to NAD+ (oxidised nicotinamide adenine dinucleotide) to produce an INH-
NAD adduct.19 It has been postulated that the isonicotinic acyl radical may be coupled
to either NAD+ or NAD· within the active site of InhA.20 The resulting INH-NAD
adduct inhibits the function of InhA, thus disrupting the synthesis of mycolic acids,
and results in bacterial cell death.21 Resistance mechanisms of M. tuberculosis against
isoniazid include mutations in katG and InhA enzymes.21
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Figure 1.3. Activation and mechanism of action of isoniazid, where R is adenine
dinucleotide.19, 21
Interestingly structurally-related nicotinamide has been shown to be active against M.
tuberculosis and human immunodeficiency virus (HIV), however studies need to be
conducted to investigate if it is effective in treating HIV-M. tuberculosis coinfection.22
1.2. Metals in medicine
Metals are important for many functions in the human body, for example iron is
involved in dioxygen storage and transport (e.g. haemoglobin), zinc is involved in
carbon dioxide transport (e.g. carbonic anhydrase) while cobalt is in found in vitamin
B12.23 However all metals whether they are essential (e.g. iron and zinc) or
nonessential (e.g. mercury and lead) are toxic in excess.24
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Metals have been used for medical applications for thousands of years. Copper sulfate
was used by Egyptians to sterilise their potions, gold was used in China in medical
preparations in c.a. 2500 BC, and mercury was used to treat syphilis in the 16th
century.23 It was not until the early 1900’s when the term chemotherapy was first
invented by Paul Ehrlich, with the meaning of using chemicals to treat diseases.25 The
first modern chemotherapeutic agent discovered and synthesised in Ehrlich’s lab was
an organoarsenic compound Arsphenamine (also known as Salvarsan), and was used
to treat syphilis. His “magic bullet” concept aimed to synthesise drugs that go to its
intended cell target, leaving healthy cells unharmed, which has since given way to
targeted medicine.26
1.2.1. Ruthenium
Ruthenium is a rare transition metal that is part of the platinum group metals. It has
various properties that make it suitable for medical applications27:
 Rate of ligand exchange (similar exchange kinetics to platinum(II) complexes
currently used for cancer treatment e.g. cisplatin).
 A range of accessible oxidation states under physiological conditions (Ru(II),
Ru(III) and Ru(IV)).
 Ability to mimic iron (thought to be why ruthenium drugs have a low toxicity
to healthy cells).
Relatively inert chlorido Ru(III) complexes can be activated by reduction to give
active chlorido Ru(II) complexes in diseased tissue, for example a cancer cell has a
very reducing environment with high levels of glutathione, low oxygen concentration
and low pH.27 Currently there are three Ru(III) anti-cancer complexes in clinical trials;
NAMI-A, KP1019 and NKP-1339, see Figure 1.4.28 For KP1019 and NKP-1339, it is
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proposed that plasma proteins albumin and transferrin act as transporters and delivery
systems for the complexes to cancer cells.28
Figure 1.4. Ruthenium(III) complexes currently in clinical trials
In the case of Ru(II), many half-sandwich complexes have been investigated for their
anticancer activity, some examples are shown in Figure 1.5. RM175, [(η6-
biphenyl)RuCl(en)]+ where en is ethylenediamine, exhibited a similar potency to the
anticancer drug carboplatin against an ovarian cancer cell line (A2780) and were found
to bind covalently to DNA via guanine.29 RAPTA-C, [Ru(η6-p-cymene)Cl2(pta)]
where pta is 1,3,5-triaza-7-phosphaadamantane, reduced the growth of an ovarian
tumour by ~75% and was shown to have an anti-angiogenic effect.30 Attachment of a
bidentate ligand based on a protein kinase inhibitor (indolocarbazole alkaloid) to a
Ru(II) centre resulted in a complex, DW12, that is inert towards nucleic acids however
exhibits anticancer activity due to its potent inhibition of a protein kinase (GSK-3).31-
32
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Figure 1.5. Anticancer ruthenium(II) arene complexes
1.2.1.1. Antibacterial
Ru(II) complexes have been extensively studied for their antibacterial activity.33
Ru(II) polypyridyl complexes containing extended aromatic ligands, for example
[Ru(2,9-Me2phen)2(DPPZ)]2+ where 2,9-Me2phen is 2,9-dimethyl-1,10-
phenanthroline and DPPZ is dipyrido[3,2-a:2′,3′-c]phenazine, are able to intercalate 
into DNA and were found to be active against Gram-positive B. subtilis and S. aureus,
but was inactive against Gram-negative E. coli.34 Interestingly in the case of
[Ru(bpy)2(NPDA)]2+, where NPDA is N-phenyl-substituted diazofluorene, the
complex is active against methicillin resistant S. aureus (MRSA) and produced
reactive oxygen species (ROS) when incubated with MRSA.35 Dinuclear complexes
have also been studied (see Figure 1.6), where rigid linkers between metal centres
showed lower activity (e.g. ΔΔ-{[Ru(phen)2]2(μ-bpm)}2+ where phen is 1,10-
phenanthroline and bpm is 2,2′-bipyrimidine) compared to flexible linkers (e.g. 
[(Ru(phen)2)2(μ-bb16)]2+ where bb16 is bis[4(4′-methyl-2,2′-bipyridyl)]-1,16-alkane) 
when tested against S. aureus and E. coli.36 The activity was proposed to be linked to
lipophilicity, as increased lipophilicity results in increased penetration through the cell
membrane and therefore increased uptake.37
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Figure 1.6. Dinuclear ruthenium(II) antibacterial complex
Another strategy to design antibacterial agents is to attach an existing organic
antibacterial agent to a Ru(II) centre, for example attachment of β-lactam to a 
cyclopentadiene moiety or using ofloxacin as a chelating ligand.38-39 This strategy can
be used either to try and overcome resistance, or to investigate a potential synergistic
effect between the metal and the antibacterial agent.
1.2.1.2. Tuberculosis
Currently there are a few examples of Ru(II) complexes that are being developed for
anti-tuberculosis activity. Complexes containing phosphine, diimine and picolinate
moieties have shown promising activity against M. tuberculosis.40-42 For example cis-
[Ru(pic)(dppe)2]+, where pic is 2-pyridinecarboxylate and dppe is 1,2-
bis(diphenylphosphino)ethane, had a better activity than isoniazid against M.
tuberculosis and retained its activity against an isoniazid resistant strain.41-42
An interesting strategy to induce dormancy in mycobacteria is to block hydrophilic
nutrient channels, and Ru(II) quaterpyridinium complexes have been found to bind to
MspA (porin A from M. smegmatis) which leads to the formation of large MspA
aggregates.43-44
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1.2.2. Other metals
Cisplatin, carboplatin and oxaliplatin are platinum(II) anticancer drugs approved for
clinical use globally, see Figure 1.7, while nedaplatin, lobaplatin and heptaplatin are
approved in Japan, China and Korea respectively.45 Carboplatin was designed to
overcome the side effects of cisplatin by replacing the chloride ligands with 1,1-
cyclobutanedicarboxylate which aquates at a slower rate, while oxaliplatin overcomes
cisplatin resistance by forming different adducts with DNA.45
Figure 1.7. Globally approved platinum(II) anticancer complexes
Addition of a biologically-active ligand to an iron(II) centre has been investigated for
applications in treatment of malaria and tuberculosis, see Figure 1.8. A chloroquine
(currently used to treat malaria) mimicking ferrocene complex, known as ferroquine,
is 22 times more active than chloroquine against the causative agent of malaria
(Plasmodium falciparum).46 Ferroquine is currently in phase II clinical trials.47 In the
case of tuberculosis, the complex [Fe(CN)5(isoniazid)]3- was found to inhibit the
isoniazid target InhA (discussed in Section 1.1.2) without being activated by the
enzyme KatG; KatG activation is blocked in isoniazid resistant strains of M.
tuberculosis.48-50
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Figure 1.8. Iron(II) antimalarial (ferroquine) and anti-tuberculosis
([Fe(CN)5(isoniazid)]3- complexes.
1.3. Photoactive metal complexes
1.3.1. Photochemistry
The absorption of one photon (hν) by one molecule (R) causes excitation of an electron 
to promote the molecule into an electronically excited state (R*):
R + hν → R* 
The energy required to produce this electronically excited state is dictated by the
energy gap between ground state (E1) and the excited state (E2).51 As a result only a
photon with that energy can cause photoexcitation, see Equation 1.1.
where h is Planck’s constant, ν is the frequency, c is the speed of light and λ is the 
wavelength. The theoretical probability of an electronic transition is known as the
oscillator strength (f) and is related to the transition dipole moment (µ), mass of an
electron (me) and the charge of an electron (e), see Equation 1.2.52 The oscillator
Equation 1.1∆E = |E   − E  | = hv = hcλ
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strength is related to the experimentally obtained extinction coefficient (ε) and 
wavenumber (ν  ) by equation, see Equation 1.3.51  The extinction coefficient (ε) is 
related to the absorbance (A) and concentration (c) of a compound and the path length
of light (l) by the Beer-Lambert Law, see Equation 1.4.
The oscillator strength (f) has a value approaching unity for strongly allowed
transitions.53 Selection rules dictate that electronic transitions are forbidden (and thus
have a transition dipole moment of zero) if: 52
 The transition is between states of equal parity (g → g or u → u). This is known 
as a Laporte-forbidden transition (∆l = ± 1 for allowed transitions). 
 The transition is between states of different multiplicity. This is known as a
spin-forbidden transition (∆S = 0 for allowed transitions). 
Relaxation of these rules can be encountered to make formally forbidden transitions
allowed, which will be discussed below.
1.3.2. Electronic transitions and deactivation pathways
Excitation of a metal complex into an electronically excited state occurs when an
electron is promoted from the highest occupied molecular orbital (HOMO) to the
lowest unoccupied molecular orbital (LUMO). In an octahedral transition metal
Equation 1.2f ≡ 8π  m  ν|μ|  3he  
Equation 1.3
Equation 1.4A = εcl
f ≡ 4.3 × 10      εdν 
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complex the molecular orbitals can be described according to the predominant atomic
orbital contributions see Figure 1.9.
Figure 1.9. Molecular orbital diagram and the electronic transitions that can occur in
an octahedral transition metal complex.54-55
Thus the following electronic transitions can occur in octahedral transition metal
complexes:
 d-d transition from πM (t2g) to σM* (eg) known as metal-centred transition (MC)
 transition from πM (t2g) to πL* known as metal-to-ligand charge transfer
(MLCT)
 transition from πL to σM* (eg) known as ligand-to-metal charge transfer
(LMCT)
 transition from πL to πL* known as ligand-centred transition (LC)
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As discussed previously, the selection rules govern the probability of an electronic
transition. However the Laporte selection rule can be relaxed if a molecule departs
from a centrosymmetric structure, as is the case for many d-d transitions. For example
a molecule may be distorted and the inversion centre removed either partially (by an
asymmetric vibration caused by vibronic coupling) or permanently (e.g. by Jahn-
Teller distortion), and d and p orbital mixing results in a “mixed” character d-d
transition.56 As a result the intensity of absorption bands, and thus extinction
coefficients εmax, vary depending if a transition is allowed or forbidden by the selection
rules, see Table 1.1.
Table 1.1. Typical extinction coefficients (εmax) observed for metal complexes.57
Selection rules
Type of transition Spin Laporte εmax (M-1 cm-1)
ΔS ≠ 0 Forbidden Forbidden <1
MC (with centre of
symmetry)
Allowed Forbidden 1 – 102
MC (without centre
of symmetry)
Allowed Forbidden 102 – 103
MLCT / LMCT Allowed Allowed 103 – 105
Once the electronically excited state has been formed, there are various deactivation
pathways that can occur, see Figure 1.10. Initial photoexcitation results in a vertical
electronic transition to populate a vibrational level of the excited state which has same
multiplicity (i.e. S0(v=0) → S1(v>0)). This is known as the Franck-Condon principle, and
as a result the excited level is called the Franck-Condon state. From this state
vibrational relaxation occurs rapidly whereby energy is dissipated to the surrounding
environment, for example by colliding with a solvent molecule. Radiationless
processes can occur whereby another excited state of the same multiplicity (ΔS = 0) is 
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populated, known as internal conversion (IC), or an excited state of a different
multiplicity (ΔS ≠ 0) is populated, known as intersystem crossing (ISC). Similarly 
radiative processes can occur from the lowest vibrational level of the lowest excited
state to the ground state that results in no change in multiplicity  (ΔS = 0), known as 
fluorescence, or a change in multiplicity (ΔS ≠ 0), known as phosphorescence.  
Figure 1.10. Jablonski diagram of deactivation pathways.
Typical timescales for the deactivation processes are listed in Table 1.2. Kasha’s rule
states that radiative processes (fluorescence and phosphorescence) or chemical
reactions can occur only from the lowest vibrational level of the lowest excited state
(S1 or T1). This can be rationalised due to the fast timescale of internal conversion /
vibrational relaxation (femtoseconds to picoseconds) when compared to other decay
processes such as fluorescence and phosphorescence (picoseconds to milliseconds).
Processes involving a change in multiplicity (e.g. phosphorescence) are much longer
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lived than those involving no change in multiplicity (e.g. fluorescence) as these are
spin-forbidden processes.
Table 1.2. Typical timescales of deactivation processes.58
Process Example transition Timescale (s)
Vibrational relaxation Sn(v>0) → Sn(v=0) 10-13 – 10-9
Internal conversion Sn → S1 10-14 – 10-11
Internal conversion S1 → S0 10-9 – 10-7
Intersystem crossing S1 → T1 10-11 – 10-8
Fluorescence S1 → S0 + hν 10-12 – 10-6
Phosphorescence T1 → S0 + hν 10-3 – 10-2
1.3.3. Photochemistry of Ru(II) complexes
Due to the increased energy difference between t2g and eg orbitals in Ru(II) complexes
[Ru(N-N′)3]2+, where N-N′ is a bidentate polypyridyl ligand, the lowest excited state is
MLCT in character followed by MC and LC states, see Figure 1.11.55
Figure 1.11. Typical UV-visible absorption spectrum of [Ru(N-N′)3]2+ complexes (A)
with molecular orbitals and possible electronic transitions (B), where subscripted M/L
is a metal/ligand based orbital respectively.55
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After photoexcitation of [Ru(N-N′)3]2+ complexes in their MLCT band, different
photochemical/photophysical events may occur. Intersystem crossing is very efficient
in ruthenium complexes due to spin-orbit coupling, therefore population of the 3MLCT
state occurs rapidly.59 Interestingly if this is the lowest lying triplet state
phosphorescence is observed, however if the 3MC state is accessible from the 3MLCT
state, ligand dissociation occurs, see Figure 1.12.60
Figure 1.12. Photochemical/photophysical pathways observed in [Ru(N-N′)3]2+
complexes.
For example, photolysis of cis-[Ru(bpy)2(py)2](Cl)2, where bpy is 2,2′-bipyridine and 
py is pyridine, in low polarity solvents such as dichlormethane results in the
photorelease of py ligands and the binding of the coordinating counter ion61:
[Ru(bpy)2(py)2](Cl)2
   
→ [Ru(bpy)2(py)(Cl)]Cl + py
[Ru(bpy)2(py)(Cl)]Cl
   
→ [Ru(bpy)2(Cl)2] + py
However in water or acetonitrile the solvent binds instead of the counter ion.61
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1.4. Photoactive metal complexes in medicine
The various treatments that involve the use of light to treat a disease can be categorized
as follows62:
 Phototherapy – the general term to describe the use of ultraviolet, visible and
near-infrared light to treat a disease. Thus a specific area of the body is
photoirradiated.
 Photochemotherapy – involves the administration of a photosensitizer that is
activated once photoirradiated (discussed in Section 1.4.2.).
 Photodynamic therapy – involves the administration of a photosensitizer which
once photoirradiated produces reactive oxygen species (discussed in Section
1.4.1.).
 Photopheresis – an extracorporeal procedure where the blood is removed from
the body, treated with a photosensitizer and photoirradiated. Once complete,
the blood is flowed back into the body.
Phototherapy and photochemotherapy have been used for thousands of years (for
example ancient Egypt and Greece), while photodynamic therapy has been used over
the past 100 years.63 Photopheresis is a relatively modern technique, with the first
clinical trial for the treatment of cutaneous T-cell lymphoma using photopheresis with
8-methoxypsoralen reported in 1987.64 Subsequently in 1988 the food and drug
administration (FDA) agency approved photophoresis for the treatment of cutaneous
T-cell lymphoma.65
1.4.1. Photodynamic therapy
Photodynamic therapy (PDT) is a type of treatment whereby a non-toxic sensitizer
(commonly based on a porphyrin or phthalocyanine type structure) is administered to
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the patient and a light source is used to photoirradiate the sensitizer in a specific area
of the body, for example a cancerous tumour. The main advantage of this technique is
that only a certain area is affected, leaving surrounding healthy tissue unharmed. The
first PDT agent to be approved by a health agency was Photofrin® (see Figure 1.13)
in 1993 for the treatment of bladder cancer in Canada, and since then has been
approved for the treatment of lung cancer and oesophageal cancer in parts of Europe,
Japan and US.66
Figure 1.13. Structure of Photofrin®.67
The photosensitizer requires oxygen to produce toxic species by either a Type I or
Type II mechanism, see Figure 1.14. The Type I mechanism involves promoting the
photosensitizer to its triplet excited state (3P*) via light and subsequent interaction
with a substrate molecule (S) involving either an electron or hydrogen transfer. As a
result the Type I mechanism involves the production of radicals and, in the presence
of oxygen, superoxide radical anion (O2·-) that can produce reactive oxygen species
(ROS) such as hydroxyl radical (·OH) and hydrogen peroxide (H2O2). The Type II
mechanism involves the production of singlet oxygen (1O2) by energy transfer from
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the photosensitizer in its triplet excited state (3P*, via light) to molecular oxygen (O2).
Reactive oxygen species (including singlet oxygen 1O2) are very reactive and can
efficiently oxidize biomolecules to cause biological damage.68
Figure 1.14. Mechanisms of photodynamic therapy (PDT), Type I and Type II, where
P is the photosensitizer, 3P* is the triplet excited state of the photosensitizer, S is the
substrate and ROS is reactive oxygen species.69
1.4.1.1. Role of metal complexes in PDT
The chelation of diamagnetic transition metals and lanthanide ions to photosensitizers
produces complexes with promising PDT properties due to the enhanced rate of
intersystem crossing (ISC) as a result of the heavy metal effect.70 For example,
chelating diamagnetic ions such as Zn2+, Al3+ and Ga3+ to phthalocyanine results in
high singlet oxygen quantum yields and long lifetimes of the triplet excited state.71
Ruthenium(II) polypyridyl complexes, for example [(Ph2phen)2Ru(dpp)]2+ where
Ph2phen is 4,7-diphenyl-1,10-phenanthroline and dpp is 2,3-bis(2-pyridyl)pyrazine,
produce singlet oxygen and photocleave DNA due to the quenching of the 3MLCT
state by molecular oxygen, however the efficiency of quenching was only c.a. 5%.72
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Another approach is to attach a Ru(II) arene complex to the peripheral of 5,10,15,20-
tetra(4-pyridyl)porphyrin (TPP), for example [Ru4(η6-hmb)4(TPP)Cl8] where hmb is
hexamethylbenzene, in order to obtain a dual activity complex where Cl is
photorelease of from the Ru(II) centre and the PDT effect comes from the porphyrin
system, see Figure 1.15.73
Figure 1.15. Dual activity ruthenium(II) porphyrin complex, [Ru4(η6-
hmb)4(TPP)Cl8].
Curcumin was found to be a PDT agent however it is relatively unstable in phosphate
buffer and in cell culture media.74-75 Interestingly binding curcumin to an
oxovanadium(IV) complex, [VO(cur)(DPPZ)Cl] where cur is depronated curcumin
and DPPZ is dipyrido[3,2-a:2′,3′-c]phenazine, stabilises curcumin and results in a 
PDT agent that is more potent than curcumin alone and Photofrin® against HeLa
cancer cells.76
1.4.2. Metal complexes in photochemotherapy
One disadvantage of PDT is that it requires the presence of oxygen and hypoxia (low
levels of oxygen) is a common problem for certain diseases, for example cancer.77
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Thus it is important to develop prodrugs that have a different mechanism of action to
PDT (i.e. do not rely on the presence of oxygen).78 This section describes metal
complexes developed for that purpose.
1.4.2.1. Photorelease of bioactive molecules
Nitric oxide (NO) is endogenously produced in the human body and is an important
bioregulator inducing vasodilation, regulating programmed cell death and acting as a
neurotransmitter.79 However the physiological effect of NO depends on the local
concentration, for example at low NO concentrations tumour growth and cancer cell
proliferation are promoted, whereas high NO concentrations can either induce cancer
cell apoptosis or inhibit cancer cell growth.80 As a result, the controlled delivery and
release of NO have been extensively investigated by the use of photoactivation. The
enzyme nitrile hydratase has an iron in the active site bound to a carboxamide frame
and NO, and upon light exposure NO is released. This inspired the synthesis of Fe(III),
Mn(II) and Ru(III) nitrosyl complexes containing the pentadentate PaPy3 ligand,
[Mn+(PaPy3)NO]n-1+, where PaPy3 is deprotonated N,N-bis(2-pyridylmethyl)amine-N-
ethyl-2-pyridine-2-carboxamide, able to release NO upon photoactivation.81-84
Increasing the conjugation of the pentadentate ligand increases the quantum yield of
photorelease and shifts the activation to a longer wavelength.82-83 In the case of
[Mn(PaPy2Q)(NO)]+, where PaPy2Q is deprotonated N,N-bis(2-pyridylmethyl)amine-
N-ethyl-2-quinoline-2-carboxamide, the activation is shifted to near IR (810 nm), see
Figure 1.16.82
Interestingly for a Cr(III) nitrito complex, trans-[Cr(cyclam)(ONO)2]+ where cyclam
is 1,4,8,11-tetraazacyclotetradecane, photoaquation of NO2 occurs in deaerated
aqueous solution. However in an aerated aqueous solution, β-cleavage of the CrO-NO 
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bond occurs upon photoactivation to produce a Cr(IV) intermediate trans-
[Cr(cyclam)(O)(ONO)]+.85
Figure 1.16. Photoactive nitrosyl and nitrito complexes
Carbon monoxide (CO) is also endogenously produced in the human body. It has been
implicated in neuron and vascular signalling, and has therapeutic effects such as anti-
apoptosis, anti-proliferative and anti-inflammatory.86 However high concentrations of
exogenous CO can cause tissue hypoxia, due to the increased affinity of haemoglobin
for CO when compared to O2 (210 times greater).87 Similarly to NO, the controlled
delivery and release of CO has been investigated by the use of metal complexes that
photorelease CO. A Mn(I) carbonyl complex, fac-[Mn(pqa)(CO)3]+ where pqa is (2-
pyridylmethyl)(2-quinolylmethyl)amine, was found to release CO upon exposure to
visible light.88 Interestingly a Re(I) complex, fac-[Re(bpy)(CO)3(thp)]+ where bpy is
2,2′-bipyridine and thp is tris(hydroxymethyl)phosphine, photoreleased CO with 
visible light and the differing luminescence of the starting material (λem = 515 nm) and
photoproduct (λem = 585 nm) allowed the transformation to be followed by confocal
fluorescence microscopy in a prostate cancer cell line, see Figure 1.17.89
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Figure 1.17. Photoreleasing CO complexes.
The photorelease of biologically active organic moieties from a Ru(II) polypyridyl
scaffold has been explored, for example the release of anti-cancer agents and
neurocompounds / neurotransmitters.90-93 The complex cis-[Ru(bpy)2(5-CU)2]2+,
where bpy is 2,2′-bipyridine and 5-CU is 5-cyanouracil (an anti-cancer compound), 
releases two equivalents of 5-CU upon exposure to visible light and forms cis-
[Ru(bpy)2(H2O)2]2+ (see Figure 1.18) which is able to bind covalently to DNA.90
Figure 1.18. Photorelease of 5-cyanouracil (5-CU) from [Ru(bpy)2(5-CU)2]2+ with
visible light.
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1.4.2.2. Imaging
Cyclometallated iridium(III) complexes have gained significant interest for their high
phosphorescent quantum yields and ability to “colour-tune” by changing the structure
of the cyclometallating ligand.94 There are many examples of Ir(III) complexes with
groups attached to the periphery of the complex that bind to biomolecules and thus
allow the complex to act as a chemical / biological probe.95 For example
[Ir(ppy)2(phen-DPA)]+, where ppy is deprotonated 2-phenylpyridine and phen-DPA
is 5-(di-2-picolylamino)-1,10-phenanthroline, binds Zn2+ ions via the phen-DPA
moiety which subsequently enhances the emission of the complex by c.a. 5 fold.96
Similarly for [Ir(pq)2(bpy-ind)]+, where pq is deprotonated 2-phenylquinoline and
bpy-ind is 4-((2-(indol-3-yl)ethyl)aminocarbonyl)-4′-methyl-2,2′-bipyridine, the 
indole moiety (bpy-ind) binds to bovine serium albumin and the emission of the Ir(III)
complex increases.97
Imaging has also been extended to Ru(II) complexes. A dinuclear Ru(II) polypyridyl
complex, [(phen)2Ru(tpphz)Ru(phen)2]4+ where phen is 1,10-phenanthroline and
tpphz is tetrapyrido[3,2-a:2′,3′-c:3″,2″-h:2‴,3‴-j]phenazine, binds to DNA and 
luminesces to act as a DNA stain in both eukaryotic and prokaryotic cells.98
1.4.2.3. Interaction with DNA
Simple metal complexes such as [Ru(bpy)3]2+, where bpy is 2,2′-bipyridine, interact 
with DNA via electrostatic interactions, however complexes containing extended
planar aromatic ligands intercalate between adjacent base pairs in double helical
DNA.99
Light switch complexes have been developed, such as [Ru(bpy)2(DPPZ)2]2+ where
bpy is 2,2′-bipyridine and DPPZ is dipyrido[3,2-a:2′,3′-c]phenazine), that only 
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luminesce in the presence of double-helical DNA due to intercalative binding.100 The
absence of luminescence in aqueous solution is due to deactivation of the excited state
by hydrogen bonding with DPPZ ligand, however once the complex is intercalated
into DNA it is shielded from the solvent and thus luminescence is restored.101-102
Interestingly the complex [Rh(bpy)2(chrysi)]3+ (see Figure 1.19), where chrysi is 5,6-
chrysenequinone diimine, intercalates into mismatched sites of DNA and is able to
photocleave the adjacent DNA backbone.103-104
In contrast [Ru(TAP)2(bpy)]2+ (see Figure 1.19), where TAP is 1,4,5,8-
tetraazaphenanthrene, is able to form covalent adducts with a nucleotide (guanosine
monophosphate, GMP) via the TAP ligand after photoirradiation and is a result of an
electron transfer process.105
Figure 1.19. Complexes that interact with DNA.
Ru(II) arene complexes are able to covalently bind to DNA after photoirradiation. For
example the complex [(η6-p-cymene)Ru(bpm)(RBP)]2+, where bpm is 2,2'-
bipyrimidine and RBP is a receptor binding peptide, releases RBP upon
photoirradiation and the resulting aqua complex binds to DNA via guanine.106
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1.4.3. Importance of wavelength of activation
Longer wavelength light (> 600 nm) penetrates deeper into human tissue than shorter
wavelength light (< 600 nm), as shown in Figure 1.20. As a result the optimum
wavelength of light used to activate a photoactive therapeutic agent (from a clinical
perspective) is known as the phototherapeutic window, and is typically between 600
nm – 1000 nm.
Figure 1.20. Depth of penetration of various wavelengths of light.107
This range is selected for the following reasons: a) tissues absorb lower wavelengths
light (< 600 nm) due to endogenous chromophores such as deoxyhemoglobin, b)
tissues scatter lower wavelengths of light, and c) water absorbs significantly at
wavelengths > 1,300 nm.67 Thus a clinically applicable photosensitizer should have a
strong absorption band in this phototherapeutic window. However for some metal
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complexes this is not possible, and several methods have been adopted to overcome
this problem.
1.4.3.1. Ligand modification
Modifying the ligands surrounding a metal can change the photochemical and
photophysical properties of a metal complex. The complex [Ru(biq)2(phen)]2+, where
phen is 1,10-phenanthroline and biq 2,2′-biquinoline, photoreleased one biq ligand in 
aqueous solution with >600 nm light, with photoactivation aided by the increase in
aromaticity (causing a red shift in the MLCT band) and increased distortion due to the
bulky biq ligand (distortion from octahedral geometry lowers the energy of the
dissociative 3MC state).108
Interestingly the cyclometallated analogue containing deprotonated 2-phenylpyridin
(phpy), [Ru(biq)2(phpy)]+, had a comparatively red-shifted MLCT band (shifted by
~100 nm) however photorelease of the biq ligand did not occur.109 Cyclometallating
ligands destabilise metal-based orbitals and have little effect on the π* orbitals of the 
other ligands, thus lowering the energy of the MLCT band.110 However in the previous
example, it was found that the lack of photorelease was due to the significant
destabilisation of the eg orbitals, thus increasing the energy of the dissociative 3MC
state.109
The complex [Ru(Rterpy)(bpy)(Hmte)]3+, where Rterpy is a rhodamine B
functionalised 2,2′;6′,2′′-terpyridine moiety and Hmte is 2-(methylthio)ethanol, was 
synthesised in order to exploit the favourable properties of rhodamine B (an efficient
fluorphore with a large extinction coefficient at ~550 nm).111 The complex was able
to release Hmte upon exposure to yellow light (~570 nm) due to the overlap of the
Rterpy emission band (centred at 586 nm) with the absorption band of the
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[Ru(terpy)(bpy)Hmte]2+ (centred at ~ 450 nm), via an energy transfer process that is
known as reverse-FRET (Förster energy transfer), see Figure 1.21.111
Figure 1.21. Energy transfer by addition of a fluorophore to a ruthenium(II) complex.
1.4.3.2. Two-photon activation
Two-photon activation occurs when a molecule simultaneously absorbs two photons
of low energy (from an intense femtosecond pulsed laser) to achieve the equivalent of
a higher energy transition, see Figure 1.22.112
Figure 1.22. Schematic of one-photon and two-photon activation.
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The probability of absorbing two-photons is directly related to the transition dipole
moment and efficient two-photon activation occurs in molecules with a) terminal
donor (D) and acceptor (A) groups (for example in a conjugated molecule D-π-A) as 
this increases the displacement of charge during the transition from donor to acceptor
and b) long π-conjugated planar chains as transition moments are related to the 
distance that the charge is displaced by during the transition.113
Ru(II) polypyridyl complexes [Ru(bpy)3]2+ and [Ru(bpy)2(dcb)]2+, where bpy is 2,2′-
bipyridine and dcb is 2,2′-bipyridine-4,4′-dicarboxylic acid, luminesce from the 
3MLCT state in a one-photon regime with 440 nm excitation and in a two-photon
regime at 880 nm excitation.114 However the efficiency of two-photon absorption was
increased by adding highly conjugated fluorene units to the peripheral of the
complex.115 Additionally [Ru(L1TEG)3]2+, where L1TEG is triethylene glycol
functionalised 5-fluorene-1,10-phenanthroline, not only showed relatively efficient
two-photon activation with 740 nm excitation but also showed improved solubility in
biological media to the triethylene glycol units.116
1.4.3.3. Upconverting nanoparticles
Upconverting nanoparticles work on the principle of energy-transfer upconversion,
whereby one-photon is absorbed by an ion and energy transfer results in a
neighbouring ion populating a higher excited emitting state.117 For example 980 nm
light has been used to excite NaYF4 nanoparticles doped with Yb3+/Er3+ that emit
green light at ~540 nm which was quenched by the photoreleasing Ru(II) complex
[Ru(bpy)2(py)2]2+ adsorbed onto the nanoparticle, where bpy is 2,2′-bipyridine and py 
is pyridine, to release py into solution.118
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1.5. Aims
The general theme of this thesis is to explore the synthesis, design, photochemical and
photobiological properties of ruthenium(II) polypyridyl complexes designed as
antibacterial agents. The photoactive complexes of choice are based on cis-[Ru(N-
N′)2(L)2]2+ and cis-[Ru(N-N′)2(L)X]+, where N-N′ is a bidentate polypyridyl ligand, X
is a halide and L is either isoniazid or nicotinamide (anti-tuberculosis compounds).
The aim is to release the biologically active ligand by photoactivation, and form
reactive ruthenium(II) aqua species. The individual aims of the thesis are:
a) To investigate the solution chemistry of the ruthenium(II) polypyridyl
complexes in the dark.
b) To explore the photochemical and photophysical behaviour of the
ruthenium(II) polypyridyl complexes by photoirradiating with visible light.
c) To assess the antibacterial activity of the ruthenium(II) polypyridyl complexes
against a M. tuberculosis model, M. smegmatis, in the dark and once exposed
to various wavelengths of visible light.
d) To investigate extending the photoactivation of the ruthenium(II) polypyridyl
complexes from the visible region to the phototherapeutic window (600 nm –
1000 nm) by modifying ligands surrounding the metal.
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Chapter 2
Experimental methods and materials
This chapter describes the general techniques and instrumentation that are used in this
thesis. Additional detail will be given in the appropriate Chapter where the technique
/ instrument is used.
2.1. NMR spectroscopy
1H and 13C NMR spectra were recorded on either a Bruker DPX-300 (1H: 300.13
MHz), Bruker AV-400 (1H: 399.10 MHz) or Bruker AV III-500 HD (1H: 500.13 MHz)
spectrometer. Amber NMR tubes (5 mm diameter) were used for characterisation of
complexes while 5 mm clear NMR tubes were used for photoirradiation studies. 1H-
NMR, 13C-APT, 1H-1H COSY and 1H-13C HSQC spectra were recorded using
standard pulse sequences. Typically the data were acquired with 16-128 transients into
2048-33,000 data points over a spectral width of 21-25 ppm. The 1H and 13C
resonances were calibrated with the residual solvent peak (δH DMSO-d6 = 2.50 ppm,
δH acetone-d6 = 2.05 ppm, δC acetone-d6 = 29.84 and 206.26 ppm, and δH acetonitrile-
d3 = 1.94 ppm) or by the addition of 1,4-dioxane (δH = 3.75 ppm) in D2O.1
2.2. X-ray crystallography
Data collection and solution of the structures were performed by Dr Guy Clarkson
from Department of Chemistry at University of Warwick. Diffraction data were
collected on an Oxford Diffraction Gemini four-circle system with Ruby CCD area
detector and an Oxford Cryosystem Cryostream Cobra cooler. The structure was
solved by direct methods using SHELXS2 (TREF) with additional light atoms found
by Fourier methods. Hydrogen atoms were added at calculated positions and refined
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using a riding model with freely rotating methyl groups. Anisotropic displacement
parameters were used for all non-H atoms; H-atoms were given isotropic displacement
parameters equal to 1.2 (or 1.5 for OH and NH hydrogen atoms) times the equivalent
isotropic displacement parameter of the atom to which the H-atom is attached.
Refinement used SHELXL 97.3 The solved structures were analysed by Mercury 3.3.
2.3. Elemental analysis
Elemental analysis was performed by Exeter Analytical using a CHN/O/S Elemental
Analyser (CE440).
2.4. Light sources
Power measurements for the KiloArcTM and blue LED setup were recorded using
International Light Technologies Powermeter (ILT1400-A) equipped with SEL 033
detector and flat response visible filter F/W (400-1064 nm). The output spectrum of
each light source was measured using an Ocean Optics USB4000-UV-Vis
spectrophotometer equipped with a fibre optic cable. The data were processed using
Ocean Optics SpectraSuite software.
2.4.1. KiloArcTM lamp
The KiloArcTM broadband arc lamp was fitted with a liquid filter, monochromator and
sample compartment in order to photoirradiate samples with various wavelengths of
light, see Figure 2.1. The power and output spectrum of each wavelength used was
recorded with the appropriate high-pass cut off filter placed in the path of the beam,
see Table 2.1 and Figure 2.2.
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Figure 2.1. Image of KiloArcTM lamp setup.
Table 2.1. Wavelengths used with KiloArcTM lamp.
Wavelength (nm) High-pass filter (nm) Power (mW cm-2)
440 UV 16
465 UV 16
500 475 10
560 530 9
600 570 6
610 590 6
800 610 3
Figure 2.2. Output spectrum for each wavelength used from the KiloArcTM lamp.
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2.4.2. Blue LED
The blue LED was used to either photoirradiate a sample in a cuvette or an NMR tube,
see Figure 2.3. The blue LED was placed 4 cm away from the sample in both cases.
The output spectrum was measured and was found to be centred at 463 nm with a
power of 50 mW cm-2, see Figure 2.4.
Figure 2.3. Image of blue LED used with a sample in a cuvette.
Figure 2.4. Output spectrum of blue LED.
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2.4.3. 96-array blue LED
A 96-array of blue LED’s (see Figure 2.5) was constructed by Mr Rod Wesson,
Electrical and Electronics Workshop, Department of Chemistry from University of
Warwick. The LED’s used were Multicomp OVL-5523 5 mm LED’s with a dominant
wavelength of 465 nm and a power of 20 mW cm-2 once constructed into the array.
The design will be discussed in more detail in Chapter 5.
Figure 2.5. Image of 96-array blue LED.
2.4.4. 32-array multi-coloured LED
A 32-array of blue LED’s with individual switches (see Figure 2.6) was constructed
by Mr Rod Wesson, Electrical and Electronics Workshop, Department of Chemistry
from University of Warwick. The LED’s used were Multicomp OVL-5523 5 mm
(dominant wavelength of 465 nm), Multicomp OVL-5524 5 mm (dominant
wavelength of 520 nm), Multicomp OVL-5526 5 mm (dominant wavelength of 589
nm) and Multicomp OVL-5528 5 mm (dominant wavelength of 625 nm) with a power
of 5 mW cm-2 once constructed into the array. The design will be discussed in more
detail in Chapter 5.
Chapter 2
____________________________________________________________________
50
Figure 2.6. Image of 32-array multi-coloured LED (625 nm, 589 nm, 520 nm and 465
nm).
2.4.5. Laser set-up
The general set-up of the laser system is described below, with any changes stated in
the appropriate section. The equipment was maintained by Dr Simon E. Greenough
from Department of Chemistry at University of Warwick and has been described
previously.4-5
The sample was recirculated using a peristaltic pump (Masterflex) with PTFE tubing
throughout, at a flow speed sufficient to ensure fresh solution was sampled with each
laser shot. Pump and probe pulses were generated from a commercially available
femtosecond Ti-sapphire regenerative amplified laser system (SpectraPhysics, Spitfire
XP) operating at 1 kHz. The output of the laser system is split to give two 800 nm
beams: (i) 950 mW (pump) and (ii) 5 mW (probe). Broadband white light continuum
(340 to 675 nm) probe pulses were generated by focusing an attenuated probe beam
into a vertically translated CaF2 window and detected using a fibre couple UV/Vis
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spectrometer (Avantes, AvaSpec Ultrafast). The use of a 500 Hz mechanical chopper
(Thorlabs) in the pump beam creates an alternating pumped and non-pumped sample
from which a difference spectrum was calculated after probing. Pump–probe delays
(up to 2 ns) were created using a motorized optical delay line in the probe beam path.
The pump beam was focused behind the sample to ensure a beam waist ~3 times that
of the probe. A purpose built LabVIEW code controlled the system and acquired data.
2.4.5.1. One-photon transient absorption spectroscopy
This method was used in Chapter 4. The sample was delivered using a 1 mm path
length flow through quartz cuvette (Starna UK). The pump beam was used to pump
an optical parametric amplifier (OPA) (Light Conversion, TOPAS-C (UV-VIS)). The
OPA provides the pump source with tuneable wavelengths in the range 240–1160 nm,
here sample was excited using 340 nm (3.65 eV), 640 µW, ~50 fs pump pulses. The
pump beam was focused 10 mm behind the sample.
2.4.5.2. Two-photon transient absorption spectroscopy
This method was used in Chapter 6. The sample was delivered using a steel flow-
through cell (Harrick Scientific), comprising two CaF2 windows and a 950 µm thick
Teflon spacer, which defines the optical path length. The pump beam was attenuated
to provide a pump power of 24 mW (this maximum power limit prevented white light
generation in the sample) using a neutral density filter. Sample was excited using 800
nm (1.55 eV), ~50 fs pump pulses. This power was further attenuated, as required for
power dependence studies, with a second, variable neutral density filter to give
excitation energies in the range of 0.5-1 mW. The pump beam was focused ~20 mm
behind the sample to ensure a beam waist at the sample of 150 µm.
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2.4.5.3. Two-photon absorption spectroscopy
This method was used in Chapter 6. The sample (350 µL) was placed in a 5 mm path
length quartz cuvette and stirred using a micro-stirrer bar and magnetic stirring plate.
The pump beam was used to pump an optical parametric amplifier (OPA) (Light
Conversion, TOPAS-C) to generate tuneable wavelength fs laser pulses - here 800 nm
(1.55 eV) and 600 nm ~35 fs pump pulses were used. A fused silica lens (f = 75 mm)
was used to focus the beam in the centre of the cuvette, see Figure 2.7. Power was
attenuated using a neutral density filter to avoid undesired white light generation in
the quartz or solution. This power was further attenuated, as required for power
dependence studies, with a second, variable neutral density filter to give excitation
energies in the range of 12-24 mW. The probe beam was not necessary due to the use
of Ocean Optics USB4000-UV-Vis spectrophotometer equipped with a fibre optic
cable and Miniature Deuterium Tungsten Halogen UV-Vis-NIR Light Source (DT-
MINI-2-GS). The data were processed using Ocean Optics SpectraSuite software.
Figure 2.7. Schematic of the laser setup for two-photon activation.
2.5. Electrospray ionisation mass spectrometry (ESI-MS)
Positive ion ESI-MS spectra were obtained using an Agilent 6130B single quad
coupled to an automated sample delivery system (isocratic Agilent 1100 HPLC
This image cannot currently be displayed.
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without column) with 80% methanol: 20% H2O as the mobile phase. Samples were
diluted with either double deionised water (ddH2O) or acetonitrile. The detection of
ruthenium species was aided by its isotope pattern with natural abundance of 96Ru
(5.54%), 98Ru (1.87%), 99Ru (12.76), 100Ru (12.60), 101Ru (17.06%), 102Ru (31.55%)
and 104Ru (18.62%).
2.6. High resolution electrospray mass spectrometry (HR-MS)
Data collection was performed by Dr Lijiang Song and Mr. Phil Aston from the
Department of Chemistry at University of Warwick. Positive ion HR-MS spectra were
obtained on a Bruker MicroTOF. Samples were diluted with either double deionised
water (ddH2O) or acetonitrile. The data were processed using Bruker Daltonics
DataAnalysis version 4.1. The error was calculated using the equation below:
Error (ppm) =   Experimental (m/z) − Calculated (m/z)Calculated (m/z)   × (1 × 10     )
2.7. Liquid chromatography-high resolution mass spectrometry
(LC-HRMS)
Data collection was performed by Dr Lijiang Song from the Chemistry Department at
University of Warwick. LC-MS analysis was carried out with Dionex 3000RS UHPLC
coupled with Bruker MaXis Q-TOF mass spectrometer. An Agilent Zorbax Eclipse
plus column (C18, 100 x 2.1 mm, 1.8 µm) was used. Mobile phases consisted of A
(water with 0.1% formic acid) and B (ACN with 0.1% formic acid). A gradient of 5%
B to 100% B in 15 minutes was employed with a flow rate at 0.2 ml min-1. The UV
detector was set to detect at 254 nm. The mass spectrometer was operated in
electrospray positive mode with a scan range 50-2,000 m/z. Source conditions were:
end plate offset at -500 V; capillary at -4500 V; nebulizer gas (N2) at 1.6 bar, dry gas
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(N2) at 8 L min-1; dry temperature at 180 oC. Ion transfer conditions were: ion funnel
RF at 200 V pp; multiple RF at 200 V pp; quadruple low set at 55 m/z; collision energy
at 5.0 eV; collision RF at 600 V pp; ion cooler RF at 50-350 V pp; transfer time set at
121 µs; pre-pulse storage time set at 1 µs. Calibration was made with sodium formate
(10 mM) through a loop injection of 20 µL of standard solution at beginning of each
run. Samples were diluted with either double deionised water (ddH2O) or acetonitrile.
The data were processed using Bruker Daltonics DataAnalysis version 4.1. The error
(ppm) was calculated as in Section 2.6.
2.8. Liquid chromatography-mass spectrometry (LC-MS)
Data collection was performed by Mr. Phil Aston from the Department of Chemistry
at University of Warwick. The LC-MS spectra were obtained on an Agilent 1200
series liquid chromatography system coupled to a HCT-Ultra-ETD-PTR PTM
Discovery. An Agilent Zorbax Eclipse plus column (C18, 250 x 4.6 mm, 5 µm) was
used. Mobile phases consisted of A (water with 0.1% trifluoroacetic acid) and B (ACN
with 0.1% trifluoroacetic acid). A gradient of 10% B (0 min), 80% B (30 min), 80%
B (40 min), 10% B (41 min) and 10% B (55 min) was employed with a flow rate at 1
ml min-1 and UV detector was set to detect at 254 nm. Samples were diluted with either
double deionised water (ddH2O) or acetonitrile. The data were processed using Bruker
Daltonics DataAnalysis version 4.1.
2.9. High performance liquid chromatography (HPLC)
Data collection was performed by Mr. Adam Millett from the Department of
Chemistry at University of Warwick. HPLC was performed on an Agilent 1200
system. The column, mobile phase, gradient and detection were performed as in
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Section 2.8. Samples were diluted with either double deionised water (ddH2O) or
acetonitrile. The sample was injected (50 µL) into a 100 µL loop.
2.10. UV-visible absorption spectroscopy
UV-visible absorption spectra were recorded on a Varian Cary 300 UV-vis
spectrophotometer fitted with an external Varian Cary temperature controller. Spectra
were recorded at 298 K from 800 nm to 200 nm with a scan rate of 600 nm min-1. The
spectra were processed using UV-Winlab software.
2.11. Microplate reader
The change in optical density (OD) of a bacterial suspension at 600 nm was monitored
using Thermo Labsystems IEMS MF microplate reader with a 96-well plate. The
conditions of each experiment was a shake function before taking an OD600 nm reading
with a speed of 1020 rpm for 1 min, a background shake with speed of 360 rpm for on
time of 30 s and off time of 30 s, while maintaining the temperature throughout at 310
K. The OD600 nm was monitored over a 72 h period taking OD600 nm measurements
every 1h. The data were processed using Ascent software version 2.6. A typical OD600
nm curve can be found in Figure 2.8.
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Figure 2.8. Typical OD600 nm curve observed for a bacterial suspension over a 72 h
period fitted to a Boltzmann sigmoidal curve (red line).
The corrected final OD600 nm was calculated by taking the final OD600 nm measurement
at 72 h and subtracting the starting OD600 nm at 0 h. In a typical experiment each sample
well contained the bacteria and the drug, while the control contained bacteria with no
drug. Any changes are specified in the appropriate section. The percentage survival
was then calculated using the following:
Percentage survival (%) =   Corrected final OD      	    sampleCorrected final OD      	    control  × 100
2.12. Synthesis of starting materials
RuCl3.3H2O was purchased from Precious Metals Online. 2,2'-Bipyridine, 1,10-
phenanthroline, lithium chloride (LiCl), sodium iodide (NaI), dimethylformamide
(DMF) and acetone were purchased from Sigma Aldrich. The NMR spectroscopy
solvents acetone-d6 and DMSO-d6 were purchased from Cambridge Isotope
Laboritories Inc.
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cis-[Ru(bpy)2(Cl)2]
The complex was synthesised using a similar procedure as previously described.6
RuCl3.3H2O (1 g. 3.8 mmol), 2,2'-bipyridine (1.2 g, 7.7 mmol) and LiCl (1 g, 25
mmol) were refluxed in DMF (30 mL) under nitrogen while stirring in the dark for 8
h. The solution turned to red/violet in colour and was allowed to cool to room
temperature. Acetone (110 mL) was added and solution was stored in the freezer at
253 K for 18 h. The solution was filtered and the black precipitate washed with cold
water and diethyl ether. Yield 43% (800 mg, 1.7 mmol). Elemental analysis calculated
for C20H16Cl2N4Ru %C: 49.60, %H: 3.33, %N: 11.57; found %C: 49.44, %H: 3.25,
%N: 11.49. 1H-NMR (DMSO-d6, 300 MHz) δH: 7.1 (2H, t, J = 6.7 Hz), 7.5 (2H, d, J
= 5.5 Hz), 7.7 (2H, t, J = 7.6 Hz), 7.8 (2H, t, J = 6.6 Hz), 8.1 (2H, t, J = 7.8 Hz), 8.5
(2H, t, J = 8.1 Hz), 8.6 (2H, d, J = 8.1 Hz), 10.0 (2H, d, J = 5.5 Hz).
cis-[Ru(bpy)2(I)2]
The complex was synthesised using a similar procedure as previously described.7
Water (10 mL) was degassed by bubbling nitrogen through it for 15 min. Cis-
[Ru(bpy)2(Cl)2] was added (100 mg, 200 µmol) and solution heated at 353 K under
nitrogen while stirring in the dark for 2 h. The solution tuned brown and was cooled
to room temperature. The solution was filtered to remove any unreacted starting
material. NaI (864 mg, 5.8 mmol) was added and the solution heated at 353 K for a
further 2 h. The solution was placed in fridge at 277 K overnight, and then filtered to
isolate the black precipitate. Yield 100% (140 mg, 200 µmol). 1H-NMR (DMSO-d6,
300 MHz) δH: 7.2 (2H, t, J = 6.5 Hz), 7.5 (2H, d, J = 5.5 Hz), 7.7 (4H, m), 8.1 (2H, t,
J = 7.5 Hz), 8.5 (2H, d, J = 8.0 Hz), 8.7 (2H, d, J = 8.1 Hz), 10.4 (2H, d, J = 5.7 Hz).
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cis-[Ru(phen)2(Cl)2]
The complex was synthesised using the procedure described for cis-[Ru(bpy)2(Cl)2]
above.8 RuCl3.3H2O (100 mg, 380 µmol), LiCl (110 mg, 2.6 mmol) and 1,10-
phenanthroline (138 mg, 760 µmol) added to DMF (5 mL). Acetone (25 mL) was
added and solution was red/purple. A black precipitate was obtained. Yield 51% (104
mg, 200 µmol). Elemental analysis calculated for C24H16Cl2N4Ru %C: 54.15, %H:
3.03, %N: 10.52, found %C: 53.68, %H: 3.30, %N: 10.54. 1H-NMR (DMSO-d6, 400
MHz) δH: 7.3 (2H, dd, J = 8.2 and 5.4 Hz), 7.8 (2H, d, J = 5.4 Hz), 8.1 (2H, d, J = 8.8
Hz), 8.2 (4H, m), 8.3 (2H, d, J = 8.9 Hz), 8.7 (2H, d, J = 8.1 Hz), 10.3 (2H, d, J = 5.2
Hz).
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Chapter 3
Synthesis, characterisation and dark solution chemistry of
Ru(II) polypyridyl complexes
3.1. Introduction
Photoactivation of metal complexes has been widely studied for its use in oncology1-
5 and bacterial infections.6-8 The technique relies on the sensitizer reaching the target
unharmed, allowing selective activation by shining light on the target site. Systematic
administration of drugs encounters the issue that the drug has to pass through many
organs and cells before it can reach the target site, being exposed to different cell
components and enzymes that can deactivate the drug before it reaches its target.9 In
some cases, before a drug can interact with a biomolecule it needs to undergo a
chemical reaction. For example, the anticancer agent cisplatin hydrolyses to provide
binding sites available for binding to biomolecules such as DNA.10 Thus before
investigating the photoactivation of any potential photoactive drug, it is important to
understand its behaviour in aqueous solution in the dark.
The most common targets for drugs are either proteins (e.g. enzymes, receptors) or
nucleic acids (e.g. DNA), and a drug can bind to such targets either by a direct reaction
and thus covalent bonding, or by intermolecular bonds (e.g. hydrogen bonding,
hydrophobic interactions).11 It is well known that cisplatin binds to DNA, and its
binding properties have been extensively studied.12 Ru(II) octahedral compounds,
such as [Ru(azpy)2Cl2], where azpy is 2-(phenylazo)pyridine, have been shown to be
cytotoxic to breast cancer cell lines.13 Since DNA is an important target, the addition
of benzimidazole ligands (to simulate the binding of nucleic acids) to form cis-
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[Ru(azpy)2(MeBim)2]2+, where MeBim is methylybenzimidazole, was investigated
and the rotation behaviour of MeBim was explored.14 Similar analysis was also carried
out with cis-[Ru(bpy)2(MeBim)2]2+, concluding that more sterically-demanding
ligands rotate more slowly.15 Atropisomers occur in compounds in which rotation
about a single bond is hindered. Is it an important area of drug design, as different
atropisomers can have different binding affinities to targets and thus different
activities.16-19
This chapter concentrates on two sets of photoactive antibacterial compounds:
 Ru(II) polypyridyl bis-substitued complexes of the type cis-[Ru(N-N')2(L)2]2+,
where N-N' is 2,2'-bipyridine or 1,10-phenanthroline, and L is nicotinamide or
isoniazid (existing antibacterial organic ligands).
 Ru(II) polypyridyl halide complexes of the type cis-[Ru(bpy)2(L)X]+, where
bpy is 2,2'-bipyridine, L is either nicotinamide or isonicotinamide and X is Cl
or I.
Their dark solution chemistry has been explored, both in terms of their stability in
aqueous solution and with respect to any intramolecular interactions that may occur in
solution. Intermolecular interactions for Ru(II) polypyridyl bis-substituted complexes
have been explored in the solid state by investigating their crystals structures.
3.2. Experimental
3.2.1. Materials
Nicotinamide (NA), isonicotiamide (INA), isoniazid (INH) and NH4PF6 were
purchased from Sigma-Aldrich and used without further purification. The cis-[Ru(N-
N')2(X)2] starting materials, where N-N' is 2,2'-bipyridine (bpy) or 1,10-phenanthroline
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(phen), and X is Cl or I, were synthesised as described in Chapter 2. The solvents used
for UV-visible absorption spectroscopy were reagent grade acetone, DMSO and DMF,
and deionised water. The NMR spectroscopy solvents acetone-d6, DMSO-d6 and
methanol-d4 were purchased from Cambridge Isotope Laboritories Inc, and D2O was
purchased from Sigma-Aldrich. All solutions of complexes were kept in the dark.
3.2.2. Preparation of Ru(II) polypyridyl halide complexes
Complexes of the type cis-[Ru(bpy)2(L)X][PF6], where bpy is 2,2'-bipyridine; L is
nicotinamide or isonicotinamide; and X is Cl or I, were synthesised using a similar
procedure as previously described.20 Typically 1.2 mol equivalent of ligand L was
added to a solution of the appropriate cis-[Ru(bpy)2(X)2] starting material in 10 mL of
1:4 v/v water:ethanol mixture. The solution was refluxed under nitrogen while stirring
for 5 h, with the reaction vessel covered in foil to avoid light exposure. The resulting
solution was cooled to room temperature and filtered to remove any unreacted starting
material. The solvent was evaporated under reduced pressure and the resulting residue
re-dissolved in 7 mL water. To this, 5 mol equivalent of NH4PF6 was added to give a
precipitate and suspension was placed in the fridge at 277 K overnight to encourage
further precipitation. The precipitate was collected by filtration and washed with cold
water and diethyl ether. If necessary the precipitate was dried overnight under vacuum.
Any variation in synthetic procedure is detailed below, including weights of reactants
and volume of solvents. 13C-NMR spectroscopy data was obtained for samples where
elemental analysis data is not supplied.
cis-[Ru(bpy)2(NA)Cl][PF6] (1). A solution of cis-[Ru(bpy)2(Cl)2] (104 mg, 0.2
mmol) and nicotinamide (NA) (30 mg, 0.24 mmol) in 1:4 v/v water:ethanol turned
from light red to dark red and NH4PF6 (163 mg, 1 mmol) was added. A dark red
precipitate was obtained. Yield 82 % (118 mg, 0.16 mmol). Elemental analysis
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calculated for C26H22ClF6N6OPRu.H2O %C: 42.55, %H: 3.30, %N: 11.45; found %C:
42.26, %H: 2.86, %N: 11.34. ESI-MS calculated for C26H22ClN6ORu [M]+ m/z 571.1,
found m/z 570.9. 1H-NMR (acetone-d6, 500 MHz) δH: 6.9 (1H, NH), 7.3 (1H, ddd, J
= 7.6, 5.5 and 1.2 Hz), 7.4 (1H, ddd, J = 7.6, 5.6 and 1.2 Hz), 7.5 (1H, t, J = 7.0), 7.6
(1H, NH), 7.7 (1H, ddd, J = 7.7, 5.5 and 1.2 Hz), 7.8 (1H, d, J = 5.7 Hz), 7.9 (1H, ddd,
J = 7.6, 5.5 and 1.1 Hz), 7.9 (2H, m), 8.1 (1H, d, J = 5.7 Hz), 8.2 (2H, m), 8.3 (1H, dt,
J = 7.9 and 1.5 Hz), 8.6 (1H, d, J = 8.1 Hz), 8.6 (1H, d, J = 8.2 Hz), 8.6 (1H, d, J = 8.1
Hz), 8.7 (1H, d, J = 5.6 Hz), 8.7 (1H, d, J = 8.1 Hz), 9.1 (2H, br s), 10.1 (1H, d, J =
5.6 Hz).
cis-[Ru(bpy)2(NA)I][PF6] (2). A solution of cis-[Ru(bpy)2(I)2] (25 mg, 35 µmol) and
nicotinamide (NA) (5 mg, 42 µmol) in 2.5 mL 1:4 v/v water:ethanol turned from light
red to dark red/brown and NH4PF6 (28 mg, 17 µmol) was added. A dark red/brown
precipitate was obtained. Yield 35 % (10 mg, 12 µmol). ESI-MS calculated for
C26H22IN6ORu [M]+ m/z 663.0, found m/z 662.9. 1H-NMR (acetone-d6, 500 MHz) δH:
6.9 (1H, NH), 7.3 (1H, t, J = 6.6 Hz), 7.4 (2H, m), 7.5 (1H, NH), 7.8 (1H, t, J = 6.6
Hz), 7.9 (2H, m), 8.0 (2H, m), 8.0 (1H, d, J = 5.8 Hz), 8.2 (2H, m), 8.3 (1H, d, J = 7.9
Hz), 8.5 (1H, d, J = 8.1 Hz), 8.6 (1H, d, J = 8.0 Hz), 8.6 (1H, d, J = 8.2 Hz), 8.8 (1H,
d, J = 8.1 Hz), 8.9 (1H, d, J = 5.4 Hz), 9.3 (1H, br s), 9.3 (1H, br s), 10.6 (1H, d, J =
5.6). 13C-NMR (acetone-d6, 500 MHz) δC: 124.1, 124.5, 124.7, 124.8, 125.6, 127.0,
127.7, 128.4, 129.0, 136.2, 137.2, 137.4, 137.4, 137.9, 152.7, 153.7, 154.1, 158.6,
158.9, 159.2, 159.5, 160.1.
cis-[Ru(bpy)2(INA)Cl][PF6] (3). A solution of cis-[Ru(bpy)2(Cl)2] (104 mg, 0.2
mmol) and isonicotinamide (INA) (32 mg, 0.26 mmol) in 12 mL 1:5 v/v water:ethanol
turned from light red to dark red and NH4PF6 (163 mg, 0.1 mmol) was added. A dark
red was obtained. Yield 92 % (132 mg, 0.18 mmol). Elemental analysis calculated for
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C26H22ClF6N6OPRu.H2O %C: 42.55, %H: 3.30, %N: 11.45; found %C: 42.05, %H:
2.88, %N: 11.28. ESI-MS calculated for C26H22ClN6ORu [M]+ m/z 571.1, found m/z
571.1. 1H-NMR (acetone-d6, 400 MHz) δH: 7.1 (1H, NH), 7.3 (1H, ddd, J = 7.7, 5.6
and 1.2 Hz), 7.4 (1H, ddd, J = 7.6, 5.7 and 1.3 Hz), 7.7 (3H, m), 7.8 (1H, d, 5.6 Hz),
7.9 (1H, ddd, J = 7.6, 5.6, 1.2 Hz), 7.9 (2H, m), 8.1 (1H, d, J = 5.6 Hz), 8.2 (2H, m),
8.6 (1H, d, J = 8.2 Hz), 8.6 (1H, d, J = 8.2 Hz), 8.6 (1H, d, J = 8.2 Hz), 8.7 (1H, d, 5.5
Hz), 8.7 (1H, d, J = 8.2 Hz), 8.9 (1H, br s), 10.1 (1H, d, J = 5.6 Hz).
Nicotinamide (NA). 1H-NMR (acetone-d6, 400 MHz) δH: 6.9 (1H, NH), 7.5 (1H, dd,
J = 8.0 and 4.9 Hz), 7.7 (1H, NH), 8.3 (1H, dt, J = 8.0 and 1.9 Hz), 8.7 (1H, dd, J =
4.9 and 1.5 Hz), 9.1 (1H, d, J = 1.8 Hz).
Isonicotinamide (INA). 1H-NMR (acetone-d6, 400 MHz) δH: 7.0 (1H, NH), 7.7 (1H,
NH), 7.8 (2H, dd, J = 4.1 and 1.5 Hz), 8.7 (2H, dd, J = 4.0 and 1.4 Hz).
3.2.3. Preparation of Ru(II) polypyridyl bis-substitued complexes
Complexes of the type cis-[Ru(N-N')2(L)2][PF6]2, where N-N' is 2,2'-bipyridine or
1,10-phenanthroline and L is nicotinamide or isoniazid, were synthesised using a
similar procedure as previously described.21 Typically 10 mL water was degassed by
bubbling nitrogen through the solution for 15 min. Subsequently, 1 mol equivalent of
the appropriate cis-[Ru(N-N')2(Cl)2] starting material was added. The solution was
heated at 353 K under nitrogen while stirring for 15 min, with the reaction vessel
covered in foil to avoid light exposure. To this, 5 mol equivalent of ligand L was added
and solution heated at 353 K for 6 h. Solution was allowed to cool to room temperature
and filtered to remove any unreacted starting material. To this, 5 mol equivalent of
NH4PF6 was added to give a precipitate and suspension was placed in the fridge at 277
K overnight to encourage further precipitation. The precipitate was collected by
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filtration and washed with cold water and diethyl ether. If necessary the precipitate
was dried overnight under vacuum. Any variation in synthetic procedure is detailed
below, including the weights of reactants and volume of solvents.
cis-[Ru(bpy)2(INH)2][PF6]2 (4). The suspension of cis-[Ru(bpy)2(Cl)2] (104 mg, 0.2
mmol) in water turned to a red solution after heating. Isoniazid (INH) (137 mg, 1
mmol) was added and solution turned from red to deep red. NH4PF6 (163 mg, 1 mmol)
was added and a dark red precipitate was obtained. Yield 66 % (130 mg, 0.1 mmol).
Suitable crystals for X-ray crystallography were obtained from slow diffusion of 1,4-
dioxane into a saturated acetonitrile solution at room temperature (298 K). Elemental
analysis calculated for C32H30F12N10O2P2Ru.2H2O %C: 37.92, %H: 3.38, %N: 13.82;
found %C: 37.99, %H: 3.07, %N: 13.35. ESI-MS calculated for C32H30N10O2Ru [M]2+
m/z 344.1, found m/z 343.9. 1H-NMR (DMSO-d6, 400 MHz) δH: 4.7 (4H, NH2), 7.5
(2H, t, J = 6.4 Hz), 7.6 (4H, d, J = 6.7 Hz), 7.9 (2H, t, J = 6.5 Hz), 7.9 (2H, d, J = 5.1
Hz), 8.0 (2H, t, J = 7.5 Hz), 8.2 (2H, t, J = 7.3), 8.5 (4H, d, J = 6.4 Hz), 8.6 (2H, d, J
= 8.3 Hz), 8.7 (2H, d, J = 7.8 Hz), 9.0 (2H, d, J = 5.4 Hz), 10.2 (2H, NH).
cis-[Ru(bpy)2(NA)2][PF6]2 (5). The suspension of cis-[Ru(bpy)2(Cl)2] (104 mg , 0.2
mmol) in water turned to a red solution after heating. Nicotinamide (NA) (122 mg, 1
mmol) was added and solution heated to 2.5 h. Solution turned from red to deep red
and NH4PF6 (163 mg, 1 mmol) added. An orange precipitate was isolated. Yield 49 %
(92 mg, 97 µmol). Suitable crystals for X-ray crystallography were obtained from a
saturated water solution at 277 K. Elemental analysis calculated for
C32H28F12N8O2P2Ru %C: 40.56, %H: 2.98, %N: 11.82; found %C: 40.25, %H: 2.91,
%N: 11.48. ESI-MS calculated for C32H28N8O2Ru [M]2+ m/z 329.1, found m/z 328.9.
1H-NMR (acetone-d6, 500 MHz) δH: 7.0 (2H, NH), 7.6 (6H, m), 8.0 (2H, ddd, J = 7.8,
5.6 and 1.3 Hz), 8.1 (2H, td, J = 7.9 and 1.4 Hz), 8.3 (4H, m), 8.4 (2H, dt, J = 8.0 and
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1.5 Hz), 8.6 (2H, d, J = 8.1 Hz), 8.7 (2H, d, J = 8.0 Hz), 8.9 (2H, d, J = 5.6 Hz), 9.0
(2H, s), 9.4 (2H, d, J = 5.7 Hz).
cis-[Ru(phen)2(INH)2][PF6]2 (6). The suspension of cis-[Ru(phen)2(Cl)2] (25 mg, 47
µmol) in water turned to a red solution after heating. Isoniazid (INH) (32 mg, 0.23
mmol) added and solution turned from red to deep red. NH4PF6 (38 mg, 0.23 mmol)
was added and an orange precipitate was obtained. Yield 52% (25 mg, 24 µmol).
Suitable crystals for X-ray crystallography were obtained from a saturated water
solution with a drop of diethyl ether at 277 K. Elemental analysis calculated for
C36H30F12N10O2P2Ru.6H2O %C: 38.14, %H: 3.73, %N: 12.35; found %C: 38.50, %H:
3.20, %N: 11.00. ESI-MS calculated for C36H30N10O2Ru [M]2+ m/z 368.1, found m/z
368.2. 1H-NMR (DMSO-d6, 400 MHz) δH: 4.6 (4H, NH2), 7.6 (4H, d, J = 6.6 Hz), 7.7
(2H, dd, J = 8.5, 5.3 Hz), 8.1 (2H, d, J = 5.1 Hz), 8.2 (2H, d, J = 8.9 Hz), 8.3 (2H, dd,
J = 8.4, 5.3 Hz), 8.3 (2H, d, J = 8.9 Hz), 8.6 (2H, d, J = 8.3 Hz), 8.7 (4H, d, J = 5.8
Hz), 8.9 (2H, d, J = 8.3 Hz), 9.6 (2H, d, J = 5.2 Hz), 10.1 (2H, NH).
cis-[Ru(phen)2(NA)2][PF6]2 (7). The suspension of cis-[Ru(phen)2(Cl)2] (25 mg, 47
µmol) in water turned to a red solution after heating. Nicotinamide (NA) (29 mg, 0.23
mmol) was added and solution turned from red to deep red. NH4PF6 (38 mg, 0.23
mmol) was added and a yellow precipitate was obtained. Yield 51% (24 mg, 24 µmol).
Elemental analysis calculated for C36H28F12N8O2P2Ru.2H2O %C: 41.91, %H: 3.13,
%N: 10.86; found %C: 41.73, %H: 2.65, %N: 10.56. ESI-MS calculated for
C36H28N8O2Ru [M]2+ m/z 353.1, found m/z 352.9. 1H-NMR (DMSO-d6, 400 MHz) δH:
7.4 (2H, ds, J = 8.2, 5.8 Hz) 7.7 (2H, dd, J = 8.5, 5.3 Hz), 7.7 (2H, NH), 8.2 (4H, m),
8.2 (2H, d, J = 8.9 Hz), 8.3 (6H, m), 8.6 (2H, d, J = 8.3 Hz), 8.7 (2H, d, J = 5.6 Hz),
8.8 (2H, s), 8.9 (2H, d, J = 8.1 Hz), 9.6 (2H, d, J = 5.2 Hz).
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3.2.4. X-ray crystallography
The details of the instrumentation, data collection, and solution of the structures are
described in Chapter 2. The crystal structures of cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) discussed in this
chapter were determined by Dr Guy Clarkson from the Department of Chemistry at
University of Warwick.
3.2.5. Dark stability in aqueous solution
3.2.5.1. Hydrolysis of Ru(II) polypyridyl halide complexes
The hydrolysis of the Ru(II) polypyridyl halide complex cis-[Ru(bpy)2(NA)Cl][PF6]
(1) was monitored by UV-visible absorption spectroscopy. The identity of the
hydrolysis products was verified by ESI-MS. The complex was dissolved in either
deionised water or 5% (v/v) DMSO, acetone or DMF to give a complex concentration
of 40 µM. The absorbance over the range 200 – 800 nm was recorded at several time
intervals over 18 – 24 h at 298 K. Where applicable plots of change in absorbance
versus time were fitted to the exponential equation A = A0 + CeRt (where A is
absorbance, t is time and A0, C and R are calculated parameters) using OriginPro 9.1
to give the half-life (t1/2).
3.2.5.2. Stability of Ru(II) polypyridyl bis-substituted complexes
The stability of Ru(II) polypyridyl bis-substituted complexes cis-
[Ru(bpy)2(INH)2][PF6]2 (4), complexes cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) was monitored by
UV-visible absorption spectroscopy. The complexes were dissolved in deionised
water to give a complex concentration of 40 µM. The absorbance over the range 200
– 800 nm was recorded at several time intervals over 6 h at 298 K.
Chapter 3
____________________________________________________________________
69
3.2.6. Dynamic behaviour in solution
3.2.6.1. Dynamic behaviour studied by variable temperature 1H-NMR
Data collection was performed by Dr Ivan Provkes from Department of Chemistry at
University of Warwick. 1H-NMR spectra of Ru(II) polypyridyl complexes cis-
[Ru(bpy)2(NA)Cl][PF6] (1), cis-[Ru(bpy)2(NA)I][PF6] (2) and cis-
[Ru(bpy)2(NA)2][PF6]2 (5) in acetone-d6 were obtained initially at 10-30 K intervals
from 185-323 K on a Bruker AV-500 spectrometer (1H = 500 MHz) using 5 o.d. NMR
tubes. The concentration of each sample was 2.5 mg in 600 µL of NMR solvent (c.a.
6 mM). To obtain an accurate coalescent temperature (Tc) for 1 and 2 the intervals
were lowered to 2 K around the coalescence point. All data processing was carried out
using Bruker Topspin 2.1. By using Equation 3.1 the rate constant at coalescence (kc)
of an unequally populated two-site system can be found, where X is a value taken from
tabulated values for various population (P) differences (ΔP = (P1-P2)) and δv is the 
difference in resonance frequency of the exchange protons.22-24 The free energy of
activation (ΔGc≠) was calculated using Equation 3.2, where a is a constant with a value
of 1.914 x 10-2 kJ/mol.22
NOESY spectra were obtained at 185 K using mixing time of 0.8 s.
k   = πδv 
∆G    = aT    10.319 + log   T k      
Equation 3.1.
Equation 3.2.
Chapter 3
____________________________________________________________________
70
3.2.6.2. Solvent effect on dynamic behaviour studied by 1H-NMR
The effect of solvent on the dynamic behaviour of Ru(II) polypyridyl halide
complexes cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2) was
studied by investigating the 1H-NMR spectra at 298 K in acetone-d6 and DMSO-d6 on
a Bruker DPX-400 spectrometer (1H = 400 MHz) using 5 o.d. NMR tubes. The
concentration of each sample was 2.5 mg in 600 µL of deuterated solvent (c.a. 6 mM).
3.2.6.3. Dynamic behaviour studied by DFT
The starting geometry of the Ru(II) polypyridyl halide complexes cis-
[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2) was adapted from the
crystal structure of 5 using the Λ enantiomer, and the DFT geometry optimisation was 
performed using Gaussian 03 in the gas phase.25 Becke’s three-parameter hybrid
functional26 with Lee-Yang-Parr’s gradient-corrected correlation functional
(B3LYP)27 was used. The LanL2DZ basis set28 and effective core potential were used
for the ruthenium atom, and the split valence 3-21G basis set29 was used for all other
atoms. The nature of all stationary points were confirmed by normal mode analysis. A
relaxed potential energy surface scan was performed using the B3LYP/LanL2DZ/3-
21G optimised geometry to find a potential transition state using the same functional
/ basis set. The dihedral angle between the monodentate ligand (L) and the ruthenium
atom was adjusted by intervals of 20 degrees to simulate the rotation of nicotinamide
(NA) in complexes of the type [Ru(bpy)2(NA)X]+, where X is either Cl or I. Geometry
optimisation of the transition states were performed using B3LYP/LanL2DZ/3-21G
as above. All B3LYP/LanL2DZ/3-21G geometries were then re-optimised using
B3LPY/LanL2DZ/6-31G**+ and PB1PBE30/LanL2DZ/6-31G**+; the LanL2DZ
basis set and effective core potential was used for the ruthenium and halide atom, and
the split valence 6-31G**+ basis set31 used for all other atoms.
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The DFT free energy of activation (∆G       ), i.e. energy of the rotational barrier, was
calculated by taking the difference between total energy of the starting geometry (ES)
and total energy of the transition state (ET), see Equation 3.3.
3.3. Results
3.3.1. Synthesis and characterisation
The Ru(II) polypyridyl complexes studied in this chapter are listed in Table 3.1 with
the general structure shown in Figure 3.1.
Figure 3.1. General structures of the complexes studied in this work.
∆G       = E   − E   Equation 3.3.
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Table 3.1. Cis-[Ru(N-N')2(L)X][PF6] and cis-[Ru(N-N')2(L)2][PF6]2 complexes
studied in this work.
Complex N-N' L X
cis-[Ru(N-N')2(L)X][PF6]
1 bpy NA Cl
2 bpy NA I
3 bpy INA Cl
cis-[Ru(N-N')2(L)2][PF6]2
4 bpy INH
5 bpy NA
6 phen INH
7 phen NA
The monocationic Ru(II) polypyridyl halide complexes, cis-[Ru(bpy)2(L)X][PF6] (1 –
3), were synthesised by the reaction of the appropriate cis-[Ru(bpy)2(X)2] starting
material with 1.2-1.3 mol equivalents of pyridine based ligand L in a mixture of 1:4
v/v water:ethanol. The complexes were fully characterised by 1D and 2D 1H-NMR in
acetone-d6. For the chlorido complexes cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-
[Ru(bpy)2(INA)Cl][PF6] (3) there is one doublet located at ~10.1 ppm, which is low-
field-shifted to 10.62 ppm for the iodido complex cis-[Ru(bpy)2(NA)I][PF6] (2). The
spectrum of cis-[Ru(bpy)2(NA)Cl][PF6] (1) is shown in Figure 3.2.
An interesting feature at approximately 9-9.5 ppm for complexes 1 – 3 is a broad peak
that can be attributed to protons H9 and H10 on the monodentate ligand L that are
closest to the nitrogen of the pyridine ring. Both protons appear to be exchanging at
room temperature (298 K), attributed to the lack of COSY and NOE cross peaks in the
1H-1H NOESY spectrum of 1 at room temperature (298 K), see Figure 3.3. This
intermediate conformational exchange can be attributed to the hindered rotation of the
NA ligand.
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Figure 3.2. 1H-NMR spectrum (500 MHz) of complex cis-[Ru(bpy)2(NA)Cl][PF6] (1)
in acetone-d6 at 298 K.
Figure 3.3. 1H-1H NOESY spectrum (500 MHz) of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in
acetone-d6 at 298 K.
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The dicationic Ru(II) polypyridyl bis-substituted complexes, cis-[Ru(bpy)2(L)2][PF6]2
(4 – 6), were synthesised by the reaction of the appropriate cis-[Ru(N-N')2(Cl)2]
starting material with a 5 mol equivalent excess of pyridine based ligand L in water.
The complexes were fully characterised by 1D and 2D 1H-NMR. Unlike complexes 1
– 3, the 1H-NMR peaks for 4 – 7 are sharp and the number of proton peaks observed
is reduced by half, see Figure 3.4.
Figure 3.4. 1H-NMR spectrum (500 MHz) of cis-[Ru(bpy)2(NA)2][PF6]2 (5) in
acetone-d6 at 298 K.
3.3.2. X-Ray crystal structures
The molecular structures of bis-substituted complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4),
cis-[Ru(bpy)2(NA)2][PF6]2 (5), and cis-[Ru(phen)2(INH)2][PF6]2 (6) were determined
by single crystal X-ray diffraction. The complexes are chiral and their crystal
structures show the presence of both enantiomers (Δ and Λ) in the unit cell. For 4 and
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5 the asymmetric unit contains half a complex (i.e. half a Ru atom, one bpy ligand,
one monodentate ligand, one PF6 counter ion) and solvent molecules. In contrast, for
6 the asymmetric unit contains one and a half Ru complexes (i.e. three phen ligands,
three monodentate ligands and three PF6 counter ions). Due to the complexity of the
crystal structure for 6, both enantiomers (Λ and Δ) are highlighted. The structures are 
shown in Figure 3.5, with selected bond lengths given in Table 3.3 for complexes 4
and 5, and Table 3.4 for 6. The crystallographic data are shown in Table 3.2.
Figure 3.5. X-ray structures of the cations cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) with thermal
ellipsoids showing 50% probability. The PF6 anions and hydrogen atoms have been
omitted for clarity.
Chapter 3
____________________________________________________________________
76
Table 3.2. Crystallographic data for complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6).
4 5 6
Formula C42H48F12N10O7P2Ru C32H40F12N8O8P2 Ru
C36.88888H35.888867
F12N10O4.055553P2
Ru
Molar mass 1195.91 1055.73 1075.21
Crystal system Monoclinic Monoclinic Monoclinic
Space group C2/c C2/c C2/c
Crystal size (mm) 0.20 x 0.08 x 0.04 0.20 x 0.18 x 0.16 -
Crystal character Orange block Orange block -
a (Å) 21.9093(7) 26.6886(10) 38.4124(5)
b (Å) 15.8193(3) 10.1669(2) 20.4076(3)
c (Å) 19.1282(12) 22.3265(7) 19.0496(2)
α (o) 90 90 90
β (o) 130.884(2) 136.981(2) 114.6440(10)
γ (o) 90 90 90
T (K) 293(2) 150(2) 150(2) K
Z 4 4 12
R1 [I>2σ(I)] 0.0798 0.0405 0.0700
Table 3.3. Selected bond lengths (Å) and angles (o) for cis-[Ru(bpy)2(INH)2][PF6]2
(4) and cis-[Ru(bpy)2(NA)2][PF6]2 (5).
Bond length (Å) / angle (o) 4 5
Ru1-N1 2.066(5) 2.0683(17)
Ru1-N12 2.057(4) 2.0524(17)
Ru1-N13 2.101(4) 2.1084(17)
N1-Ru-N12 78.62(18) 79.34(7)
N12-Ru1-N13 90.26(18) 88.92(7)
N13-Ru1-N13 91.3(2) 94.36(9)
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Table 3.4. Selected bond lengths (Å) and angles (o) for cis-[Ru(phen)2(INH)2][PF6]2
(6).
6
Bond length, Å / angle, o Λ Δ 
Ru1-N1 2.090(3) 2.080(3)
Ru1-N4 2.058(3) 2.056(3)
Ru1-N15 2.071(3) 2.080(3)
Ru1-N18 2.058(3) 2.056(3)
Ru1-N29 2.088(3) 2.081(3)
Ru1-N39 2.094(3) 2.081(3)
N1-Ru1-N4 79.52(14) 79.77(13)
N15-Ru1-N18 79.94(13) 79.77(13)
N4-Ru1-N39 87.21(13) 89.04(13)
N18-Ru1-N29 91.06(13) 89.04(13)
N39-Ru1-N29 92.68(13) 89.87(18)
The bond lengths for 4 and 5 are very similar, and the bite angle for the bpy (N1-Ru1-
N12) is very similar in each case. The angle between both monodentate ligands (N13-
Ru1-N13) is bigger in the case of 5 and thus there is a smaller bpy to monodentate
ligand angle (N12-Ru1-N13) when compared to 4.
The bite angle for phen in 6 (N1-Ru1-N4 and N15-Ru1-N18) is very similar to that of
bpy in 4 and 5. Additionally for 6 the angle between the monodentate ligands (N39-
Ru1-N29) and the angle between phen and monodentate ligand (N18-Ru1-N29 and
N4-Ru1-N39) is very similar to 4. Interestingly Ru-N1 is slightly longer and the
monodentate ligand length (Ru1-N29 and Ru1-N39) is slightly smaller for 6 when
compared to both 4 and 5.
It is worth noting that for 4 there is disorder over the hydrazide group, which is not
exhibited for 6.
Chapter 3
____________________________________________________________________
78
For cis-[Ru(bpy)2(INH)2][PF6]2 (4) the unit cell comprises of pairs of enantiomers
connected via a CH-π interaction between CH of bpy from Δ-complex and the π 
system of INH from Λ-complex, see Figure 3.6. The CH(bpy)-centroid(INH) distance is
3.176 Å and the angle between the ring planes is 81.76o. The hydrazide group on the
INH ligand forms a hydrogen-bonded dimer that links enantiomers from different unit
cells, see Figure 3.7, with a bond distance of N-H-N 2.199 Å. The bpy ligand deviates
from a linear arrangement, with a twist angle between each ring plane of 3.29o.
Figure 3.6. X-ray crystal structure of cis-[Ru(bpy)2(INH)2][PF6]2 (4) showing CH(bpy)-
π(INH) interactions connecting two enantiomers in the unit cell. The PF6 anions have
been omitted for clarity.
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Figure 3.7. X-ray crystal structure of cis-[Ru(bpy)2(INH)2][PF6]2 (4) showing
hydrogen bonding between the hydrazide group of two neighbouring enantiomers
from different unit cells.
The unit cell of cis-[Ru(bpy)2(NA)2][PF6]2 (5) comprises of pairs of enantiomers
connected via both CH-π interactions and π-π interactions. The CH-π interaction 
involves a CH of bpy from Δ complex and the π system of NA from Λ-complex. The 
CH(bpy)-centroid(NA) distance is 2.733 Å and the angle between the ring planes is
83.26o. The aforementioned bpy of the Δ-complex is involved in π-π interaction with 
bpy of the Λ-complex, see Figure 3.8. The centroid-centroid distance is 4.019 Å with 
a ring plane angle of 0o. The bpy ligand deviates from a linear arrangement, with a
twist angle between each ring plane of 6.57o. Hydrogen bonding occurs between the
amide group of NA and adjacent water molecules, with N-H(NA)-OH2 distance of 2.068
Å and O(NA)-HOH distance of 1.921 Å. Additional hydrogen bonding occurs between
a fluorine from PF6 and two hydrogens from bpy, see Figure 3.9, with H(bpy)-F bond
distances of 2.288 Å and 2.565 Å.
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Figure 3.8. X-ray crystal structure of cis-[Ru(bpy)2(NA)2][PF6]2 (5) showing CH(bpy)-
π(NA) and π(bpy)-π(bpy) interactions connecting two enantiomers in the unit cell. The PF6
anions have been omitted for clarity.
Figure 3.9. X-ray crystal structure of cis-[Ru(bpy)2(NA)2][PF6]2 (5) showing
hydrogen bonding between PF6 and hydrogens of bpy.
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CH-π and π-π interactions also govern the connection of enantiomers in the unit cell 
of cis-[Ru(phen)2(INH)2][PF6]2 (6). The π-π interaction involves the centre ring of the 
phen, with a centroid-centroid distance of 3.909 Å and an angle between ring planes
of 0o, see Figure 3.10. The CH-π interaction involves CH of phen and π system of 
INH, with CH(phen)-centroid(INH) distance of 2.697 Å and the angle between the ring
planes is 86.09o. Throughout the unit cell there is extensive hydrogen bonding between
water molecules and the hydrazide group of INH.
Figure 3.10. X-ray crystal structure of cis-[Ru(phen)2(INH)2][PF6]2 (6) showing
CH(phen)-π(INH) and π(phen)-π(phen) interactions connecting two enantiomers in the unit
cell. The PF6 anions have been omitted for clarity.
3.3.3. Dark stability in aqueous solution
3.3.3.1. Hydrolysis of Ru(II) polypyridyl halide complexes
The hydrolysis of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in a) deionised water and b) a 5%
(v/v) solution of common organic solvents used to dissolve water-insoluble
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compounds (e.g. DMSO, acetone and DMF) was studied by UV-visible spectroscopy
over an 18 – 24 h period.
An aqueous solution of 1 (40 µM) exhibits a band with a maximum at 473 nm that
decreased over time, giving rise to a new band with a maximum at 466 nm, see Figure
3.11. No further changes in the spectrum were seen after 6 h. There are isosbestic
points at 470 nm and 338 nm, consistent with the stoichiometric formation of cis-
[Ru(bpy)2(NA)(H2O)]2+ with no other side products. The identity of the hydrolysis
product was confirmed by ESI-MS, see Table 3.5. The change in absorbance of the
band at 466 nm was fitted to a single exponential equation to give t1/2 of 2712 s.
Figure 3.11. Hydrolysis of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in aqueous solution
followed by UV-visible spectroscopy (left) and increase of cis-
[Ru(bpy)2(NA)(H2O)]2+ peak at 466 nm followed over time (right).
When 5% DMSO, acetone or DMF was used, this relationship was not observed. In
all cases the band at 475 nm decreases over time, and never reaches an end point, see
Figure 3.12. The isosbestic point at 327 nm shifts over time, inferring that more than
one process is occurring. The decrease in the band at 475 nm could not be fitted to a
single exponential equation, confirming the added complexity.
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Figure 3.12. Hydrolysis of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in 5% DMSO (A) 5%
acetone (B) and 5% DMF (C) followed by UV-visible spectroscopy over 24 h .
The hydrolysis products were confirmed by ESI-MS, see Table 3.5. In all cases the
mass-to-charge ratio and isotopic models obtained were consistent with the formation
of cis-[Ru(bpy)2(NA)(H2O)]2+. For 5% DMSO another product mass was observed
consistent with the formation of cis-[Ru(bpy)2(NA)(DMSO)]2+.
Chapter 3
____________________________________________________________________
84
Table 3.5. Hydrolysis products of cis-[Ru(bpy)2(NA)Cl][PF6] (1) detected by ESI-MS
when hydrolysis was performed in various solvents
Hydrolysis
solvent
ESI-MS product
mass, m/z
Calculated formula and mass of
product, m/z
Water 553.2
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
5% DMSO
758.9
[[Ru(bpy)2(NA)(DMSO)]2++PF6]+
C28H28F6N6O2PRuS: 759.1
553.0
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
5% Acetone 553.0
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
5% DMF 553.0
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
3.3.3.2. Stability of Ru(II) polypyridyl bis-substituted complexes
The dark stability of cis-[Ru(N-N')2(L)2][PF6]2 complexes 4, 5, 6, and 7 in deionised
water was investigated using a 40 µM solution at room temperature, 298 K. Over 6
hours the UV-visible absorption spectra did not change, see Figure 3.13.
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Figure 3.13. Dark stability of cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) for 6 h in water followed by UV-visible spectroscopy.
3.3.4. Dynamic behaviour in solution
The nomenclature and proton labelling for the complexes (1, 2, 3 and 5) described in
this section are show in Figure 3.14.
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Figure 3.14. General structure and labelling of complexes studied in this work.
3.3.4.1. Dynamic behaviour studied by variable temperature 1H-NMR
Variable temperature 1H-NMR was utilised to gain further information about the room
temperature (298 K) exchange behaviour observed for 1, 2, and 3 described in Section
3.3.1. For the Ru(II) polypyridyl bis-substituted complex cis-[Ru(bpy)2(NA)2][PF6]2
(5), the resonances of the NA ligand protons do not shift with increasing temperature
(up to 323 K). However upon lowering the temperature to 185 K, a complex spectrum
appears owing to the presence of 3 atropisomers (denoted A, B and C), see Figure
3.15. At such low temperature the NA ligand is held in one place for each atropisomer,
and its orientation can be described by assigning H10 as the “head group”, or H, and
H9 as the “tail”, or T.
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Figure 3.15. Variable temperature 1H-NMR spectra (500 MHz) of cis-
[Ru(bpy)2(NA)2][PF6]2 (5) in acetone-d6 at 323 K, 298 K and 185 K with nomenclature
to describe the atropisomers (top).
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Figure 3.16. 1H-1H NOESY spectrum (500 MHz) of cis-[Ru(bpy)2(NA)2][PF6]2 (5) in
acetone-d6 at 185 K.
The atropisomers were assigned by analysing the NOE interaction between H10/H9
with H1/H8, see Figure 3.16. For atropisomers A and B, there is only one environment
for each H10 and H9, thus there is one peak for each. For atropisomer A, H10 shows an
NOE interaction with H1 and H8, and H9 shows an NOE interaction with H1. For
atropisomer B, H9 shows an NOE interaction with H1 and H8, and H10 shows an NOE
interaction with H1. In the case of atropisomer C, there are two environments for H10
and two for H9, thus four peaks are exhibited for these protons. The ratio and chemical
shift of selected peaks for each atropisomer is given in Table 3.6.
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Table 3.6. Comparison of chemical shift data for atropisomers of cis-
[Ru(bpy)2(NA)2][PF6]2 (5) in acetone-d6 at 185 K and 298 K
Chemical shift (ppm)
Atropisomer H10 H9 Ratio in solution
A 9.16 8.95 0.65
B 8.93 9.10 0.3
C 8.90, 9.16 8.99, 9.13 1
5 at 298 K 9.02 8.86 -
The chemical shift difference between H10 and H9 does not change significantly
between each atropisomer (~0.2 ppm). Whether H10 or H9 is shifted downfield is
dependent on the orientation of the NA ligand. Atropisomer C is the most stable in
solution, whereas atropisomer B is the least stable in solution.
For the Ru(II) polypyridyl halide complexes cis-[Ru(bpy)2(L)X][PF6] 1, 2 and 3,
heating the sample to 323 K results in the broad peak at 9-9.5 ppm becoming sharper,
and in the case of 1 and 2, the peak begins to split into two, see Figure 3.17.
Interestingly for 2 the broad peak at 9-9.5 ppm is weakly split into two at 298 K,
whereas for 1 it is a single broad peak. When the samples of 1 and 2 are cooled to 185
K, two atropisomers are isolated (denoted as Conf. 1 and Conf. 2), see Figure 3.18.
Again the atropisomers were assigned by investigating the NOE interaction between
H10/H9 with H1/H8, see Figure 3.19.
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Figure 3.17. Variable temperature 1H-NMR spectra (500 MHz) of cis-
[Ru(bpy)2(NA)Cl][PF6] (1) (A) and cis-[Ru(bpy)2(NA)I][PF6] (2) (B) in acetone-d6 at
323 K, 298 K and 185 K.
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Figure 3.18. Structure and nomenclature of the atropisomers of cis-[Ru(bpy)2(NA)X]+
isolated at 185 K.
Figure 3.19. 1H-1H NOESY spectrum (500 MHz) of cis-[Ru(bpy)2(NA)Cl][PF6] (1)
in acetone-d6 at 185 K where blue lines represent exchange cross-peaks and orange
lines represent NOE cross-peaks.
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Whether H10 or H9 is shifted downfield is dependent on the orientation of the NA
ligand. In the case of 3 only one atropisomer is present (denoted as Conf. 1) with H9’
proton shifted downfield and H9 shifted upfield, see Figure 3.20. The chemical shift
of selected peaks for each atropisomer is given in Table 3.7.
Figure 3.20. Variable temperature 1H-NMR spectra (500 MHz) of cis-
[Ru(bpy)2(INA)2Cl][PF6] (3) at 213 K, 298 K and 323 K in acetone-d6.
The chemical shift difference between H10 and H9 for both atropisomers of 1 (1.04
ppm for Conf. 1 and 1.71 ppm for Conf. 2) is greater than that found for 2 (0.9 ppm
for Conf.1 and 1.49 ppm for Conf. 2). For both 1 and 2 the atropisomer with greatest
chemical shift difference for H10 and H9 is Conf. 2. The chemical shift difference
between H10 and H9 for both 1 and 2 is greater than that found for the free ligand (0.4
ppm for NA).
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Table 3.7. Chemical shift data for cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-
[Ru(bpy)2(NA)I][PF6] (2), cis-[Ru(bpy)2(INA)Cl][PF6] (3) and the free monodentate
ligands in acetone-d6.
Chemical shift, ppm Chemical shift, ppm
1a 2a 3b NAc INAc
Conf 1
H10 8.55 8.81 (H9’) 9.61 9.11 8.91
H9 9.59 9.71 7.86 8.71
Conf 2
H10 10.01 10.14
H9 8.30 8.65
a at 185 K, b at 213 K and c at 298 K.
For 3 the chemical shift difference between H9’ and H9 is 1.75 ppm. For both 1 and 2
Conf. 1 is more stable in solution, with the ratio of Conf. 1 to Conf. 2 being 1:0.8.
By using equations stated in Section 3.2.6.1., the experimental free energy of
activation (∆G    ) was calculated, see Table 3.8. The free energy of activation for 1 is
3.9 kJ mol-1 higher than that found for 2.
Table 3.8. Parameteres determined from variable temperature 1H-NMR experiments
in acetone-d6 with cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2)
Complex δv (s-1) kc (s-1) Tc (K) ∆G    (kJ mol-1)
1 688 1144 278 51.6 ± 0.2
2 598 994 256 47.7 ± 0.3
3.3.4.2. Solvent effect on dynamic behaviour studied by 1H-NMR
In order to understand the nature of the conformational exchange, cis-
[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2) were dissolved in
various deuterated solvents. When 2 is in DMSO-d6, the broad peaks previously at
9.32 and 9.27 ppm in acetone-d6 begin to separate and shift upfield to 9.09 and 8.97
ppm, see Figure 3.21.
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Figure 3.21. 1H-NMR spectrum (400 MHz) of cis-[Ru(bpy)2(NA)I][PF6] (2) in
DMSO-d6 at 298 K. Inset is 1H-NMR spectrum of 2 in acetone-d6 at 298 K.
Similarly the bpy H1 peak at 10.62 ppm in acetone-d6 shifts upfield to 10.39 ppm in
DMSO-d6. When 1 is in DMSO-d6, the broad peak and the bpy H1 proton previously
at 9.07 and 10.08 ppm, respectively, in acetone-d6 shifts upfield to 8.76 and 9.85 ppm.
When a drop of D2O was added to the DMSO-d6 sample, the broad peak split into two
peaks with chemical shifts of 8.92 and 8.64 ppm, and again the bpy H1 proton shifted
further upfield to 9.78 ppm, see Figure 3.22.
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Figure 3.22. 1H-NMR spectrum (400 MHz) of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in
DMSO-d6 (bottom) and with 20 µL D2O added (top). Inset is 1H-NMR spectrum of 1
in acetone-d6 at 298 K.
3.3.4.3. Dynamic behaviour studied by DFT
DFT was used to investigate whether an intramolecular interaction is the cause for the
hindered rotation of the NA ligand at room temperature (298 K) for 1 and 2. A
potential energy scan was performed to investigate the starting geometries and
transition states by changing the dihedral angle between the halide and H9, shown in
Figure 3.23.
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Figure 3.23. Potential energy surface scan of cis-[Ru(bpy)2(NA)Cl]+ (1) (left axis and
filled squares) and cis-[Ru(bpy)2(NA)I]+ (2) (right axis and empty triangles) using
B3LPY/LanL2DZ/3-21G as the functional/ basis set.
The lowest energy geometries were found to be Conf. 1 and Conf. 2. The conformation
with the lowest energy is Conf. 1. There were two transition states, labelled transition
state 1 (TS1) and transition state 2 (TS2), with TS2 having the highest energy.
Geometry optimisations were performed to gain accurate energies of the
conformations using two different functionals; B3LYP and PBE1PBE. The DFT free
energy of activation (∆G       ) was calculated as described in Section 3.2.6.3, see Table
3.9.
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Table 3.9. Free energy of activation (∆          ) calculated from geometry optimised
DFT structures of cis-[Ru(bpy)2(NA)Cl]+ (1) and cis-[Ru(bpy)2(NA)I]+ (2).
∆G       (kJ mol-1)
Functional/ Basis set
Conf 1
 TS1
Conf 1
 TS2
Conf 2
 TS1
Conf 2
 TS2
1
B3LYP/LanL2DZ/6-31G**+ 46.54 50.02 36.73 40.20
PBE1PBE/LanL2DZ/6-31G**+ 50.17 54.09 40.59 44.50
2
B3LYP/LanL2DZ/6-31G**+ 41.08 44.34 32.58 35.83
PBE1PBE/LanL2DZ/6-31G**+ 45.53 49.37 37.45 41.29
Generally the free energies of activation associated with 1 are greater than those for 2.
From exploring the ground state configurations and transitions states, the main
geometrical differences between 1 and 2 occur between the ground state
configurations. Thus from here onwards only Conf. 1 and Conf. 2 will be discussed.
The bond distance between H10/H9 and the halide X was investigated (H···X), see
Table 3.10. Both PBE1PBE and B3LYP basis sets show that Conf. 1 has a shorter
H9/H10···X distance than Conf. 2 by ~ 0.1 Å for both 1 and 2. Additionally both
atropisomers of 1 have shorter H10/H9···X bond distances than both atropisomers of
2. This can evidently be seen when visualising Conf. 1 of both 1 and 2 as the NA
ligand appears to orientate itself closer to the halide for 1, see Figure 3.24.
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Table 3.10. Bond distance of H10/H9···X from geometry optimised DFT structures of
cis-[Ru(bpy)2(NA)Cl]+ (1) and cis-[Ru(bpy)2(NA)I]+ (2)
H10/ H9···X distance (Å)
B3LYP/LanL2DZ/
6-31G**+
PBE1PBE/LanL2DZ/
6-31G**+
1 Conf. 1 2.43 2.44
Conf. 2 2.56 2.53
2 Conf. 1 2.90 2.86
Conf. 2 3.02 2.97
Figure 3.24. Overlay of geometry optimised DFT structures (PBE1PBE/LanL2DZ/6-
31G**+) of [Ru(bpy)2(NA)Cl]+ (1) (red) and [Ru(bpy)2(NA)I]+ (2) (blue) to show
orientation of NA ligand from two different angles, with (B) looking down the X-Ru
bond.
The Mulliken charges were investigated to see if there is any interaction between
H10/H9 with the halide X, see Table 3.11. The difference in Mulliken charge between
H10 and H9 on the free NA ligand was used as a guide. The difference in charge
between H10 and H9 for free NA ligand is 0.029 with H10 more positive than H9. It is
worth noting that for Conf. 1 H9 is closest to the halide, whereas for Conf. 2 H10 is
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closest to the halide. For 1, Conf. 2 H10 is more positive than H9 (with a difference of
0.044), however for Conf. 1 both H10 and H9 have the same Mulliken charge. For 2
both conformations show H10 with a higher positive Mulliken charge than H9 (with a
difference of 0.011 for Conf. 1 and 0.036 for Conf. 2). The halide for 1 and 2 is more
negative in Conf. 1 than in Conf. 2.
Table 3.11. Mulliken charges for cis-[Ru(bpy)2(NA)Cl]+ (1), cis-[Ru(bpy)2(NA)I]+
(2) and ligand alone (NA) from DFT geometry using PBE1PBE/LanL2DZ/6-31G**+.
Mulliken charge
Atom Conf. 1 Conf. 2
1
H10 0.188 0.204a
H9 0.188a 0.160
X -0.290 -0.278
2
H10 0.186 0.195a
H9 0.175a 0.159
X -0.241 -0.227
Nicotinamide
(NA)
H10 0.172
H9 0.143
a indicates which atom is closest to the halide.
3.4. Discussion
3.4.1. Synthesis and characterisation
In the 1H-NMR spectra of bis-substituted Ru(II) polypyridyl complexes, cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2, the number of peaks
observed is half the amount of protons in the complex. This is due to the presence of
a two-fold symmetry axis (C2 symmetry). For Ru(II) polypyridyl halide complexes,
cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-[Ru(bpy)2(NA)I][PF6] (2) and cis-
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[Ru(bpy)2(INA)Cl][PF6] (3), the asymmetry of the complex results in each proton in
the complex having its own unique chemical shift.
Due to the presence of the halide, one doublet from 2,2'-bipyridine is always low-field-
shifted for complexes 1 – 3; for 1 and 3 it is located at 10.1 ppm, and for 2 it is located
at 10.62 ppm. This is due to the fact that this proton is in close proximity to the halide,
and is thus desheilded. This is confirmed by the fact that the proton in 2 is more low-
field-shifted than 1 and 3; 2 contains an iodide ligand which is bigger than the chloride
ligand and therefore the proton comes into closer proximity to it.
For cis-[Ru(bpy)2(L)X][PF6] complexes 1 – 3 there is a broad peak at 9-9.5 ppm that
is due to protons from the mondentate ligand, L, closest to the nitrogen of the pyridine
ring. Interestingly, this feature is not present for cis-[Ru(N-N')2(L)2][PF6]2 complexes
4 – 7, and therefore must be due to the presence of the halide. 1H-1H NOESY spectra
confirmed that this broadening is due to conformational exchange, and thus the
rotation of the monodentate ligand must be hindered for 1 – 3 at room temperature
(298 K) on the NMR timescale (500 MHz), see Section 3.3.1. Previously it has been
found that in the complex [Ir(H)2(PPh3)2(2-AP)F] there is an intramolecular hydrogen
bond between the NH2 group of 2-AP (2-aminopyridine) and F.32 It was initially
thought that such an interaction could occur in cis-[Ru(bpy)2(NA)Cl][PF6] (1) between
the amide group in the 3- position of NA ligand and Cl. However this possibility was
rejected as the hindered rotation of the ligand still occurs in cis-
[Ru(bpy)2(INA)Cl][PF6] (3), where the amide group is in the 4- position. Thus there
must be no interaction between the amide group and the halide in complexes 1 – 3.
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3.4.2. X-Ray crystal structures
The bond lengths for cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(bpy)2(NA)2][PF6]2
(5) are very similar to each other, and the only difference is the angle between the
monodentate ligands (N13-Ru1-N13). For 4 the angle is 91.3 Å and for 5 the angle is
94.36 Å. The angle for 5 could be bigger due to the bulkier nature of the amide in the
3- position of the NA ligand. The bite angle for phen in cis-[Ru(phen)2(INH)2][PF6]2
(6) is the same as for bpy in 4 and 5. This is not surprising as the only difference
between bpy and phen is the rigidity of ligand.
CH-π interactions are commonly found in crystal structures of metal complexes, with 
strong interactions showing a CH-centroid distance of < 2.6 Å and weak interactions
<3.0 Å.33 These interactions were found for 4, 5 and 6 linking two different
enantiomers, involving the chelate ring CH of the Δ enantiomer and the aromatic ring 
of the monodentate ligand of the Λ enantiomer. The CH-centroid distance is 3.176 Å, 
2.733 Å and 2.697 Å for 4, 5 and 6 respectively. The interaction for 4 is a borderline
case, however with 5 and 6 the interaction can be classed as weak. Interestingly the
complexes with the shortest CH-π interactions (5 and 6) observed π-π stacking 
between the chelating rings of pairs of enantiomers. The centroid-centroid distance for
5 and 6 is 4.019 Å and 3.909 Å respectively, with the planes of the aromatic rings
perfectly parallel. It is thought that the reason for a better π-π interaction between the 
phen ligands of 6 is because there is an extra aromatic ring that extends out further
from the ruthenium centre, when compared to bpy, thus allowing for better overlap.
For strong π-π interactions the centroid-centroid distance is usually ~3.3 Å and for 
weak interactions is 3.6-3.8 Å. 34 Thus those exhibited for both 5 and 6 can be classed
as very weak interactions. Interestingly the bpy twist angle for 5 (6.57o) is bigger than
for 4 (3.29o); this could arise from the fact that the bpy in 5 needs to orientate itself
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parallel to an adjacent bpy in order for a π-π interaction to occur (in 4 π-π interactions 
do not occur).
Throughout the crystal structures of 4, 5 and 6 there is a wide array of hydrogen
bonding. For 4 there is a dimer that forms between two enantiomers of neighbouring
unit cells via hydrogen bonding between the hydrazide group of the INH ligand. The
bond is strong with a length of 2.199 Å. Interestingly the crystal structure for 4 exhibits
disorder over the hydrazide group, which suggest the hydrogen bond is fluxional. For
5 two forms of hydrogen bonding occur: one between the amide group of the NA
ligand and water molecules, and one between bpy aromatic protons and PF6. In the
former, the N-H(NA)-OH2 distance is 2.068 Å and O(NA)-HOH distance is 1.921 Å,
which again can be classed as strong hydrogen bonding. The bifurcated interaction
between PF6 and aromatic protons of bpy results in bond lengths of 2.565 Å and 2.288
Å, showing that the interaction is reasonably strong. This type of hydrogen bonding is
commonly found in PF6 organometallic salts, and is thought to be assisted by the
difference in charge between anion and cation.35 For 6 there is an extensive network
of hydrogen bonds between the hydrazide group of INH and water. The plethora of
intermolecular interactions exhibited by complexes 4, 5 and 6 suggests that such
interactions could be important if the complex is recognised by proteins and other
target sites.
3.4.3. Dark stability in aqueous solution
Before investigating the photoactivity of complexes, it is imperative to understand
how the complexes behave in solution in the dark. When stored in aqueous solution
over a 6 h period in the dark, bis-substitued cis-[Ru(N-N')2(L)2][PF6]2 complexes 4 –
7 show no appreciable change in the UV-visible spectrum. Thus the complexes are
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stable in the dark for the duration of the experiment. Therefore when photoactivation
studies are carried out it is certain that any change observed is due to exposure to light.
It is common for ruthenium complexes containing halido ligands to hydrolyse in
aqueous solution.36-38 In some cases, hydrolysis is needed before the complex can be
active, for example hydrolysis of the anticancer agent NAMI-A provides binding sites
so that the complex can bind to biomolecules such as DNA.39 It is always ideal for a
drug to have good aqueous solubility, however in some cases poor water solubility
means that solvents such as 5% DMSO are required to dissolve the drug. Interestingly
the use of such solvents can affect the activity of a drug, and in some instances it can
reduce the activity in vitro.40 Thus it is important to consider whether the presence of
different solvents in the formulation can affect the hydrolysis of a drug.
The UV-visible spectrum of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in aqueous solution
changes over a period of 6 h with the formation of cis-[Ru(bpy)2(NA)(H2O)]2+. There
is a decrease in the peak with a maximum at 473 nm, with a rise in a new band with a
maximum at 466 nm. The increase in absorbance at 466 nm follows a single
exponential curve to give t1/2 of 2712 s. However this behaviour was not seen when
using either 5% DMSO, 5% acetone or 5% DMF. Instead the peak with a maximum
at 475 nm consistently decreased and never reached an end point over a 24 h period.
This decrease did not follow a single exponential relationship. ESI-MS confirmed that
hydrolysis was still occurring in these cases by the presence of cis-
[Ru(bpy)2(NA)(H2O)]2+, but another process must be interfering with the hydrolysis
process. For 5% DMSO a product mass was observed consistent with the formation
of cis-[Ru(bpy)2(NA)(DMSO)]2+. Thus if an organic solvent is present at a
concentration of 5% and can act as a σ-donor ligand, the organic solvent can bind to 
Ru(II) and interfere with the hydrolysis process. This could have implications for
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biological testing, as it may affect the activity of the complex in vitro. Additionally
the kinetics of the photoreaction are more difficult to measure if more than one process
is occurring. Thus for photoirradiation experiments pure water will be used.
3.4.4. Dynamic behaviour in solution
At room temperature (298 K) in acetone-d6, the rotation of the monodentate ligands
(NA) in cis-[Ru(bpy)2(NA)2][PF6]2 (5) around the Ru-N axis appears to be fast on the
NMR timescale (500 MHz) at 298 K; heating the solution to 323 K does not change
the spectrum. However once the solution was cooled to 185 K, the NA ligands rotate
much slower on the NMR timescale allowing atropisomers to be viewable in the 1H-
NMR spectrum. The same temperature dependent behaviour was observed for a
similar complex cis-[Ru(bpy)2(4Pic)2]2+, where 4Pic is 4-picoline.41 In the case of 5,
3 atropisomers were in slow exchange at 185 K, termed A, B and C, and were
characterised using 1H-1H NOSEY. All regions of the 1H-NMR spectrum at 185 K
were too complicated to analyse completely, apart from the H9 and H10 region at ~9
ppm (protons of the NA ligand closest to the nitrogen of the pyridine ring). Either H10
or H9 is shifted downfield depending on its environment, and it is characteristic for
each atropisomer. The proton of one NA ligand that is located over the centre of the
ring of the other NA will be shielded, see Figure 3.25. Thus for atropisomer A, H9 is
high-field-shifted compared to H10, for atropisomer B H10 is high-field-shifted
compared for H9, and in the case of atropisomer C each proton is consistently in a
different environment (the atropisomer is asymmetric).
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Figure 3.25. Structures of the atropisomers of cis-[Ru(bpy)2(NA)Cl][PF6] (1)
highlighting the position of the NA ligands and the environments of the protons. H
and T refers to the “head” and “tail” orientation of the NA ligand, respectively.
Interestingly for cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-[Ru(bpy)2(NA)I][PF6] (2) and
cis-[Ru(bpy)2(INA)Cl][PF6] (3) the rotation of the monodentate ligand is hindered at
room temperature (298 K) in acetone-d6 on the NMR timescale (500 MHz). For 1 and
2 there is a broad peak at 9-9.5 ppm at 298 K which is due to NA protons H9 and H10.
Heating an acetone-d6 solution of cis-[Ru(bpy)2(NA)Cl][PF6] (1) to 323 K results in
this broad peak sharpening and splitting into two peaks. Interestingly an acetone-d6
solution of cis-[Ru(bpy)2(NA)I][PF6] (2) at room temperature (298 K) exhibits a broad
peak at ~9-9.5 ppm that is shaper and weakly split into two. Heating the solution to
323 K results in the peaks becoming even sharper and two peaks can be clearly
observed. All of the above suggests that the rotation of the monodentate ligand in 2 is
faster than for 1. When both 1 and 2 in acetone-d6 are cooled to 185 K, two
atropisomers are revealed, termed Conf. 1 and Conf. 2. Again the atropisomers were
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characterised by 1H-1H NOESY. For Conf. 1, H9 is low-field-shifted (i.e. desheilded)
compared to H10 because of its close proximity to the halide, and the opposite is true
for Conf. 2 (chemical shift of H10 > H9). The chemical shift difference between H9 and
H10 for the free ligand (NA) is 0.4 ppm whereas for 1 and 2 is >1 ppm. This shift
suggests that the halide is interacting with the aromatic protons of the mondentate
ligand (H9 and H10), which could hinder rotation at room temperature. This is proven
by the fact that more polar solvents disrupt this interaction (e.g. DMSO-d6 and D2O),
resulting in more resolved peaks for H9 and H10. It is hypothesised that the interaction
can be classed as hydrogen bonding, which will be discussed in detail later.
The energy barrier to rotation was calculated experimentally by 1H-NMR (∆G    ) and
theoretically by DFT (∆G       ). The DFT results correlate well with the experimental
results, with the PBE1PBE basis set performing the best, see summary in Table 3.12.
The PBE1PBE functional has been shown to predict hydrogen bond energies well.42
Table 3.12. Summary of the values obtained for the free energy of activation of cis-
[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2) from variable
temperature 1H-NMR experiments (∆       ) and DFT (∆          ).
∆G       (kJ mol-1) a ∆G    (kJ mol-1)
[Ru(bpy)2(NA)Cl]+ (1)
Conf. 1 50.17
51.6 ± 0.2
Conf. 2 40.59
[Ru(bpy)2(NA)I]+ (2)
Conf. 1 45.53
47.7 ± 0.3
Conf. 2 37.45
a only PBE1PBE/LanL2DZ/6-31G**+ and Conf. 1/2 – TS1 values are shown.
Both show that the free energy of activation is greater for 1 when compared to 2. This
can be attributed to the greater acceptor ability of Cl when compared to I, thus for 1
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the rotation of the NA ligand is more hindered. This is supported by the fact that the
NA ligand orientates itself closer to the halide in 1, as shown by the DFT geometry.
Similarly the Mulliken charge of the proton that is closest to the halide becomes more
positive, and greater positive charges are found in the case of 1. Interestingly both
DFT free energy of activation values and 1H-NMR show that Conf. 1 is more stable
than Conf. 2, which is shown with the ratio of each in acetone-d6 at 298 K (1 for Conf.
1 and 0.8 for Conf. 2). This can be attributed to the fact that in the free ligand, H10 has
a more positive Mulliken charge than H9 due to an intramolecular interaction between
H10 and the oxygen of the amide, see Figure 3.26. The orientation is supported by the
DFT geometry. Therefore it will be unfavourable for H10 to hydrogen bond with the
halide, thus rendering Conf. 2 unfavourable (with H10 in close proximity to the halide).
Figure 3.26. Structures of the atropisomers of cis-[Ru(bpy)2(NA)Cl][PF6] (1) and
[Ru(bpy)2(NA)I][PF6] (2).
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To confirm that the interaction can be classed as hydrogen bonding, the bond length
of CH···X from the DFT geometries were compared to literature hydrogen bonding
values, see Table 3.13.
Table 3.13. CH···X bond distances from geometry optimised DFT structures of cis-
[Ru(bpy)2(NA)Cl]+ (1) and cis-[Ru(bpy)2(NA)I]+ (2) and literature.
CH···X Bond distance (Å)
[Ru(bpy)2(NA)Cl]+ (1)
Conf. 1 2.44a
Conf. 2 2.53a
[Ru(bpy)2(NA)I]+ (2)
Conf. 1 2.86a
Conf. 2 2.97a
Literature
C-H···Cl 2.77 ± 0.15b
C-H···I 3.14 ± 0.16b
a PBE1PBE/LanL2DZ/6-31G**+ and b values taken from43
Interestingly the bond distances found for 1 and 2 are shorter than those found in
literature for CH···X, where the CH is part of an aryl moiety, suggesting that the
interaction is indeed hydrogen bonding in nature.
3.5. Summary
In this Chapter two sets of novel photoactive antibacterial compounds were
synthesised; a) Ru(II) polypyridyl bis-substituted complexes cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7), and b) Ru(II)
polypyridyl halide complexes cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-
[Ru(bpy)2(NA)I][PF6] (2) where bpy is 2,2'-bipyridine, phen is 1,10-phenanthroline,
NA is nicotinamide and INH is isoniazid. In the dark, complexes 4 – 7 are stable in
aqueous solution, allowing further photoactive-studies to be carried out. Cis-
[Ru(bpy)2(NA)Cl][PF6] (1) was shown to hydrolyse in aqueous solution, forming the
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mono-aqua adduct cis-[Ru(bpy)2(NA)(H2O)]2+, which could bind to biomolecules
such as proteins or DNA. If 1 is in the presence of either 5% DMSO, 5% DMF or 5%
acetone the hydrolysis is complicated by the addition of the organic solvent to the
complex; for example in the case of 5% DMSO cis-[Ru(bpy)2(NA)(DMSO)]2+ is
formed. The intra- and intermolecular interactions of all complexes have been
investigated by the use of X-ray crystallography, 1H-NMR spectroscopy and DFT
calculations. From X-ray crystallography there was an extensive array of
intermolecular interactions for 4, 5 and 6, which include CH-π interactions, π-π 
interactions and hydrogen bonding. Such interactions may be important in
biomolecule recognition and binding. 1H-NMR has shown that for cis-
[Ru(bpy)2(NA)2][PF6]2 (5) the NA ligand is rotating freely at 298 K on the NMR
timescale (500 MHz), however complexes cis-[Ru(bpy)2(NA)Cl][PF6] (1) and cis-
[Ru(bpy)2(NA)I][PF6] (2) observe hindered rotation of L at the same temperature.
Both 1H-NMR spectroscopy and DFT calculations have shown that this hindered
rotation is due to hydrogen bonding between the NA protons closest to the nitrogen of
the pyridine ring and the halide. Interestingly Cl hinders rotation more than I, which
corresponds to hydrogen bonding ability. This has implications that if a biomolecule
(BM) binds to form cis-[Ru(bpy)2(L)(BM)]2+ and has a lone pair available for
donation, the rotation of ligand L will be hindered, which may potentially affect the
way the biomolecule binds.
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Chapter 4
Photochemical and photophysical properties of Ru(II)
polypyridyl complexes
4.1. Introduction
The photochemistry of complexes of the type [Ru(bpy)2(L)2]2+ and [Ru(bpy)3]2+,
where bpy is 2,2'-bipyridine and L is a pyridine / amine / nitrile based ligand, has been
widely studied and generally involves the following mechanism: a) initial
photoexcitation to form a singlet metal-to-ligand charge transfer state (1MLCT), b)
efficient intersystem crossing (ISC) to the triplet metal-to-ligand charge transfer state
(3MLCT), c) internal conversion (IC) to the triplet metal-centred state (3MC), if
accessible, which is a highly dissociative state that causes bond breakage, or d) if the
3MC state is not accessible from the 3MLCT state, deactivation to the ground state will
occur either with the emission of light (luminescence) or by non-radiative decay.1-3 If
photorelease of ligands occurs in aqueous solution it will do so via the following:
[Ru(bpy)2(L)2]2+
   
→ [Ru(bpy)2(L)(H2O)]2+ + L
   
→ [Ru(bpy)2(H2O)2]2+ + L
It is important to note that MLCT refers to a transfer of charge from the metal to the
chelating ligand, bpy. The accessibility of the 3MC state is important, for example, in
the design of photoreleasing Ru(II) polypyridyl prodrugs and the efficiency of Ru(II)
polypyridyl dye-sensitised solar cells (DSSC).4-6 In the former it is desirable to have a
thermally accessible 3MC state in order to aid photorelease of bioactive ligands,
whereas in the latter case the 3MC state should be thermally inaccessible in order to
avoid ligand loss. The energy level of the 3MLCT and 3MC states can be altered by
changing the ligands around the Ru(II) centre. For [Ru(NH3)5(py-X)]2+, where py-X
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is a substituted pyridine, more electron-withdrawing groups lower the 3MLCT(Ru-py-X)
state which renders the complex unreactive to photosubstitution, while less electron-
withdrawing groups result in an easily accessible 3MC state and render the complex
reactive to photosubstitution.7 Similarly in the case of [Ru(N-N')3]2+, where N-N' is
2,2'-bipyridine or 2,2'-bipyridine-4,4'-dicarboxylic acid, the more electron
withdrawing ligands decrease the energy of the 3MLCT state.8
This chapter focuses on exploring the photophysical/photochemical properties of cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7), where bpy is 2,2'-
bipyridine, phen is 1,10-phenanthroline, NA is nicotinamide and INH is isoniazid, by
utilising experimental and theoretical techniques. Experimentally their
photochemistry was investigated by UV-visible spectroscopy, fluorescence
spectroscopy, liquid chromatography, mass spectrometry and transient-absorption
spectroscopy. Density functional theory (DFT) and time-dependent density functional
theory (TD-DFT) were used to rationalise theoretically how the ligands in a complex
affect the photophysical/photochemical processes involved.
4.2. Experimental
4.2.1. Materials
The synthesis of complexes cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) studied in this
chapter is described in Chapter 3. The solvent used for UV-visible absorption
spectroscopy was deionised water. The NMR spectroscopy solvent acetonitrile-d3 was
purchased from Cambridge Isotope Laboritories Inc. All solutions of complexes were
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kept in the dark. A description of the photoirradiation setups can be found in Chapter
2.
4.2.2. Photoirradiation followed by UV-visible absorption spectroscopy
The general procedure used in this section is detailed below. Any differences are noted
in the appropriate section. Ru(II) polypyridyl complexes 1, 4, 5, 6 and 7 were dissolved
in deionised water to give a complex concentration of 40 µM. The solution (600 µL)
was placed into a 1 cm path length quartz cuvette and photoirradiated using a blue
LED (λirr = 463 nm, 50 mW cm-2) at 298 K for various times. The UV-visible spectrum
of each sample was recorded on a Cary 300-Scan spectrophotometer. The absorbance
over the range 200 – 800 nm was recorded at 298 K. The data were processed using
OriginPro 9.1 and, where applicable, plots of change in absorbance versus time were
fitted to the exponential equation A = A0 + CeRt (where A is absorbance, t is time and
C, A0 and R are calculated parameters) to give the half-life of formation (t1/2). The
student’s t-test was performed to determine if the t1/2 values were statistically different
(p value ≤ 0.01). The structures of the photoproducts were confirmed by ESI-MS. 
4.2.2.1. Wavelength dependence
Aqueous solutions of cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-
[Ru(phen)2(INH)2][PF6]2 (7) were photoirradiated using the KiloArcTM light source at
different wavelengths (λirr = 440 nm, 465 nm, 500 nm, 560 nm, 610 nm) at 298 K for
various times. See Chapter 2 for the power of each wavelength. The half-life of
formation (t1/2) at each wavelength of photoirradiation was determined.
4.2.2.2. Stability of photoproducts
An aqueous solution of cis-[Ru(bpy)2(INH)2][PF6]2 (4) was photoirradiated for
various times (50 s, 1 h and 1 h 30 min) and kept in the dark for 1 hour to investigate
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the stability of the photoproducts. The UV-visible spectrum of each sample was
recorded on a Cary 300-Scan spectrophotometer over the range of 200 – 800 nm at
298 K.
4.2.3. Photoirradiation followed by LC-HRMS
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was dissolved in deionised water to give
a complex concentration of 40 µM. The solution (600 µL) was placed into a 1 cm path-
length quartz cuvette and irradiated using a blue LED (λirr = 463 nm, 50 mW cm-2) at
298 K for various times. The sample was diluted with deionised water and injected
into the LC-HRMS instrument. Details of the LC-HRMS setup can be found in
Chapter 2.
4.2.4. Power dependence followed by LC-MS
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was dissolved in deionised water to give
a complex concentration of 40 µM. Two aliquots of the sample were treated using two
different methods of photoirradiation; a) 600 µL was added to a 1 cm path length
quartz cuvette and photoirradiated using a blue LED (λirr = 463 nm, 50 mW cm-2) at
298 K for 3 hours, and b) 200 µL was added to a black 96-well plate and
photoirradiated using the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) at 298 K for
3 hours. Each sample was diluted with deionised water and injected into the LC-MS
instrument. Details of the LC-MS setup can be found in Chapter 2.
4.2.5. Photoirradiation using 96-array blue LED followed by HPLC
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was dissolved in deionised water to give
a complex concentration of 40 µM. An aliquot (200 µL) was added to a black 96-well
plate and photoirradiated using the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) at
298 K for various times. After each time point the solution was diluted with deionised
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water and injected into the HPLC instrument. Details of the HPLC setup can be found
in Chapter 2.
4.2.6. Photoirradiation followed by 1H-NMR spectroscopy
The chlorido complex cis-[Ru(bpy)2(NA)Cl][PF6] (1) was dissolved in acetonitrile-d3
to give a complex concentration of ~ 6 mM and placed in a 5 mm o.d. NMR tube. The
sample was photoirradiated using a blue LED (λirr = 463 nm, 50 mW cm-2) at 298 K
for various times. The 1H-NMR spectrum of each sample was recorded on a Bruker
AV-400 spectrometer at 298 K. All data processing was carried out using Bruker
Topspin 2.1. The sample was diluted with acetonitrile and the structure of the
photoirradiation products were confirmed by HR-MS, see Chapter 2 for details of the
instrumentation.
4.2.7. Emission properties
Complexes 4, 5, 6 and 7 were dissolved in deionised water to give a complex
concentration of 40 µM. The solution (3 mL) was placed into a 1 cm path length quartz
cuvette and the emission was measured on a Jasco FP-6500 fluorometer at 298 K using
an excitation wavelength of 450 nm; the excitation and the emission slit widths were
5 nm; response time was 1 second; sensitivity was high; scan rate was 200 nm min-1.
4.2.8. Computational analysis
The starting geometry of complexes 4, 5 and 6 was adapted from their corresponding
crystal structures discussed in Chapter 3, while complex 7 was adapted from the
crystal structure of 5. All calculations were performed using Gaussian 03.9 Becke’s
three-parameter hybrid functional10 with the Lee-Yang-Parr’s gradient-corrected
correlation functional11 (B3LYP) was used with LanL2DZ basis set12 and effective
core potential for the ruthenium atom, and the split valence 6-31G** basis set13-14 for
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all other atoms. Geometry optimisations of the ground state (S0) and the lowest-lying
triplet state (T1) were performed in the gas phase and the nature of all stationary points
was confirmed by normal mode analysis. For the lowest-lying triplet states, the
unrestricted Kohn-Sham method (UKS) was utilised with unrestricted B3LYP
functional (UB3LYP). The electronic structure and excited states in solution were
calculated using the conductor-like polarisable continuum model method15-17 (CPCM)
with water as the solvent. Fifty singlet excited states (with corresponding oscillator
strengths) and sixteen triplet excited states (starting from the lowest-lying triplet state
geometry) were calculated by time-dependent density functional theory (TD-DFT).18-
19 The electronic distribution and localisation of the excited states were visualised
using electron density difference maps (EDDMs).20 GaussSum1.021 was used for the
simulation of the electronic absorption spectrum and calculation of the EDDMs.
4.2.9. Transient-absorption spectroscopy
Transient-absorption spectroscopy experiments were performed by Dr Simon E.
Greenough from Chemistry Department at University of Warwick, and have been
published.22 See Chapter 2 for the set-up of the transient-absorption spectroscopy
system. The complex cis-[Ru(bpy)2(NA)2][PF6]2 (4) in aqueous solution (890 µM)
was flowed through a 1 mm path length quartz cuvette and photoirradiated at 340 nm
using a 650 µW pump laser pulse.
4.3. Results
4.3.1. Photoirradiation followed by UV-visible spectroscopy
When aqueous solutions (40 µM) of cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) were exposed to blue
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light (λirr = 463 nm, 50 mW cm-2) at 298 K for < 1 min, there were changes in their
UV-visible spectra, see Figure 4.1. For 1, there was a blue shift in the absorption band
whereby the peak at 474 nm decreased in intensity and the peak at 466 nm increased,
producing isosbestic points at 471 nm, 406 nm and 337 nm. For 4, 5, 6 and 7 there was
a red shift of the absorption band whereby the peak at ~ 420 nm decreased and the
peak at ~ 460 nm increased, producing an isosbestic point at ~ 450 nm. The presence
of an isosbestic point suggests that a stoichiometric reaction is occurring. For all
complexes, in < 1 min the production of the photoproduct reaches a plateau, see Figure
4.1. The identity of the photoproducts was confirmed by ESI-MS, see Table 4.1.
Figure 4.1. UV-visible spectra (left) of aqueous solutions (40 µM) of cis-
[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(INH)2][PF6]2 (4) photoirradiated using
blue light (λirr = 463 nm, 50 mW cm-2) at 298 K with kinetic traces of increase of the
photoproduct (right).
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Figure 4.1. (Continued). UV-visible spectra (left) of aqueous solutions (40 µM) of
cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) photoirradiated using blue light (λirr = 463 nm, 50 mW
cm-2) at 298 K with kinetic traces of increase of the photoproduct (right).
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Table 4.1. Photoirradiation products detected by ESI-MS when aqueous solutions (40
µM) of cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) were photoirradiated using blue light (λirr = 463 nm, 50
mW cm-2) at 298 K.
Complex
ESI-MS product
mass, m/z
Calculated formula and mass of
product, m/z
1 553.2
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
4 568.0
[[Ru(bpy)2(INH)(H2O)]2+-H]+
C26H24N7O2Ru: 568.1
5 553.0
[[Ru(bpy)2(NA)(H2O)]2+-H]+
C26H23N6O2Ru: 553.1
6 616.2
[[Ru(phen)2(INH)(H2O)]2+-H]+
C30H24N7O2Ru: 616.1
7 601.0
[[Ru(phen)2(NA)(H2O)]2+-H]+
C30H23N6O2Ru: 601.1
Table 4.2. Half-life of formation of photoproducts (t1/2) obtained when aqueous
solutions (40 µM) of cis-[Ru(bpy)2(NA)Cl][PF6] (1), cis-[Ru(bpy)2(INH)2][PF6]2 (4),
cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) were photoirradiated using blue light (λirr = 463 nm, 50
mW cm-2) at 298 K.
Complex t1/2 (s)
1 3.8
4 8.4 ± 0.7
5 6.4 ± 0.4
6 5.7 ± 0.6
7 4.4 ± 0.3
Interestingly in the case of 1 the photoproduct is cis-[Ru(bpy)2(NA)(H2O)]2+,
confirming the release of the Cl ligand. For 4, 5, 6 and 7 the photoproducts were cis-
[Ru(N-N')2(L)(H2O)]2+, where N-N' is 2,2'-bipyridine (bpy) or 1,10-phenanthroline
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(phen) and L is isoniazid (INH) or nicotinamide (NA), confirming the release of one
ligand (L). The half-lives for formation (t1/2) of the photoproduct were compared in
order to ascertain a structure-activity relationship, see Table 4.2. When following the
increase of the cis-[Ru(N-N')2(L)(H2O)]2+ peak at ~ 460 nm for all complexes, a single
exponential relationship was observed which was fitted in order to obtain the t1/2 value.
Complex 1 photolysed at the fastest rate. Complexes that contain 1,10-phenanthroline
(phen) photolysed faster than complexes containing 2,2'-bipyridine (bpy) when they
contain the same monodentate ligand, photolysis rate of cis-[Ru(phen)2(INH)2][PF6]2
(6) > cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(NA)2][PF6]2 (7) > cis-
[Ru(bpy)2(NA)2][PF6]2 (5). Complexes that contain nicotinamide (NA) photolysed
faster than complexes that contain isoniazid (INH) when they contain the same
chelating ligand, photolysis rate of cis-[Ru(bpy)2(NA)2][PF6]2 (5) > cis-
[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(NA)2][PF6]2 (7) > cis-
[Ru(phen)2(INH)2][PF6]2 (6). Thus the general order of rate of photolysis is 1 > 7 > 6
~ 5 > 4.
4.3.1.1. Wavelength dependence
Both complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (7)
exhibited wavelength-dependent behaviour, see Figure 4.2. When both complexes in
aqueous solution (40 µM) were exposed to green light (λirr = 500 nm) at 298 K, the t1/2
value was < 50 s. However upon exposure to near yellow light (λirr = 560 nm) the t1/2
value increased significantly to 435 s and 476 s for 4 and 7, respectively. When
photoirradiated with red light (λirr = 610 nm) there is no photoactivity. As a result for
both complexes there was an inverse relationship between t1/2 and extinction
coefficient in the range of 440 nm - 560 nm; as the wavelength of photoirradiation
increased, the extinction coefficient decreased and the photoactivity decreased.
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Figure 4.2. Relationship between half-life of photoproduct formation (t1/2) and
extinction coefficient for cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-
[Ru(phen)2(INH)2][PF6]2 (7) when photoirradiated using various wavelengths of
photoactivation.
4.3.1.2. Stability of photoproducts
The stability of cis-[Ru(bpy)2(INH)2][PF6]2 (4) in aqueous solution (40 µM) at 298 K
was investigated by irradiating the sample with blue light (λirr = 463 nm, 50 mW cm-
2) for various times, and storing the resulting solution in the dark for 1 h. Changes in
the UV-visible spectrum were monitored, see Figure 4.3. At all photoirradiation times
(50 s, 30 min and 1 h 30 min) the photoproducts appeared to be stable in solution, as
there were no changes in the UV- visible spectrum after 1 h of incubation in the dark
at 298 K.
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Figure 4.3. Change in UV-visible spectrum of cis-[Ru(bpy)2(INH)2][PF6]2 (4) when
photoirradiated with blue light (λirr = 463 nm, 50 mW cm-2) for various times at 298
K and subsequently incubated in the dark for 1 h.
4.3.2. Photoirradiation followed by LC-HRMS
In order to fully characterise the photoirradiation products at photoirradiation times >
1 min, liquid chromatography coupled to a high resolution mass spectrometer (LC-
HRMS) was employed. An aqueous solution (40 µM) of cis-[Ru(bpy)2(INH)2][PF6]2
(4) was photoirradiated with blue light (λirr = 463 nm, 50 mW cm-2) at 298 K for 50 s
and 2 h 20 min. The chromatogram at each time point of photoirradiation and
corresponding high resolution mass of each product for each peak can be found in
Figure 4.4 and Table 4.3, respectively.
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Figure 4.4. HR-LCMS chromatograms of cis-[Ru(bpy)2(INH)2][PF6]2 (4) when
photoirradiated with blue light (λirr = 463 nm, 50 mW cm-2) at 298 K for various times.
Peak A (cis-[Ru(bpy)2(INH)2]2+), B (cis-[Ru(bpy)2(INH)(H2O)]2+), C (INH), D
([Ru(bpy)2(H2O)2]2+) and E ([Ru(bpy)2(H2O)(OH)]2+) are assigned, see text.
With no photoirradiation, there was only one peak in the chromatogram (peak A) with
a retention time of 1.4 min, which corresponds to the starting material cis-
[Ru(bpy)2(INH)2]2+ (4). After 50 s of photoirradiation, peak A was no longer present
and there were two new peaks at 1.9 min (peak B) and 1.3 min (peak C), which
correspond to cis-[Ru(bpy)2(INH)(H2O)]2+ and INH respectively. After 2 h 20 min of
photoirradiation there were two new peaks at 2.3 min (peak D) and 1.2 min (peak E),
which correspond to [Ru(bpy)2(H2O)2]2+ and [Ru(bpy)2(H2O)(OH)]2+, respectively.
At this time point of photoirradiation, peak B and peak C were still present, however
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peak B decreased in intensity and peak C increased in intensity. For peaks A, B and D
the mass-to-charge ratio and isotopic models obtained were consistent with the
formation of ruthenium(II) species. However for peak E, the mass-to-charge ratio and
isotopic models were consistent with the formation of a ruthenium(III) species, see
Figure 4.5.
Table 4.3. Photoirradiation products detected by HR-MS for each peak in the LC-
HRMS chromatograms in Figure 4.4.
Peak
Retention
time (min)
HR-MS product
mass (m/z)
Calculated formula and mass
of product (m/z)
Error
(ppm)
A 1.4 344.0794
cis-[RuII(bpy)2(INH)2]2+
C32H30N10O2Ru: 344.0797
0.87
B 1.9 284.5553
cis-[RuII(bpy)2(INH)(H2O)]2+
C26H25N7O2Ru: 284.5555
0.70
C 1.3 138.0663
[INH+H]+
C6H7N3O: 138.0662
0.72
D 2.3 225.0306
[RuII(bpy)2(H2O)2]2+
C20H20N4O2Ru: 225.0312
2.67
E 1.2 224.5273
[[RuIII(bpy)2(H2O)2]3+-H]2+
C20H19N4O2Ru: 224.5273
0
At this point it is worth noting that the starting material, cis-[Ru(bpy)2(INH)2]2+ has a
cis geometry, however from the experiments above the geometry of the
photoirradiation products [Ru(bpy)2(H2O)2]2+ and [Ru(bpy)2(H2O)(OH)]2+ cannot be
confirmed.
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Figure 4.5. Experimental and calculated HR-MS peak for the photoproduct cis-
[Ru(bpy)2(H2O)(OH)]2+.
4.3.3. Power dependence followed by LC-MS
In order to investigate the effect of power on the photochemical pathways for cis-
[Ru(bpy)2(INH)2][PF6]2 (4), two blue light sources were employed (λirr = 463 nm, 50
mW cm-2 and λirr = 465 nm, 20 mW cm-2). Two aliquots of an aqueous solution of 4
(40 µM) were photoirradiated with each light source for 3 h and the samples were
analysed by LC-MS, see Figure 4.6. Interestingly for the sample that was
photoirradiated with the 20 mW cm-2 light source, there was one additional peak (peak
F) at a retention time of 6.6 min that was not observed for the sample photoirradiated
with the 50 mW cm-2 light source.
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Figure 4.6. LC-MS chromatograms of cis-[Ru(bpy)2(INH)2][PF6]2 (4) in aqueous
solution (40 μM) after photoirradiation with blue light; λirr = 463 nm, 50 mW cm-2
(bottom) and λirr = 465 nm, 20 mW cm-2 (top) for 3 h at 298 K for various times. Peak
B (cis-[Ru(bpy)2(INH)(H2O)]2+), C (INH), D1, D2 and D3 (collectively assigned to
originate from cis-[Ru(bpy)2(H2O)2]2+), E (trans-[Ru(bpy)2(H2O)(OH)]2+) and F
(trans-[Ru(bpy)2(H2O)2]2+) are assigned, see text.
The product mass was obtained from mass spectra of each peak to confirm the identity
of the photoproducts, see Table 4.4. The characterisation data for peak B, C and E
agree with those obtained in Section 4.3.2. There are three peaks close together at a
retention time of ~9 min (D1, D2 and D3), however the mass spectrum of each only
differs by the intensity of the product m/z peaks. It is thought that collectively peak
D1, D2 and D3 originates from cis-[Ru(bpy)2(H2O)2]2+ and three chromatographic
peaks are present due to the formation of adducts with the HPLC mobile phase
(H2O/acetonitrile/trifluoroacetic acid).
Chapter 4
____________________________________________________________________
131
Table 4.4. Photoirradiation products detected by MS for each peak in the LC-MS
chromatograms in Figure 4.6.
Peak label
Retention
time (min)
ESI-MS
product mass
(m/z)
Calculated formula and mass of
product (m/z)
B 8.2 568.0
cis-[[RuII(bpy)2(INH)(H2O)]2+-H]+
C26H24N7O2Ru: 568.1
C 3.1 137.9
[INH+H]+
C6H7N3O: 138.1
D1, D2, D3 9-10
448.9
cis-[[RuII(bpy)2(H2O)2]2+-H]+
C20H19N4O2Ru: 449.1
526.9
cis-[[RuII(bpy)2(TFA)]2+-H]+
C22H16F3N4O2Ru: 527.0
471.9
cis-[[RuII(bpy)2(ACN)(H2O)]2+-H]+
C22H20N5ORu: 472.1
E 4.1 447.9
trans-[[RuIII(bpy)2(H2O)(OH)]2+-H]+
C20H18N4O2Ru: 448.1
F 6.6 447.9
trans-[[RuIII(bpy)2(H2O)(OH)]2+-H]+
C20H18N4O2Ru: 448.1
The UV-spectra of peaks D, E and F were very distinctive; peak D had an absorption
band at 474 nm, peak F had an absorption band at 505 nm and peak E had no
absorption band in the region of 400-600 nm, see Figure 4.7. These features are
characteristic of cis-[Ru(bpy)2(H2O)2]2+, trans-[Ru(bpy)2(H2O)2]2+ and trans-
[Ru(bpy)2(H2O)(OH)]2+ respectively, and these spectral properties are comparable to
those in the literature.23-24 Thus is it apparent that with a lower power of blue light
trans-[Ru(bpy)2(H2O)2]2+ (peak F) was present as a photoproduct, however when
using a higher power of light, it was absent. It is worth noting that peak F is assigned
to trans-[Ru(bpy)2(H2O)2]2+, however in the mass spectrum it was found as trans-
[Ru(bpy)2(H2O)(OH)]2+. This could be due to the higher susceptibility of trans-
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[Ru(bpy)2(H2O)2]2+ to air oxidation (which will be discussed later in this chapter) and
oxidation may occur during the ESI-MS process.25-26
Figure 4.7. UV-visible spectra of peaks D (red), E (blue) and F (black) from LC-MS
chromatograms in Figure 4.6.
The percentage of each peak was calculated by comparing peak area with sum of all
peak areas (ignoring peak C as this is before the solvent front), see Table 4.5. When
comparing 20 mW cm-2 to 50 mW cm-2, peak B and E increased in intensity while
peak D remained constant.
Table 4.5. Percentage (%) area of each peak in the LC-MS chromatograms in Figure
4.6.
Percentage area (%)
Peak 20 mW cm-2 50 mW cm-2
B 13 17
D1, D2 and D3 71 71
E 10 12
F 6 0
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4.3.4. Photoirradiation using 96-array blue LED followed by HPLC
It was important to photoirradiate a solution (40 µM) of cis-[Ru(bpy)2(INH)2][PF6]2
(4) using similar conditions as those used for biological cells. The 96-array blue LED
(λirr = 465 nm, 20 mW cm-2) was used to photoirradiate a sample of 1 (200 µL) in a
black 96 well-plate for various times. Each sample was analysed by HPLC, see Figure
4.8.
Figure 4.8. HPLC chromatograms of cis-[Ru(bpy)2(INH)2][PF2]2 (4) in aqueous
solution (40 μM) photoirradiated with 96-array blue LED (λirr = 465 nm, 20 mW cm-
2) at 298 K for various times. Peak assignments are the same as those in Figure 4.6.
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Interestingly even though the power of the light source has been reduced, after 1 min
of photoirradiation the starting material (peak A) cis-[Ru(bpy)2(INH)2]2+ had almost
disappeared with the almost exclusive production of cis-[Ru(bpy)2(INH)(H2O)]2+
(peak B) and INH (peak C). With increased time of photoirradiation, peak B
decreased, however 1-2 h photoirradiation was necessary to gain an appreciable yield
of photoproduct [Ru(bpy)2(H2O)2]2+ (peak D and F). Interestingly trans-
[Ru(bpy)2(H2O)(OH)]2+ (peak E) is produced after 1 h photoirradiation.
4.3.5. Photoirradiation followed by 1H-NMR
An acetonitrile-d3 (ACN-d3) solution (6 mM) of cis-[Ru(bpy)2(NA)Cl][PF6] (1) was
photoirradiated with blue light (λirr = 463 nm, 50 mW cm-2) for 2 h 20 min at 298 K,
with the 1H-NMR recorded before and after photoirradiation, see Figure 4.9. Prior to
photoirradiation, the 1H-NMR spectrum exhibited 20 aromatic peaks attributed to the
starting material cis-[Ru(bpy)2(NA)Cl]+. After photoirradiating the sample for 2 h 20
min, there were two new sets of peaks. The first set contains 16 aromatic peaks
attributed to cis-[Ru(bpy)2(ACN-d6)(Cl)]+. The second set contains 4 aromatic peaks
attributed to free NA in solution. There was a third minor set which consisted of 4
peaks attributed to trans-[Ru(bpy)2(ACN-d6)(Cl)]+. The identity of the
photoirradiation product was confirmed by HR-MS (after diluting the sample with
acetonitrile), see Table 4.6.
Chapter 4
____________________________________________________________________
135
Figure 4.9. 1H-NMR spectrum of cis-[Ru(bpy)2(NA)Cl][PF6] (1) in acetonitrile-d3
photoirradiated with blue light (λirr = 463 nm, 50 mW cm-2) at 298 K for various times.
A schematic of the photoreaction is also shown (top).
A wide variety of fragment ions were seen by MS that confirm the NA ligand was
released leaving the chloride ligand bound to the ruthenium(II) centre. The mass-to-
charge ratio and isotopic models obtained were consistent with the formation of
[Ru(bpy)2(ACN-d6)Cl]+, see Figure 4.10.
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Table 4.6. Photoirradiation products detected by HR-MS for cis-
[Ru(bpy)2(NA)Cl][PF6] (1) in acetonitrile-d3 photoirradiated with blue light (λirr = 463
nm, 50 mW cm-2) at 298 K for 2 h 20 min.
HR-MS product
mass (m/z)
Calculated formula and mass of
product (m/z)
Error (ppm)
449.0108
[[Ru(bpy)2Cl]+
C20H16ClN4Ru: 449.0103
1.11
467.0205
[[Ru(bpy)2(H2O)Cl]+
C20H18ClN4ORu: 467.0209
0.86
490.0393
[[Ru(bpy)2(ACN)Cl]+
C22H19ClN5Ru: 490.0369
4.90
493.0543
[[Ru(bpy)2(ACN-d3)Cl]+
C22H16D3ClN5Ru: 493.0558
3.04
Figure 4.10. Experimental and calculated HR-MS peak for the photoproducts
[Ru(bpy)2(ACN-d3)Cl]+ and [Ru(bpy)2(ACN)Cl]+.
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4.3.6. Emission properties
The emission properties of cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2
(5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) were
investigated by measuring their emission maximum (λem) in aqueous solution (40 µM)
using an excitation wavelength (λex) of 450 nm, see Figure 4.11
Figure 4.11. Emission spectra for cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) in aqueous solution (40 μM) with λex = 450 nm at 298 K.
All complexes exhibit a broad emission band with a maximum centred at ~580 nm,
see Table 4.7. The emission maxima for 4 and 5 are very similar, with a difference of
3 nm. Similarly the emission maxima for 6 and 7 only differ by 1 nm. When comparing
4 and 5 with 6 and 7, the emission maxima differ by only 4-8 nm.
560 580 600 620 640 660
0.0
0.2
0.4
0.6
0.8
1.0
N
or
m
al
iz
ed
In
te
ns
ity
(a
u)
Wavelength (nm)
cis-[Ru(bpy)2(INH)2][PF6]2 (4)
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Table 4.7. Emission maxima (λem) for cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) in aqueous solution with λex = 450 nm at 298 K.
Complex Emission maximum, λem (nm)
4 580
5 583
6 576
7 575
4.3.7. Computational analysis
Density functional theory (DFT) was employed to investigate the ground state (S0)
and lowest lying triplet state (T1) geometry of cis-[Ru(bpy)2(INH)2]2+ (4), cis-
[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and cis-[Ru(phen)2(NA)2]2+ (7).
Additionally the composition and nature of the molecular orbitals were explored.
Time-dependent density functional theory (TD-DFT) was employed to investigate the
singlet and triplet excited state transitions.
4.3.7.1. Ground state (S0) geometry
The optimised geometry of the ground state (S0) for 4, 5, 6 and 7 was calculated by
DFT in the gas phase, with the corresponding bond lengths shown in Table 4.8.
Nomenclature for the atoms is in Figure 4.12.
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Figure 4.12. Atom labels for cis-[Ru(N-N')2(L)2]2+, where N1, N2, N3 and N4 belong
to the chelating ligand (N-N'), and L5 and L6 belong to the monodentate ligand (L).
Table 4.8. Bond distances (Å) for the ground state (S0) geometry of cis-
[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7) in comparison to crystal structures determined in Chapter
3.
Bond distance (Å)
4 5 6 7
DFT X-Ray DFT X-Ray DFT X-Ray DFT
Ru-N1 2.127 2.066 2.130 2.068 2.136 2.090 2.141
Ru-N2 2.109 2.057 2.107 2.052 2.119 2.058 2.116
Ru-N3 2.109 2.057 2.107 2.052 2.118 2.058 2.115
Ru-N4 2.127 2.066 2.130 2.068 2.135 2.071 2.140
Ru-L5 2.177 2.101 2.174 2.108 2.169 2.088 2.167
Ru-L6 2.177 2.101 2.173 2.108 2.171 2.094 2.168
The calculated Ru-Nn/Ru-Ln bond distances for 4, 5 and 6 are very similar to those
obtained from the structures determined by X-ray crystallography (see Chapter 3)
and differ only by 0.05 Å - 0.08 Å. From the calculated bond distances all complexes
have very similar Ru-N / Ru-L bond distances, and only differ by < 0.07 Å.
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4.3.7.2. Ground state (S0) molecular orbitals
The composition of ground state (S0) molecular orbitals for complexes 4, 5, 6 and 7
are found in Figure 4.13, where L is either isoniazid (INH) or nicotinamide (NA) and
N-N' is either 2,2'-bipyridine (bpy) or 1,10-phenanthroline (phen), with images of the
frontier orbitals in Figure 4.14.
Figure 4.13. Molecular orbitals for the ground state (S0) geometry of cis-
[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7), where N-N' is the chelating ligand and L is the mondentate
ligand.
Interestingly the HOMO for cis-[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(INH)2]2+
(6) is delocalised over the hydrazide group of the monodentate ligand L (INH),
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whereas for cis-[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(NA)2]2+ (7) is delocalised
predominantly over the ruthenium centre (~ 80 %) with a contribution from the
bidentate ligand N-N' (~ 20 %). For 5 and 7, it is HOMO-3 that is delocalised over the
amide group of the monodentate ligand L (NA). The occupied L-centred orbitals of 4
and 6 (HOMO-3) are ~ 0.7 eV higher in energy than those for 5 and 7 (HOMO). The
energy difference between L-centred HOMO’s and metal-centred HOMO’s is very
small for 4 and 6 (< 0.15 eV), however for 5 and 7 is larger (~ 0.6 eV). The energy of
the metal-centred HOMO’s is very similar for all complexes, with a difference of <
0.3 eV.
For all complexes, the LUMO is delocalised over the bidentate ligand N-N' (> 90 %).
Interestingly for 4 and 5 there are two LUMO’s delocalised over the bidentate ligand
N-N' (LUMO and LUMO+1 at -7.5 eV for 4 and -7.3 eV for 5), whereas for 6 and 7
there are four LUMO’s (LUMO, LUMO+1, LUMO+2 and LUMO+3 between -7.1 eV
and -7.3 eV for 6 and -6.9 eV and -7.1 eV for 7). For all complexes, LUMO+10 and
LUMO+11 are delocalised predominantly over the metal centre (~ 70 %). Importantly
they show σ*-antibonding character towards the monedentate ligands L and bidentate
ligands N-N' (with either d    or d          character), see Figure 4.14.
The energy gap between metal centred HOMO’s and LUMO’s is very similar for all
complexes (~ 5.7 eV for the lowest energy gap). Similarly the energy gap between
metal-centred HOMO’s and bidentate ligand N-N'-centred LUMO’s is very similar for
all complexes (~ 3.7 eV).
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Figure 4.14. Frontier orbitals (HOMO and LUMO) and σ*-antibonding orbitals 
(LUMO+11 and LUMO+11) for the ground state geometry (S0) of cis-
[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7). Green and red indicate different phases of the orbitals.
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4.3.7.3. Lowest-lying triplet state (T1) geometry
The optimised geometry of the lowest lying triplet state (T1) for 4, 5, 6 and 7 was
calculated by DFT in the gas phase, with the corresponding bond lengths shown in
Table 4.9. Nomenclature for the atoms is in Figure 4.15.
Figure 4.15. Atom labels for cis-[Ru(N-N')2(L)2]2+, where N1, N2, N3 and N4 belong
to the chelating ligand (N-N'), and L5 and L6 belong to the monodentate ligand (L).
Table 4.9. Bond distances (Å) for the lowest-lying triplet state (T1) geometry of cis-
[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7).
Bond distance (Å)
4 5 6 7
Ru-N1 2.118 2.184 2.128 2.177
Ru-N2 2.062 2.404* 2.007 2.433*
Ru-N3 2.062 2.113 2.111 2.134
Ru-N4 2.118 2.115 2.153 2.123
Ru-L5 2.196 2.964* 2.224 2.925*
Ru-L6 2.196 2.170 2.162 2.161
* indicates where the T1 structure has deviated more than 0.3 Å from the
S0 geometry
Interestingly the lowest lying triplet state (T1) geometries for cis-[Ru(bpy)2(NA)2]2+
(5) and cis-[Ru(phen)2(NA)2]2+ (7) show major deviations in bond distances from the
ground singlet state (S0, see Table 4.8), whereas for cis-[Ru(bpy)2(INH)2]2+ (4) and
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cis-[Ru(phen)2(INH)2]2+ (6) the structures are very similar. In the case of 5 and 7, the
bond distances for Ru-N2 and Ru-L5 increased by 0.3 Å and 0.8 Å, respectively, to
give final bond distances of ~2.4 Å and ~2.9 Å. This can be seen to a great extent when
the ground singlet state geometry (S0) and the lowest lying triplet state geometry (T1)
are superimposed, see Figure 4.16. Interestingly, for 5 and 7 the Ru-L6 monodentate
ligand (NA) has rotated out of its plane by 19o, which can be clearly seen in Figure
4.16.
Figure 4.16. Superimposition of the ground state (S0) geometry (red) and lowest-lying
triplet state (T1) geometry (green) of cis-[Ru(bpy)2(INH)2]2+ (4) and cis-
[Ru(bpy)2(NA)2]2+ (5).
4.3.7.4. Lowest-lying triplet state (T1) molecular orbitals
The composition of lowest-lying triplet state (T1) molecular orbitals (l-SOMO and h-
SOMO) for complexes 4, 5, 6 and 7 as well as the spin density distribution for the state
are in Figure 4.17, where l-SOMO corresponds to the lowest singly-occupied
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molecular orbital and h-SOMO corresponds to the highest singly-occupied molecular
orbital.
Figure 4.17. Lowest-singly occupied orbitals (l-SOMO), highest-singly occupied
orbitals (h-SOMO) and spin density distribution of of the lowest-lying triplet state (T1)
of cis-[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6)
and cis-[Ru(phen)2(NA)2]2+ (7). Aqua and green indicate different phases of the
orbitals, while dark blue represents spin density.
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For all complexes the l-SOMO in centred on the monodentate ligand L; in the case of
INH it is centred mainly on the hydrazide group. Interestingly for cis-
[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(NA)2]2+ (7) the h-SOMO is mainly centred
on the metal and shows significant σ*-antibonding character (d    character) towards
one of the mondentate ligands L (NA) and one of the pyridine units of the bidentate
ligand N-N' trans to it. For cis-[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(NA)2]2+ (6)
the h-SOMO is based on the bidentate ligand N-N' and the metal centre. The spin
density distribution for 4 and 6 is mainly located over the bidentate ligands N-N' and
the metal centre, whereas for 5 and 7 is located on the metal centre. The spin density
distribution confirms that the nature of the lowest-lying triplet state (T1) for cis-
[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(INH)2]2+ (6) is 3MLCT in character and for
cis-[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(NA)2]2+ (7) is 3MC in character.
4.3.7.5. Absorption spectra and singlet excited states
The complexes 4, 5, 6 and 7 were dissolved in water and their UV-visible spectra were
recorded at 298 K giving the extinction coefficients listed in Table 4.10. The
absorption spectrum for each complex was compared to the singlet transitions
calculated by TD-DFT, see Figure 4.18 and Table 4.11. Selected electron density
distribution maps (EDDMs) for 5 can be found in Figure 4.19. These were utilised in
order to characterise each singlet transition.
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Table 4.10. Experimental extinction coefficients for cis-[Ru(bpy)2(INH)2][PF6]2 (4),
cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-[Ru(phen)2(INH)2][PF6]2 (6) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) in aqueous solution.
Complex Wavelength (nm) Extinction Coefficient (M-1 cm-1)
4
424 15900
375 17300
288 42300
5
442 12800
345 16300
287 44700
6
438 (sh) 13800
405 15500
264 58400
7
439 (sh) 11300
408 13300
264 58400
Figure 4.18. Experimental absorption spectra (red line, left axis) and TD-DFT
calculated vertical singlet transitions (black bars, right axis) for cis-
[Ru(bpy)2(INH)2]2+ (4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7) with water as the solvent.
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The experimental absorption spectrum and calculated singlet transitions are in
reasonable agreement. For all complexes the calculated transitions are blue-shifted
compared to the experimental absorption spectrum by 10 nm – 30 nm. For cis-
[Ru(bpy)2(INH)2]2+ (4), 1MLCT(Ru-bpy) and 1MLLCT(Ru/bpy-INH) TD-DFT predicted
bands were found at 401 nm (3.1 eV) and 364 nm (3.4 eV) respectively, which fits
well with the experimental bands at 424 nm and 375 nm, respectively. Similarly for
cis-[Ru(bpy)2(NA)2]2+ (5), 1MLCT(Ru-bpy) and 1MLCT(Ru-NA) TD-DFT predicted bands
were found at 410 nm (3.0 eV) and 334 nm (3.7 eV) respectively, which fits well with
the experimental bands at 442 nm and 334 nm. It is interesting to note that for 4 and 5
S1 to S6 have 1MLCT(Ru-bpy) character. For cis-[Ru(phen)2(INH)2]2+ (6) and cis-
[Ru(phen)2(NA)2]2+ (7), experimentally there is a broad band that extends over the
region of 340 nm – 500 nm (with a small shoulder at ~ 438 nm). This appears to be
due to the closely spaced and equal oscillator strength of 1MLCT(Ru-phen) and
1MLCT(Ru-INH) states. For complexes 6 and 7 the TD-DFT predicted 1MLCT(Ru-phen)
band has a transition with the largest oscillator strength at 405 nm (3.1 eV) and 407
nm (3.1 eV) respectively, which fits well with the experimental bands at 405 nm and
408 nm, respectively. It is interesting to note that for 6 and 7 S1 to S12 have 1MLCT(Ru-
phen) character.
For all complexes, the 1MC state can be found at 350 – 360 nm (3.5 eV). For 4 and 6,
the 1MC major contribution is from HOMO to LUMO+10 (which is σ*-antibonding
in character), and for 5 and 7 is from HOMO or H-2 to LUMO+11 (which again is σ*-
antibonding in character).
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Table 4.11. TD-DFT calculated vertical singlet transitions for cis-[Ru(bpy)2(INH)2]2+
(4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and cis-
[Ru(phen)2(NA)2]2+ (7).
Sn Energy (eV) f Major contribution Character
4
1 2.81 (441) 0.003 HOMO→LUMO (81%) MLCT(Ru-bpy)
3 2.91 (427) 0.004 H-1→LUMO (79%) MLCT(Ru-bpy)
5 3.05 (407) 0.092 H-2→L+1 (76%) MLCT(Ru-bpy)
6 3.09 (401) 0.100 H-2→LUMO (53%) MLCT(Ru-bpy)
11 3.41 (364) 0.161 H-2→L+2 (78%) MLLCT(Ru/bpy-INH)
12 3.50 (354) 0.013 HOMO→L+10 (55%) MC
15 3.62 (343) 0.084 H-2→L+3 (28%) MC/MLCT(Ru-INH)
45 4.47 (278) 0.364 HOMO→L+9 (37%) MLCT(Ru-INH)/LC(bpy)
5
1 2.81 (442) 0.003 HOMO→L+1 (70%) MLCT(Ru-bpy)
3 2.89 (429) 0.002 H-1→L+1 (75%) MLCT(Ru-bpy)
5 3.02 (410) 0.104 H-2→LUMO (70%) MLCT(Ru-bpy)
6 3.10 (400) 0.06 H-2→L+1 (51%) MLCT(Ru-bpy)
10 3.54 (351) 0.016 H-1→L+2 (51%) MC/MLLCT(Ru/bpy-NA)
11 3.54 (350) 0.001 H-2→L+11 (44%) MC
14 3.71 (334) 0.094 H-2→L+3 (82%) MLCT(Ru-NA)
42 4.48 (277) 0.5488 H-4→LUMO (31%) MLLCT(Ru/NA-bpy)/LC(bpy)
6
1 2.89 (430) 0.006 HOMO→LUMO (61%) MLCT(Ru-phen)
3 2.97 (418) 0.001 H-1→LUMO (55%) MLCT(Ru-phen)
5 3.06 (405) 0.086 H-2→L+1 (44%) MLCT(Ru-phen)
10 3.27 (379) 0.083 H-1→L+2 (31%) MLCT(Ru-phen)/MLCT(Ru-INH)
12 3.33 (373) 0.001 H-1→L+3 (66%) MLCT(Ru-phen)/MLCT(Ru-INH)
17 3.44 (360) 0.129 H-2→L+4 (48%) MLCT(Ru-INH)
18 3.48 (357) 0.027 HOMO→L+10 (43%) MC
7
1 2.87 (431) 0.017 HOMO→LUMO (84%) MLCT(Ru-phen)
3 2.95 (420) 0.001 H-1→L+1 (69%) MLCT(Ru-phen)
5 3.05 (407) 0.093 H-2→LUMO (57%) MLCT(Ru-phen)
7 3.22 (385) 0.089 HOMO→L+2 (57%) MLCT(Ru-phen)
12 3.35 (370) 0.037 H-2→L+3 (80%) MLCT(Ru-phen)
13 3.46 (359) 0.002 HOMO→L+11 (40%) MC
20 3.70 (335) 0.080 H-2→L+5 (79%) MLLCT(Ru/phen-NA)
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Figure 4.19. Selected electron density distribution maps (EDDMs) of singlet excited
state transitions for cis-[Ru(bpy)2(NA)2]2+ (5), where orange indicates an increase in
electron density while purple indicates a decrease in electron density.
4.3.7.6. Triplet excited states
The triplet transitions were calculated by TD-DFT for 4, 5 and 6 from the lowest-lying
triplet state geometry, see Table 4.12. Selected electron density distribution maps
(EDDMs) for 4 can be found in Figure 4.20. These were utilised in order to
characterise each triplet transition. The triplet transitions of 7 could not be obtained as
the calculation failed to optimise.
For cis-[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(INH)2]2+ (6) T1 is confirmed to be
of 3MLCT(Ru-bpy) and 3MLCT(Ru-phen) in character respectively, with both states at an
energy of 2.5 eV. In the case of cis-[Ru(bpy)2(NA)2]2+ (5) T1 is confirmed to be of
3MC character at an energy of 2.3 eV. For both 4 and 6 the 3MC state is much higher
in energy (3.4 eV) and the major contribution is HOMO-1 to LUMO+10 (which is σ*-
antibonding in character). Interestingly for 5 there is a mixing of 3MC/3MLCT(Ru-bpy)
at 3.1 eV, and a 3MC at higher energy (5 eV) with a major contribution from HOMO-
1 to LUMO+11 (σ*-antibonding in character).
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Table 4.12. TD-DFT calculated vertical triplet transitions for cis-[Ru(bpy)2(INH)2]2+
(4), cis-[Ru(bpy)2(NA)2]2+ (5), cis-[Ru(phen)2(INH)2]2+ (6) and cis-
[Ru(phen)2(NA)2]2+ (7).
Tn Energy (eV) f Major contribution Character
4
1 2.53 (491) 0 HOMO→L+1 (82%) MLCT(Ru-bpy)
2 2.57 (482) 0 HOMO→LUMO (86%) MLCT(Ru-bpy)
3 2.83 (438) 0 H-1→LUMO (84%) MLCT(Ru-bpy)
10 3.30 (375) 0 H-2→L+2 (50%) MLCT(Ru-INH)
13 3.39 (366) 0 H-1→L+10 (74%) MC
5
1 2.26 (549) 0 H-2→LUMO (91%) MC
2 3.14 (395) 0 H-1→LUMO (46%) MC / MLCT(Ru-bpy)
3 3.52 (353) 0 HOMO→LUMO (60%) MC / MLCT(Ru-bpy)
4 4.15 (299) 0 HOMO→L+2 (31%) MC / MLCT(Ru-bpy)
13 4.99 (248) 0 H-1→L+11 (32%) MC
6
1 2.47 (501) 0 HOMO→LUMO (87%) MLCT(Ru-phen)
2 2.87 (432) 0 H-1→LUMO (70%) MLCT(Ru-phen)
3 2.91 (425) 0 HOMO→L+1 (43%) MLCT(Ru-phen)
4 3.00 (414) 0 H-2→LUMO (88%) MLLCT(Ru/INH-phen)
10 3.37 (368) 0 H-1→L+10 (28%) MC
Figure 4.20. Selected electron density distribution maps (EDDMs) of triplet excited
state transitions for cis-[Ru(bpy)2(INH)2]2+ (4), where turquoise indicates an increase
in electron density while yellow indicates a decrease in electron density.
Chapter 4
____________________________________________________________________
152
4.3.8. Transient-absorption spectroscopy
The transient-absorption spectrum for cis-[Ru(bpy)2(NA)2][PF6]2 (5) in aqueous
solution is shown in Figure 4.21. At early pump-probe delays (< 25 ps, see Figure
4.21A) there was a ground state bleach (GSB) signal at 420 nm due to the promotion
of cis-[Ru(bpy)2(NA)2]2+ (5) to an excited state after absorption of a photon. At ~ 370
nm there is an absorption band attributed to the bpy- state of the 3MLCT that can be
formally represented as [RuIII(bpy)(bpy-)(NA)2]2+.27-28 There should also be an
absorption feature at ~ 450 nm – 550 nm attributed to the 3MLCT state, however this
is convoluted with the GSB. The broad absorption feature at > 550 nm can be
attributed to the cis-[Ru(bpy)2(NA)]2+ penta-coordinate intermediate (PCI).29
Interestingly this feature is present after only 0.5 ps pump-probe delay. Between 0.5
ps and 25 ps the 3MLCT absorption decreases and narrows, which can be attributed to
vibrational cooling of the 3MLCT state. This may also account for the decrease in the
GSB feature over this time frame, as the GSB feature is overlapped with 3MLCT
features. Additionally the PCI feature decreases over this time frame, attributable to
vibrational cooling of the PCI.
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Figure 4.21. UV-visible transient-absorption spectra of cis-[Ru(bpy)2(NA)2][PF6]2 (5)
in aqueous solution after early pump-probe delays, -1 ps to 25 ps (A), and longer
pump-probe delays, -1 ps to 1.2 ns (B). Features are 3MLCT excited state absorption
(i), ground state bleach of 5 (ii), absorption of the penta-coordinate intermediate (iii)
and absorption of the photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+ (iv).
At longer pump-probe delays (25 ps to 1.2 ns, see Figure 4.21B), the ground state
bleach recovers and the 3MLCT absorption feature decreases in intensity, with a quasi-
isosbestic point at ~ 390 nm. Similarly the absorption of the PCI at > 550 nm decreases
and a new absorption feature at 475 nm increases, attributable to the absorption of the
photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+, with a quasi-isosbestic point at ~ 490 nm.
Interestingly over this longer time period the ground state bleach never fully recovers
back to ΔA = 0, confirming that some of the molecules of 5 that were initially
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photoexcited never return to the ground state (i.e. form the photoproduct). In order to
calculate the timescales of the various photophysical/photochemical pathways, a
“target-analysis” approach was adopted using the KOALA spectral analysis package
that can decompose a transient-absorption spectrum into its individual components.30
The kinetic traces of the integrated area of each individual component over time can
be fitted to first/pseudo-first order kinetic equations to afford lifetimes, τ. The kinetic 
traces can be found in Figure 4.22, along with photochemical/photophysical pathways
for the photoexcitation of 5 in Figure 4.23 and lifetime values in Table 4.13.
Figure 4.22. Kinetic traces labelled from top to bottom: decay of the 3MLCT
absorption (dark blue), decay of the penta-coordinate intermediate (PCI) absorption
(green), growth of the photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+ absorption (light
blue) and recovery of the ground state bleach (orange).
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Figure 4.23. Photochemical/photophysical pathways following the photoexcitation of
cis-[Ru(bpy)2(NA)2]2+ (5).
Table 4.13. Lifetimes (τ) of the various photochemical/photophysical pathways of 
cis-[Ru(bpy)2(NA)2]2+ (5) obtained from the kinetic traces in Figure 4.22.
Process Lifetime Time (ps)
Vibrational transfer τVET 3.6
Ground state recovery τGSR 180
Dissociation τd 0.4
Germinate recombination τGR 263
Diffusional separation τs 377
Mono aquation τMA < 1
Intersystem crossing τISC < 0.1
It is worth noting that some assumptions have been made. Firstly, intersystem crossing
(ISC) is ultrafast and in the case of [Ru(bpy)3]2+ occurs in < 0.1 ps (τISC).12, 15 Secondly,
after dissociation of NA the PCI is termed to be ‘caged’ as the NA is in close proximity
where germinate recombination may occur (τGR), however after diffusional separation
of the NA and PCI (τs) the PCI is termed as ‘separated’ and a H2O molecule can bind
rapidly (τMA < 1 ps) to from photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+.
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4.4. Discussion
4.4.1. Effect of solvent on the photorelease
This chapter aims to investigate the structure-activity relationship between ligands in
Ru(II) polypyridyl complexes and the photoactivity of the complexes. However it is
notable that the photorelease was found to be solvent-dependent in the case of cis-
[Ru(bpy)2(NA)Cl][PF6] (1). When an aqueous solution of 1 (40 µM) was
photoirradiated using blue light (λirr = 463 nm, 50 mW cm-2), there were changes in
the UV-visible spectrum concurrent with the photorelease of a ligand in < 1 min of
photoirradiation, see Figure 4.1. The photoproduct was confirmed to be cis-
[Ru(bpy)2(NA)(H2O)]2+ by ESI-MS. This was unsurprising as the complex hydrolyses
(releasing Cl) in the dark (see Chapter 3) but at a much slower rate than the photolysis
(t1/2 of 2712 s for hydrolysis and 3.8 s for photolysis). Thus the photorelease of the Cl
as opposed to NA must be favoured due to the tendency of water to solvate Cl- well.
Conversely when 1 was photoirradiated in acetonitrile, changes in the 1H-NMR
spectrum (Figure 4.9) were consistent with the release of NA to produce
[Ru(bpy)2(Cl)(ACN)]+, with the photoproduct confirmed by HR-MS. This can be
attributed to poorer solvation of Cl- by acetonitrile compared to water, and therefore
its photorelease is less favourable. The effect of solvent on the photoactivation of
Ru(II) polypyridyl complexes was not investigated further, and the studies discussed
below were carried out in aqueous solution.
4.4.2. Assessment of structure-activity relationships
When cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) in aqueous solution
(40 µM) were photoirradiated using blue light (λirr = 463 nm, 50 mW cm-2), there were
changes in their UV-visible spectra concurrent with the photorelease of a ligand in <
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1 min, see Figure 4.1. The photoproducts were confirmed to be cis-[Ru(N-
N')2(L)(H2O)]2+ by ESI-MS, where N-N' is 2,2'-bipyridine (bpy) or 1,10-
phenanthroline and L is isoniazid (INH) or nicotinamide (NA). It is well known that
for complexes of the type [Ru(bpy)3]3+, the 1MLCT(Ru-bpy) band is commonly found at
~ 450 nm.2, 31 Interestingly the 1MLCT(Ru-bpy) band for cis-[Ru(bpy)2(NA)Cl]+ (1) is at
474 nm whereas for cis-[Ru(bpy)2(NA)(H2O)]2+ is at 466 nm. Therefore a blue shift
was observed by photoirradiating cis-[Ru(bpy)2(NA)Cl]+ (1) in aqueous solution. This
is due to H2O being a stronger field ligand than Cl, as a result the d-d energy gap (o)
increases and therefore the 1MLCT(Ru-bpy) will increase in energy. The opposite
relationship was found in the case of photoirradiating 4, 5, 6 and 7, where the
photoproduct was cis-[Ru(N-N’)2(L)(H2O)]2+. The 1MLCT(Ru-N-N’) band was found at
~ 420 nm for cis-[Ru(N-N’)2(L)2]2+ and ~ 460 nm for cis-[Ru(N-N’)2(L)(H2O)]2+. This
red shift is due to H2O being a weaker field ligand than L (which is pyridine based),
as a result the d-d energy gap (o) decreases and therefore 1MLCT decreases in energy.
The photoactivity of each complex was followed by UV-visible spectroscopy to give
the half-life of formation of mono-aqua species (t1/2). The order of photoactivity was
found to be cis-[Ru(phen)2(NA)2]2+ (7) > cis-[Ru(phen)2(INH)2]2+ (6) ~ cis-
[Ru(bpy)2(NA)2]2+ (5) > cis-[Ru(bpy)2(INH)2]2+ (4). General correlations can be
made: complexes containing 1,10-phenanthroline (phen) are more photoactive than
complexes containing 2,2ʹ-bipyridine (bpy) (e.g. 7 > 5), and complexes containing
nicotinamide (NA) are more photoactive than complexes containing isoniazid (INH)
(e.g. 5 > 4). However it is notable that all t1/2 values are < 9 s and the greatest difference
between t1/2 values is 4 s. Therefore there is only a very minor difference between the
photoactivity of each complex.
Chapter 4
____________________________________________________________________
158
4.4.2.1. Qualitative assessment by DFT/TD-DFT
DFT and TD-DFT were employed to investigate if computational techniques can be
used to qualitatively assess why there is a difference in photoactivity, see Section
4.3.7. Investigating the molecular orbitals in the ground state geometry showed that
the energy gap between the metal centred HOMO’s and LUMO’s for 4, 5, 6 and 7 is
very similar (~ 5.7 eV). Again the energy gap between metal centred HOMO’s and
bidentate ligand N-N' LUMO’s is similar for all complexes (~ 3.7 eV). This results in
all complexes having similar energies of 1MLCT and 1MC (~ 3.0 eV for 1MLCT and
~ 3.5 eV for 1MC). It is worth noting that the 1MLCT state is non-dissociative, however
the 1MC state is dissociative and involves either LUMO+11 or LUMO+10 which are
σ*-antibonding in character (due to either d     or d          ). One major difference is the
number of 1MLCT states: complexes cis-[Ru(bpy)2(INH)2]2+ (4) and cis-
[Ru(bpy)2(NA)2]2+ (5) have 6 1MLCT states whereas cis-[Ru(phen)2(INH)2]2+ (6) and
cis-[Ru(phen)2(NA)2]2+ (7) have 12. This can be attributed to the fact that for 6 and 7
there are more lower lying 1,10-phenanthroline (phen)-based LUMO’s than 2,2'-
bipyridine (bpy)-based LUMO’s for 4 and 5 (4 c.f. 2). This increase in number of
available states may confirm why 6 and 7 are more photoactive than 4 and 5, as there
is a greater possibility of occupying the 1MLCT state in 6 and 7.
Another interesting difference can be found in the energy level of the HOMO orbitals
that are centred on the monodentate ligand. In complexes cis-[Ru(bpy)2(INH)2]2+ (4)
and cis-[Ru(phen)2(INH)2]2+ (6) the HOMO (~ -11 eV) is located on the hydrazide
group of isoniazid (INH), whereas in cis-[Ru(bpy)2(NA)2]2+ (5) and cis-
[Ru(phen)2(NA)2]2+ (7) the HOMO-3 (~ -12 eV) is located on the amide group of the
nicotinamide ligand. The reason for the higher energy of the hydrazide HOMO is due
to the alpha effect: when two lone pairs are adjacent to each other they interact and
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destabilise the HOMO, which subsequently produces a stronger nucleophile.32 This
occurs for isoniazid, resulting in the hydrazide group becoming less electron-
withdrawing than the amide group in nicotinamide. It has been previously suggested
that in complexes of the type cis-[Ru(bpy)2(L)2]2+, where L is an amine-based ligand,
ligands (L) with greater π-accepting properties can enhance the photodissociation 
yield by favouring electron transfer to the leaving ligand.33 Following this logic, the
reason for the increased photoactivity of nicotinamide containing complexes
compared to isoniazid containing complexes (cis-[Ru(bpy)2(NA)2]2+ (5) > cis-
[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(NA)2]2+ (7) > cis-[Ru(phen)2(INH)2]2+ (6))
may be the greater π-accepting properties of nicotinamide ligand, linked to the 
presence of the amide group (compared to isoniazid and the hydrazide group).
Interestingly triplet state calculations showed dramatic differences between 4, 5, and
6 that supports the previous statement.
The lowest-lying triplet state geometry of cis-[Ru(bpy)2(NA)2]2+ (5) and cis-
[Ru(phen)2(NA)2]2+ (7) shows large changes in bond distances when compared to the
ground state geometry. The Ru-L5 bond (L5 is nicotinamide) elongates by 0.8 Å while
the Ru-N2 bond (N2 is the chelating ligand bpy or phen) trans to it elongates by 0.3 Å,
resulting in bond distances of ~2.9 Å and ~2.4 Å, respectively. At this bond distance
the Ru-nicotinamide bond would be broken, however due to chelation the Ru-bpy/Ru-
phen bond remains intact and is therefore shorter in comparison. From inspection of
the h-SOMO of cis-[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(NA)2]2+ (7) it is clear
that the lowest-lying triplet state is 3MC in character and is σ*-antibonding towards
the Ru-nicotinamide bond and the Ru-bpy/Ru-phen bond trans to it (due to the d   
character). The spin density maps also confirm this assignment, as the spin density is
located on the metal centre. Conversely for cis-[Ru(bpy)2(INH)2]2+ (4) and cis-
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[Ru(phen)2(INH)2]2+ (6), the h-SOMO and spin density maps confirm that the lowest-
lying triplet state is 3MLCT in character, with no σ*-antibonding character.
Interestingly this difference in character between 3MLCT and 3MC correlates well
with previous literature.33-34 The triplet excited states were calculated and are shown
graphically in Figure 4.24.
Figure 4.24. Singlet and triplet excited states for cis-[Ru(bpy)2(INH)2]2+ (4), cis-
[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(INH)2]2+ (6).
For both cis-[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(INH)2]2+ (6), the 3MLCT state
(~ 2.5 eV) is found below the 3MC state (~ 3.4 eV). However for cis-
[Ru(bpy)2(NA)2]2+ (5) there is mixing of 3MC/3MLCT (3.1 eV) very close in energy
to the 1MLCT state (3.0 eV). As a result for complex cis-[Ru(bpy)2(NA)2]2+ (5) after
initial photoexcitation to the 1MLCT state, efficient ISC may occur through mixing of
3MC/3MLCT which allows efficient population of the dissociative 3MC state.33 The
reason why complexes cis-[Ru(bpy)2(NA)2]2+ (5) and cis-[Ru(phen)2(NA)2]2+ (7) have
a lowest-lying triplet state of 3MC character is that they contain nicotinamide which is
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a stronger π-acceptor than isoniazid, discussed above. Thus favourable leaving 
properties of the monodentate ligand lowers the energy of the 3MC state, resulting in
a more photoactive complex, and hence the photoactivity order 5 > 4 and 6 > 7.
4.4.3. Wavelength dependence
The photoactivity of cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2
(7) was investigated at different wavelengths of photoactivation. There was an inverse
relationship between t1/2 and extinction coefficient, see Figure 4.2. Similar results have
been reported for a platinum(IV) photoactive complex.35 This is due to the fact that all
photophysical/photochemical processes activated by visible light for Ru(II)
polypyridyl complexes arise from the population of the 1MLCT state. The 1MLCT
band for 4 and 7 decreases dramatically over the 440 nm – 560 nm range due to the
lack of 1MLCT transitions available in that wavelength range. As a result the
photoactivity decreases upon increasing wavelength of photoactivation.
4.4.4. Photochemical pathways
The photoirradiation of cis-[Ru(bpy)2(INH)2]2+ (4) in aqueous solution (40 µM) using
blue light (λirr = 463 nm, 50 mW cm-2) at 298 K was followed by HR-LCMS in order
to characterise the photoproducts. Interestingly the first step involves release of a
ligand (INH) and produces cis-[Ru(bpy)2(INH)(H2O)]2+ exclusively after 50 s
photoirradiation. However continued photoirradiation and release of the second ligand
(INH) produces two species, cis-[RuII(bpy)2(H2O)2]2+ and trans-[RuIII(bpy)2(H-
2O)(OH)]2+. Interestingly if a lower power light source is used (λirr = 465 nm, 20 mW
cm-2) a third species is produced, trans-[RuII(bpy)2(H2O)2]2+, which is not present
when using a higher power light source (λirr = 463 nm, 50 mW cm-2). When cis-
[Ru(bpy)2(H2O)2]2+ is photoirradiated in aqueous solution it photoisomerises to trans-
[Ru(bpy)2(H2O)2]2+, however a photostationary state is achieved as the trans isomer
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can photoisomerise back the cis isomer.23 The cis to trans photoisomerisation is
postulated to be more favourable due to the lower energy of the triplet state of the
trans-penta-coordinate species when compared to the cis-penta-coordinate species.36
The complex trans-[Ru(bpy)2(H2O)2]2+ is a stronger reducing agent than cis-
[Ru(bpy)2(H2O)2]2+ and therefore the trans isomer is sensitive to oxidation by
molecular oxygen (O2) to form trans-[Ru(bpy)2(H2O)2]3+.23 Interestingly trans-
[Ru(bpy)2(H2O)2]3+ is isolated as trans-[Ru(bpy)2(H2O)(OH)]2+ in aqueous solution
due to the strongly acidic nature of the Ru(III) complex; the pKa for
[Ru(bpy)2(py)(H2O)]3+ is reported to be 0.85 while for [Ru(bpy)2(py)(H2O)]2+ was
found to be 10.8.23, 37 It is hypothesised that the results found in this chapter indicate
that a higher power light source promotes photochemical oxidation of trans-
[Ru(bpy)2(H2O)2]2+ to trans-[Ru(bpy)2(H2O)(OH)]2+ by molecular oxygen, as a result
there is much less trans-[Ru(bpy)2(H2O)2]2+ found when a higher power light source
is used.
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was photoirradiated using the 96-array
blue LED (λirr = 465 nm, 20 mW cm-2) to investigate which photoproducts could be
formed in the biological setting. Interestingly even though the light source is half the
power than that used in previous experiments, after 1 min photoirradiation cis-
[Ru(bpy)2(INH)(H2O)]2+ is formed almost exclusively. Continued photoirradiation for
2 h again produced cis-[Ru(bpy)2(H2O)2]2+, trans-[Ru(bpy)2(H2O)2]2+ and trans-
[Ru(bpy)2(H2O)(OH)]2+, however there is still some cis-[Ru(bpy)2(H2O)(INH)]2+
present. It is worth noting that all the photoproducts formed were stable in solution for
1 h when incubated in the dark at 298 K, as shown by lack of changes in their UV-
visible spectra.
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4.4.5. Ultrafast studies
Once cis-[Ru(bpy)2(NA)2][PF6]2 (5) is photoirradiated, the 1MLCT state is populated
and efficient intersystem crossing (τISC < 0.1 ps) populates the 3MLCT state. Two
pathways are possible from this point; either vibrational relaxation to the v=0 3MLCT
state (τVET = 3.6 ps) or dissociation of a NA ligand (τd = 0.4) to form the ‘caged’ penta-
coordinate intermediate (PCI) via the 3MC state. In the former pathway, vibrational
relaxation will be followed by ground state recovery (τGSR = 180 ps) with the emission
of a photon (luminescence). Due to the fact that the lifetime of the 3MLCT state is not
dependent only on the dissociation of the NA ligand (i.e. τGSR >> τd), there must be a
barrier to coupling of the 3MLCT state with the 3MC state. Interestingly, from TD-
DFT calculations in Section 4.3.7.6., this barrier was found to be relatively small at ~
0.1 eV. Furthermore, 5 was found to be emissive at room temperature in water,
supporting the barrier hypothesis. After formation of the ‘caged’ PCI, the PCI and NA
may geminately recombine to form 5 (τGR = 263 ps) or the PCI and NA may diffusively
separate to form ‘separated’ PCI (τs = 377 ps), allowing a water molecule to bind (τMA
< 1 ps) to form the photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+. The analysis above
shows that diffusional separation (i.e. τs) is the rate-limiting step in the formation of
the photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+. Interestingly this may open up the
possibility of altering the time of this separation by using smaller or larger ligands.
4.5. Summary
Density functional theory (DFT) and time-dependent functional theory (TD-DFT) was
used to qualitatively assess how changing the ligands around the ruthenium(II) centre
can affect the photoactivity of complexes of the type cis-[Ru(N-N')2(L)2]2+. Firstly, it
showed that for cis-[Ru(phen)2(INH)2]2+ (6) and cis-[Ru(phen)2(NA)2]2+ (7), there are
more 1MLCT transitions than cis-[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(bpy)2(NA)2]2+
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(5). As a result 6 and 7 are more photoactive than 4 and 5, as the photorelease pathway
depends on the population of 1MLCT states. Secondly, the calculations suggest that
nicotinamide (NA) is a better π-acceptor than isoniazid (INH) and as a result 
complexes 5 and 7 are more photoactive than 4 and 6. This was further emphasized
by the fact that in the case of cis-[Ru(bpy)2(NA)2]2+ (5), the lowest-lying triplet state
(T1) was found to be 3MC in character and had considerable σ*-antibonding character
towards the NA ligand. Conversely for complexes containing isoniazid (INH), cis-
[Ru(bpy)2(INH)2]2+ (4) and cis-[Ru(phen)2(INH)2]2+ (6), the lowest-lying triplet state
was found to be 3MLCT in character which had no σ*-antibonding character. It is 
thought that the favourable leaving properties (i.e. better π-acceptor) of the NA ligand 
lowers the energy of the 3MC state, thus enhancing its photoactivity. Interestingly it
was found that different photoproducts were formed depending on the power of the
light source used. In the case of cis-[Ru(bpy)2(INH)2][PF6]2 (4), when photoirradiated
with a higher power light source no trans-[Ru(bpy)2(H2O)2]2+ photoproduct was
observed, however when a lower light power light source was used it was present. It
is hypothesised that this is due to the fact that a higher power light source promotes
photooxidation of trans-[Ru(bpy)2(H2O)2]2+ to trans-[Ru(bpy)2(H2O)(OH)]2+ by
molecular oxygen. The photochemical/photophysical pathways of complex cis-
[Ru(bpy)2(NA)2]2+ (5) were explored by transient-absorption spectroscopy. The rate
determining step was found to be the diffusional separation of the penta-coordinate
intermediate (PCI) and the leaving ligand NA (τs = 377 ps) allowing a water molecule
to bind with formation of the photoproduct cis-[Ru(bpy)2(NA)(H2O)]2+.
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Chapter 5
Photobiological properties of Ru(II) polypyridyl complexes
5.1. Introduction
Ruthenium(II) polypyridyl complexes have been studied for anticancer and
antibacterial applications.1 Interestingly, complexes of the type [Ru(N-N')3]2+, where
N-N' is 2,2'-bipyridine or 1,10-phenanthroline, are active against Staphylococcus
aureus and Mycobacterium tuberculosis at concentrations ranging between 0.5 µM –
25 µM.2 Functionalising the N-N' ligand with increasing number of methyl groups
resulted in increased activity against both bacteria, highlighting the importance of
hydrophobicity.2 It is important to consider the target of potential antibacterial agents.
Ru(II) polypyridyl complexes of the type [Ru(bpy)2(L)2]n+, where bpy is 2,2'-
bipyridine and L is Cl (n = 0) or H2O (n = 2), have been found to bind to DNA at N7
of guanine.3-4 As a result DNA has been an interesting target for many photoactive
Ru(II) polypyridyl anticancer complexes that produce [Ru(N-N')2(H2O)2]2+ in aqueous
solution once photoactivated.5-7 With respect to Ru(II) polypyridyl complexes as
antimicrobial agents, recently efforts have been placed in investigating the
intercalation into DNA and damage by the production of singlet oxygen (1O2).8-11
The complexes synthesised in Chapter 3 were developed as anti-tuberculosis agents.
M. tuberculosis is highly pathogenic and very slow growing (24 h doubling time),
therefore an alternative bacterium was needed to predict the anti-tuberculosis activity
of the complexes. M. smegmatis is comparatively fast growing (2 – 3 h doubling time),
non-pathogenic and 69.8% of M. tuberculosis protein-coding genes have orthologues
in M. smegmatis.12 As a result M. smegmatis is commonly used as an M. tuberculosis
model.
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This chapter focuses on establishing the antibacterial activity of the isoniazid (INH)
and nicotinamide (NA) complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) against E. coli, B.
subtilis, and M. smegmatis. Particular focus is on the difference in activity of the
complexes in the dark and once exposed to light. Information about whether the
complexes disrupt the membrane integrity of the bacteria was also obtained using the
BaclightTM assay. The ability of the complexes to bind to 9-ethylguanine and L-
cysteine was explored by 1H-NMR and HR-MS.
5.2. Experimental
5.2.1. Materials
The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5) and
cis-[Ru(phen)2(INH)2][PF6]2 (6) were synthesised in Chapter 3. L-Cysteine, 9-
ethylguanine, Middlebrook 7H9 Broth Base, glycerol, dextrose, sodium chloride,
bovine serum albumin, Tween® 80, phosphate-buffered saline tablets and tryptic soy
broth were purchased from Sigma Aldrich. The LIVE/DEAD® BacLightTM bacterial
viability kit was purchased from Life Technologies. The bacteria B. subtilis 168 and
E. coli C43(DE3) were kindly provided by Anne Smith from the Chemical Biology
Department at University of Warwick, while M. smegmatis mc2155 was kindly
provided by Professor Christopher Dowson from the School of Life Sciences at the
University of Warwick. The description of each photoirradiation setup can be found
in Chapter 2.
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5.2.3. Photoirradiation in the presence of 9-ethylguanine and L-cysteine
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was dissolved in D2O (4 mM) together
with 1.1 mol equivalent excess of either 9-ethylguanine (9-EtG) or L-cysteine (Cys).
The sample was placed in a 5 mm o.d. NMR tube and photoirradiated using a blue
LED (λirr = 463 nm, 50 mW cm-2) at 298 K for 50 min. The 1H-NMR spectrum of each
sample was recorded on a Bruker AV-400 spectrometer at 298 K. The samples were
incubated in the dark for 24 h at 298 K and the spectrum of each sample was recorded
again. All data processing was carried out using Bruker Topspin 2.1. The 1H-NMR
signals were referenced to 1,4-dioxane as an internal reference (δ = 3.75). The
structure of the photoirradiation products were confirmed by HR-MS, see Chapter 2
for details of the instrumentation.
5.2.4. Photoactivity against B. subtilis and E. coli
The tryptic soy broth (TSB) and phosphate buffer saline (PBS) were prepared as per
manufacturer’s instructions. An overnight culture of E. coli in TSB was centrifuged
and the cell pellet was re-suspended in PBS to give a final OD of 0.015. The E. coli
suspension was added to wells in a black 96-well plate (100 µL). The complex cis-
[Ru(bpy)2(INH)2][PF6]2 (4) dissolved in PBS was added to the wells (100 µL) to give
final complex concentrations of 200 µM, 100 µM and 10 µM. In the dark and light
control wells only PBS (100 µL) was added. Each well was prepared in triplicate. Two
black 96-well plates were prepared; one for photoirradiation and one for the dark
controls. Both black 96-well plates were incubated initially in the dark for 3 h at 298
K. Subsequently, one of the black 96-well plates was photoirradiated using the 96-
array blue LED (λirr = 465 nm, 20 mW cm-2) at 298 K for 2 h 20 min, while the other
black 96-well plate was kept in the dark. The contents of each well (100 µL) were
plated onto TSB agar plates and incubated overnight at 310 K. After incubation the
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number of colony forming units (CFU/mL) were counted. The same procedure was
performed using B. subtilis. The student’s t-test was performed with two-tail
distribution and unequal variance to determine p values (* denotes p ≤ 0.05 while ** 
denotes p ≤ 0.01); the light samples were compared to the dark samples. 
5.2.5. Photoactivity against M. smegmatis
The 7H9 media was prepared from Middlebrook 7H9 broth base, glycerol, dextrose,
sodium chloride, bovine serum albumin and Tween 80 as per the manufacturer’s
instructions. To ensure reproducibility, 20% glycerol stock solutions of M. smegmatis
in 7H9 media were made from an overnight culture and diluted to OD 0.01. The M.
smegmatis stock suspensions were stored at 193 K for up to 3 months.
5.2.5.1. Photoirradiation using the 96-array blue LED
Prior to use, the M. smegmatis stock suspension was diluted to OD 0.002 with 7H9
media. The resulting solution was placed into wells of a black 96-well plate (100 µL).
The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) were dissolved in
7H9 media and were added to the wells (100 µL) to give various final complex
concentrations. In the dark and light control wells only 7H9 media (100 µL) was
added. Each well was prepared in triplicate. Two black 96-well plates were prepared.
Both black 96-well plates were incubated initially in the dark for 1 h at 298 K.
Subsequently, one of the black 96-well plates was irradiated using the 96-array blue
LED (λirr = 465 nm, 20 mW cm-2) at 298 K for various times of irradiation, while the
other black 96-well plate was kept in the dark. The contents of both black 96-well
plates were transferred to a clear 96-well plate which was placed into a Thermo
Labsystems IEMS MF microplate reader. The growth of M. smegmatis was monitored
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by measuring the change in OD at 600 nm at 310 K over 72 h. The percentage survival
was calculated by comparing the values obtained to the appropriate control; light
exposed samples were compared to the light control and the dark samples were
compared to the dark controls. Details of the microplate reader setup can be found in
Chapter 2. The student’s t-test was performed with two-tail distribution and unequal
variance to determine p values (* denotes p ≤ 0.05 while ** denotes p ≤ 0.01); the 
light samples were compared to the dark sample. The minimum inhibitory
concentration (MIC) is defined at the minimum concentration that produced < 5%
survival of bacteria.
5.2.5.2. Photoirradiation using the 32-array multi-coloured LED
The same procedure as above was used using the 32-array multi-coloured LED (λirr =
465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2).
5.2.6. BaclightTM assay with M. smegmatis
The method was adapted from the manufacturer’s instructions for the LIVE/DEAD®
BacLightTM bacterial viability kit. A calibration graph of percentage live cells versus
fluorescence ratio (F530 nm/F630 nm) was created by preparing mixtures of live and dead
cells. For live cells, M. smegmatis was suspended in 0.85% w/v NaCl, and for dead
cells was suspended in 1% v/v toluene.13 Both live and dead cells had an OD 0.2 and
were incubated at 298 K for 1 h. Various mixtures of live and dead cells (100 µL total
volume) were placed into wells of a clear 96-well plate along with 100 µL dye mixture
(10 µM SYTO 9 and 60 µM propidium iodide) and 3.2 µL DMSO. Each well was
prepared in triplicate. The clear 96-well plate was incubated at 298 K in the dark for
15 min. The fluorescence at 530 nm and 630 nm was measured using an excitation
wavelength of 470 nm on a Varioskan Flash Multimode microplate reader. The data
were processed using SkanIt software version 2.4.3. The complexes cis-
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[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) were dissolved in
DMSO to give various complex concentrations and added (3.2 µL) to live cells (100
µL) in wells of a black 96-well plate. Each well was prepared in triplicate. Two black
96-well plates were prepared. Both were incubated at 298 K in the dark for 30 min.
One black 96-well plate was photoirradiated with the 96-array blue LED (λirr = 465
nm, 20 mW cm-2) for 1 min, while the other was kept in the dark. After
photoirradiation both were incubated at 298 K in the dark for 30 min. The contents of
each well was transferred to a clear 96-well plate and 100 µL dye mixture (10 µM
STYO 9 and 60 µM propidium iodide) was added. The clear 96-well plate was
incubated at 298 K in the dark for 15 min. The fluorescence at 530 nm and 630 nm
was measured using an excitation wavelength of 470 nm on a Varioskan Flash
Multimode microplate reader and the fluorescence ratio (F530 nm/F630 nm) was
calculated. The students t-test was performed with two-tail distribution and unequal
variance to determine p values (* denotes p ≤ 0.05 while ** denotes p ≤ 0.01); each 
sample was compared to the positive control, isoniazid (220 µM).
5.3. Results
5.3.1. Design of 96-array blue LED
The blue LED (λirr = 463 nm, 50 mW cm-2) that was used for photirradiating a sample
in a cuvette or an NMR tube was not suitable for photoirradiating samples in a 96-well
plate. Therefore a 96-array blue LED (λirr = 465 nm, 20 mW cm-2) was designed,
Figure 5.1.
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Figure 5.1. Complete setup of the 96-array blue LED (λirr = 465 nm, 20 mW cm-2)
(A), showing the 96-array of blue LED’s connected to a heat sink (B) with the black
96-well plate with glass bottom on top of the LED’s (C) and the plastic holder that
holds the black 96-well plate that will contain the bacteria (D).
The 96-array of blue LED’s was housed on a heat sink in order to remove excess heat
produced by the LED’s. When in use, a black 96-well plate with a glass bottom was
used to cover the LED’s. A plastic holder was made that could hold the black 96-well
plate that would contain the bacteria as well as allowing the 96-array of blue LED’s to
sit on top without sliding around, see Figure 5.1. In order to see if the heat sink was
performing efficiently, heat maps of the black 96-well plate in the plastic holder were
measured upon photoirradiation for various times, see Figure 5.2.
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Figure 5.2. Heat maps to show the temperature of the black 96-well plate that will
hold the bacteria after 1 h and 2 h 30 min photoirradiation with the 96-array blue LED
(λirr = 465 nm, 20 mW cm-2).
After 1 h photoirradiation the middle of the black 96-well plate is the hottest region
reaching 312 K. After 2 h 30 min photoirradiation the middle of the black 96-well
plate raises temperature slightly to 315 K, while the outside edge of the plate is much
cooler at 305 K. Interestingly the top of the black 96-well plate is 6 degrees hotter than
the bottom of the plate (315 K c.f. 309 K) after 2 h 30 min photoirradiation.
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5.3.2. Photoirradiation in the presence of 9-ethylguanine and L-cysteine
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was dissolved in D2O (4 mM) and
photoirradiated with a blue LED (λirr = 463 nm, 50 mW cm-2) for 50 min. The
photoreaction was followed by 1H-NMR, see Figure 5.3.
Figure 5.3. 1H-NMR spectrum (400 MHz) of cis-[Ru(bpy)2(INH)2][PF6]2 (4) (4 mM)
in D2O before (top spectrum) and after 50 min photoirradiation (bottom spectrum)
using the blue LED (λirr = 463 nm, 50 mW cm-2) at 298 K, with schematic of the
photoreaction. Cis-[Ru(bpy)2(INH)2]2+ = (with bound INH ), cis-
[Ru(bpy)2(INH)(H2O)]2+ = (with bound INH ), free INH = .
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After 50 min photoirradiation, the 10 peaks attributed to the starting material cis-
[Ru(bpy)2(INH)2]2+ decreased and two new sets of peaks increased. The first set of 2
peaks are due to the released free ligand (INH) in solution (8.68 ppm and 7.69 ppm),
while the second set of 18 peaks are attributed to the formation of the photoproduct
cis-[Ru(bpy)2(INH)(D2O)]2+. The photoirradiation of 4 was performed in the presence
of L-cysteine (Cys), see Figure 5.4.
Figure 5.4. 1H-NMR spectrum (400 MHz) of cis-[Ru(bpy)2(INH)2][PF6]2 (4) (4 mM)
in D2O with 1.1 mol equivalent excess L-cysteine (Cys) after 50 min photoirradiation
using a blue LED (λirr = 463 nm, 50 mW cm-2) at 298 K (top) and after 24 h incubation
in the dark at 298 K (bottom). Cis-[Ru(bpy)2(INH)(H2O)]2+ = (with bound INH ),
free INH = .
After 50 min photoirradiation, the same two sets of peaks were observed as in the case
of 4 photoirradiated in the absence of L-cysteine. After incubating the sample in the
dark at 298 K for 24 h, the spectrum does not change. The photoirradiation of 4 was
also performed in the presence of 9-ethylguanine (9-EtG), see Figure 5.5.
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Figure 5.5. 1H-NMR spectrum (400 MHz) of cis-[Ru(bpy)2(INH)2][PF6]2 (4) (4 mM)
in D2O with 1.1 mol equivalent excess 9-ethylguanine (9-EtG) after 50 min
photoirradiation (top spectrum) using a blue LED (λirr = 463 nm, 50 mW cm-2) at 298
K and after 24 h incubation in the dark at 298 K (bottom spectrum). Cis-
[Ru(bpy)2(INH)(H2O)]2+ = (with bound INH ), free INH = , cis-
[Ru(bpy)2(INH)(9-EtG)]2+ = * (species A) and * (species B).
Initially after photoirradiation for 50 min, there was a new bound 9-EtG peak for H8
found at 6.84 ppm (c.f. free 9-EtG H8 at 7.81 ppm), along with a new set of peaks
which are hidden underneath existing proton peaks, attributed to the production of the
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photoadduct cis-[Ru(bpy)2(INH)(9-EtG)]2+. All aforementioned peaks are labelled as
species A (*). The percentage binding was estimated to be ~16%. Interestingly after
24 h dark incubation at 298 K, the bound 9-EtG peak for H8 at 6.84 ppm decreased
and a new bound 9-EtG peak H8 increased at 7.29 ppm. Additionally a new set of
peaks also increased, however it was difficult to identify them as they were hidden
underneath existing peaks. These aforementioned peaks are labelled as species B (*).
The identity of the photoadduct cis-[Ru(bpy)2(INH)(9-EtG)]2+ was confirmed by HR-
MS, see Figure 5.6. It is important to note that there was no product peak for cis-
[Ru(bpy)2(9-EtG)(H2O)]2+ or cis-[Ru(bpy)2(9-EtG)2]2+.
Figure 5.6. Calculated and experimentally observed HR-MS peaks for cis-
[Ru(bpy)2(INH)(9-EtG)]2+ after cis-[Ru(bpy)2(INH)2][PF6]2 (4) was photoirradiated
for 50 min using a blue LED (λirr = 463 nm, 50 mW cm-2) in the presence of 1.1 mol
equivalent excess of 9-ethylguanine (9-EtG) at 298 K.
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5.3.3. Photoactivity against B. subtilis and E. coli
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was tested against Gram-positive and
Gram-negative models B. subtilis and E. coli, respectively. Complex 4 was incubated
with B. subtilis and E. coli and either incubated at 298 K in the dark or photoirradiated
using the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) for 2 h 20 min. After placing
the solutions onto agar plates and incubating at 310 K overnight, the number of colony
forming units (CFU/mL) were measured, see Figure 5.7.
Figure 5.7. Activity of cis-[Ru(bpy)2(INH)2][PF6]2 (4) against E. coli (left) and B.
subtilis (right) when incubated in the dark (grey bars) and photoirradiated for 2 h 20
min (blue bars) using the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) at 298 K. P
values were calculated by comparing the light samples to the dark samples and are
labelled as follows, p ≤ 0.05 = *, p ≤ 0.01 = **. 
When 4 was tested against E. coli, the Log10 CFU/mL was found to be ~7 for all
concentrations of 4 (200 µM, 100 µM and 10 µM) both in the dark and photoirradiated.
Additionally the Log10 CFU/mL for the control (cells not exposed to drug) and the
isoniazid ligand alone (400 µM) was also ~7 both in the dark and once photoirradiated.
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When 4 was tested against B. subtilis, for concentrations of 200 µM and 100 µM the
Log10 CFU/mL was ~6 in the dark, and decreased to ~3 once photoirradiated. The
Log10 CFU/mL for the control, 10 µM 4 and ligand alone (400 µM) was ~6 for both
dark incubation and once photoirradiated.
5.3.4. Photoactivity against M. smegmatis
The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5) and
cis-[Ru(phen)2(INH)2][PF6]2 (6) were tested against M. smegmatis using either the 96-
array blue LED (λirr = 465 nm, 20 mW cm-2) or the 32-array multi-coloured LED (λirr
= 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2).
5.3.4.1. Photoirradiation using the 96-array blue LED
Initially M. smegatis was photoirradiated for 1 min, 30 min, 1 h and 2 h using the 96-
array blue LED (λirr = 465 nm, 20 mW cm-2) at 298 K in the absence of any complex.
The growth of each sample was monitored over a 72 h period at 310 K and was
compared to the dark control to calculate the survival (%), see Figure 5.8.
Figure 5.8. Photoirrdiation of M. smegmatis using the 96-array blue LED (λirr = 465
nm, 20 mW cm-2) at 298 K. P values were calculated by comparing the light samples
to the dark control and are labelled as follows, p ≤ 0.05 = *, p ≤ 0.01 = **. 
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Interestingly 1 min photoirradiation only observed 43% survival, while 30 min and 1
h photoirradiation observed 57% and 62% survival respectively. After 2 h irradiation
there was 94 % survival. The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) were incubated in the
dark for 1 h at 298 K with M. smegmatis and the samples were photoirradiated for 1
min, 30 min, 1 h and 2 h at 298 K, see Figure 5.9.
Figure 5.9. Activity of cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5)
and cis-[Ru(phen)2(INH)2][PF6]2 (6) against M. smegmatis when incubated in the dark
(grey bars) and photoirradiated (1 min – 2 h displayed in blue colour gradient) using
the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) at 298 K. P values were calculated
by comparing the light samples to the dark samples and are labelled as follows, p ≤ 
0.05 = *, p ≤ 0.01 = **. 
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The survival for each complex at each photoirradiation time point was compared to
the light control in the absence of complex, while the survival for each complex in the
dark was compared to the dark control in the absence of complex to calculate the
survival (%). For cis-[Ru(bpy)2(INH)2][PF6]2 (4) in the dark, the survival of M.
smegmatis increased at lower concentrations of complex, with survival of 42%, 71%
and 89% for 50 µM, 30 µM and 10 µM, respectively. The same trend was observed
for cis-[Ru(phen)2(INH)2][PF6]2 (6) in the dark, with survival of 41%, 57% and 85%
for 50 µM, 30 µM and 10 µM respectively. For cis-[Ru(bpy)2(NA)2][PF6]2 (5) in the
dark, the survival was > 100% at all complex concentrations.
The survival after 1 min, 30 min, 1 h and 2 h photoirradiation for complex 4 was < 4%
at all complex concentrations, and similarly for complex 6 was < 2%. There appears
to be no trend between irradiation time and survival for complexes 4 and 6. The
monodentate ligand for 4 and 6 is isoniazid (INH) and at 22 µM produced a survival
of < 2%. This is the minimum inhibitory concentration (MIC) for isoniazid,
comparable to literature values (c.f. 29 µM).14 For complex 5 the general trend
observed for each photoirradiation time point was increased survival with decreasing
complex concentration, e.g after 2 h photoirradiation the survival was 45%, 64% and
77% for 50 µM, 30 µM and 10 µM respectively. However, the survival of bacteria for
all complex concentrations of 5 and all time points of photoirradiation was > 30%.
Interestingly for each complex concentration of 5, the survival of bacteria generally
increased in the order of 1 min < 2 h < 30 min < 1 h. The monodentate ligand for 5 is
nicotinamide (NA) and at a concentration of 100 µM produces a survival of 66%. The
minimum inhibitory concentration (MIC) was determined for cis-
[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) when
photoirradiated for 1 min, see Figure 5.10. For both complexes 4 and 6 in the dark at
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complex concentrations of 0.5 µM – 10 µM the survival was > 60%. The MIC when
photoirradiated for 1 min was found to be 4 µM for complex 4 and 8 µM for complex
6.
Figure 5.10. Activity of cis-[Ru(bpy)2(INH)2][PF6]2 (4) (left) and cis-
[Ru(phen)2(INH)2][PF6]2 (6) (right) against M. smegmatis when incubated in the dark
(grey bars) and photoirradiated for 1 min (light blue bar) using the 96-array blue LED
(λirr = 465 nm, 20 mW cm-2) at 298 K. P values were calculated by comparing the light
samples to the dark samples and are labelled as follows, p ≤ 0.05 = *, p ≤ 0.01 = **. 
5.3.4.2. Photoirradiation using the 32-array multi-coloured LED
Initially M. smegatis was photoirradiated for 30 min using the 32-array multi-coloured
LED (λirr = 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2) at 298 K in the absence
of any complex. The growth of each sample was monitored over a 72 h period at 310
K and was compared to the dark control to calculate the survival (%), see Figure 5.11.
The survival of M. smegmatis when exposed to blue (465 nm), green (520 nm), yellow
(589 nm) and red (625 nm) light was > 85% in all cases.
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Figure 5.11. Photoirradiation of M. smegmatis using the 32-array multi-coloured LED
(λirr = 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2) at 298 K for 30 min. P values
were calculated by comparing the light samples to the dark control and are labelled as
follows, p ≤ 0.05 = *, p ≤ 0.01 = **. 
The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6)
were incubated with M. smegmatis in the dark for 1 h at 298 K and the samples were
photoirradiated for 30 min at 298 K. The survival for each complex at each
photoirradiation wavelength was compared to the light control in the absence of
complex to calculate the survival (%), see Figure 5.12.
For both complexes 4 and 6, the general trend is increased survival as the wavelength
of photoirradiation increased. For complex 4, the survival when exposed to blue,
green, yellow and red light was 0.5%, 4%, 94% and 96% respectively, while for
complex 6 was 0.6%, 1%, 81% and 101% respectively. The dark survival for both
complex 4 and 6 was > 80%.
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Figure 5.12. Activity of cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-
[Ru(phen)2(INH)2][PF6]2 (6) against M. smegmatis when incubated in the dark (grey
bars) using the 32-array multi-coloured LED (λirr = 465 nm, 520 nm, 589 nm and 625
nm, 5 mW cm-2) at 298 K for 30 min. P values were calculated by comparing the light
samples to the dark samples and are labelled as follows, p ≤ 0.05 = *, p ≤ 0.01 = **. 
5.3.5. BaclightTM assay with M. smegmatis
The principle of the BaclightTM assay is that the dye SYTO 9 enters and binds to
nucleic acids (observes fluorescence, λem = 530 nm, λex = 470 nm) of all bacteria
independent of membrane integrity, while ethidium bromide only enters and binds to
nucleic acids (observes fluorescence, λem = 630 nm, λex = 470 nm) of bacteria which
have damaged membranes. Therefore the ratio between green and red fluorescence
(F530 nm/F630 nm) can be used to investigate the membrane integrity.
The BaclightTM assay was performed with M. smegmatis in the presence of cis-
[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) both in the dark and
after photoirradiation for 1 min with 96-array blue LED (λirr = 465 nm, 20 mW cm-2),
see Figure 5.13. For the purpose of the calibration graph, intact membranes are
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associated with “live cells” while damaged membranes are associated with “dead”
cells.
Figure 5.13. Calibration graph of percentage live cells verses F530 nm/F630 nm ratio (top)
and F530 nm/F630 nm ratios obtained after various concentrations of cis-
[Ru(bpy)2(INH)2][PF6]2 (4) (bottom left) and cis-[Ru(phen)2(INH)2][PF6]2 (6) (bottom
right) were exposed to M. smegmatis when incubated in the dark (grey bars) and
photoirradiated for 1 min (light blue bars) using the 96-array blue LED (λirr = 465 nm,
20 mW cm-2) at 298 K. P values were calculated by comparing the light and dark
samples to the 10xMIC isoniazid (220 µM) control and are labelled as follows, p ≤ 
0.05 = *, p ≤ 0.01 = **.  
Isoniazid (INH) was used as a positive control for no membrane damage, and at a
concentration of 10xMIC (220 µM) an F530 nm/F630 nm ratio of 1.23 was observed. For
complex 4 at both concentrations (MIC is 4 µM and 4xMIC is 16 µM) in the dark and
after photoirradiation, the F530 nm/F630 nm ratio was ≥1. Interestingly only the 
photoirradiated 4xMIC sample was significantly different from the isoniazid positive
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control with an F 530 nm/F 630 nm ratio of 0.99. For complex 6 at both concentrations
(MIC is 8 µM and 4xMIC is 32 µM) in the dark and once photoirradiated, the F530
nm/F630 nm ratio is ≤1 and in all cases the ratios were significantly different to the 
isoniazid positive control. At MIC concentration, the ratio of F530 nm/F630 nm in the dark
and once photoirradiated was ~1.0 while at 4xMIC concentration was ~0.8. In general
for each complex there was no difference in F530 nm/F630 nm ratio between dark and
photoirradiated at each concentration.
5.4. Discussion
5.4.1. Light sources
A further description of all the light sources used for this work can be found in Chapter
2. The blue LED (λirr = 463 nm, 50 mW cm-2) was sufficient for photoirradiating a
sample in a cuvette or an NMR tube as the light beam was uniformly distributed over
the entire sample area (~ 6 cm x 1 cm). However this would not be the case for a 96-
well plate, as the sample area was much larger (~ 11 cm x 7.5 cm). Therefore a 96-
array blue LED was developed (λirr = 465 nm, 20 mW cm-2) in order to photoirradiate
samples in a 96-well plate. In this way, each well receive a uniformly distributed dose
of light. This was further aided by placing a black 96-well plate with a glass bottom
on top of the LED’s. This not only created a “channel” for the light to pass through
and thus avoided light leaking through into the next well, but it also aided with aseptic
working as the glass acts as a protective barrier so the bacteria never come into contact
with the LED’s. A heat sink was added to the system in order to reduce the transfer of
heat produced by the LED’s to the samples. Heat maps of the black 96-well plate that
would contain the bacteria after photoirradiation aided assessment of the effectiveness
of the heat sink. After 2 h 30 min of photoirradiation, the temperature of the black 96-
well plate did not exceed 315 K. This temperature should not hinder the growth of M.
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smegmatis as the bacteria can grow at 298 K and up to 323 K.15 A 32-array multi-
coloured LED (λirr = 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-2) was also
developed in order to screen for the optimal wavelength of activation. The system was
used in an analogous manner to the 96-array blue LED. A heat sink was not necessary
for this setup, as the LED’s are 4 times less powerful than those in the 96-array blue
LED setup and thus heat production should be negligible.
5.4.2. Photoirradiation in the presence of 9-ethylguanine and L-cysteine
L-Cysteine is an amino acid and 9-ethylguanine is a guanine nucleobase. Both are
building blocks of biomolecules such as proteins (L-cysteine) and DNA (guanine). If
a metal complex can bind to either, it may disrupt the biological action of either
proteins or DNA in vitro.
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) in aqueous solution (4 mM, D2O) was
photoirradiated with a blue LED (λirr = 463 nm, 50 mW cm-2) in the presence of L-
cysteine (Cys) and 9-ethylguanine (9-EtG) and the reaction followed by 1H-NMR at
298 K. In the absence of Cys and 9-EtG, after 50 min photoirradiation the
photoproduct cis-[Ru(bpy)2(INH)(D2O)]2+ had formed, characterised by the INH free
ligand peaks (found at 8.68 ppm and 7.69 ppm) and a new set of 18 peaks
corresponding to the Ru(II) photoproduct. Interestingly when 4 was photoirradiated
for 50 min in the presence of L-cysteine the photoadduct cis-[Ru(bpy)2(INH)(Cys)]2+
was not formed. Even after 24 h dark incubation at 298 K, L-cysteine did not bind as
was evident from the lack of changes in the 1H-NMR resonances for the photoproduct.
Conversely when 4 was photoirradiated for 50 min in the presence of 9-EtG, a new set
of peaks (species A) occurred which can be attributed to the photoadduct cis-
[Ru(bpy)2(INH)(9-EtG)]2+, see Figure 5.5. The H8 resonance of 9-ethylguanine shifted
upfield from 7.81ppm to 6.84 ppm as a result of binding to the metal. The percentage
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of binding was low (16%) which can be attributed to the bulky nature of the 9-EtG
ligand and the photoproduct cis-[Ru(bpy)2(INH)(D2O)]2+. The bulky nature of 9-EtG
has been noted previously, for example reacting cis-[Ru(bpy)2(H2O)2]2+ with an excess
of 9-EtG in aqueous solution at 310 K gives only the mono-adduct cis-[Ru(bpy)2(9-
EtG)(H2O)]2+.16 In order to form bis-adducts vigorous conditions are needed, such as
an ethanol reflux for an extended period of time.17 After the resulting photoirradiation
mixture of 4 and 9-EtG was incubated at 298 K in the dark for 24 h, the bound 9-EtG
H8 resonance at 6.84 ppm decreased and a new bound 9-EtG H8 resonance increased
downfield at 7.29 ppm (species B). This new product is related to the photoproduct
cis-[Ru(bpy)2(INH)(9-EtG)]2+, which was detected by HR-MS, see Figure 5.6. In fact
no other photoadduct was found in HR-MS, such as cis-[Ru(bpy)2(9-EtG)2]2+ or cis-
[Ru(bpy)2(9-EtG)(H2O)]2+. The presence of two bound 9-EtG H8 peaks is due to the
high energy rotation barrier of the 9-EtG ligand and therefore is a result of the
atropsiomers (species A and B) that can be formed (see Chapter 3 for in depth
discussion about the concept of atropisomerism due to hindered rotation). It has been
noted previously that in complexes of the type cis-[Ru(bpy)2(9-EtG)(X)]n+ and cis-
[Ru(bpy)2(9-MeG)2]2+, where X is either Cl (n = 1) or H2O (n = 2) and 9-MeG is 9-
methylguanine, rotation of the purine moieties does not occur because of their bulky
nature.16-17 Interestingly in the case of cis-[Ru(bpy)2(9-MeG)2]2+, due to the different
orientations of each MeG unit, there are two H8 proton resonances that are separated
by ~ 1.2 ppm (at 8 ppm and 6.8 ppm).17 This correlates well with data obtained above.
It is hypothesised that the first resonance seen at 6.84 ppm is from the kinetic
atropisomer (species A) and the second resonance seen at 7.29 ppm after a longer
period of time (24 h dark incubation at 298 K) is from the thermodynamic atropisomer
(species B), see Figure 5.14.
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Figure 5.14. Diagram of the proposed cis-[Ru(bpy)2(INH)(9-EtG)]2+ atropisomers.
It is thought that in the kinetic atropisomer the bulky “tail” portion of 9-EtG is placed
in between the bipyridyl rings, as this orientation is more favourable sterically. In the
kinetic atropisomer the H8 will be shielded by INH ring and thus is upfield-shifted. In
the thermodynamic atropisomer it is hypothesised that the carbonyl oxygen in 9-EtG
interacts favourably with the π-system of the INH ligand. Previously it has been found 
that such interaction between carbonyl oxygen and an aromatic π-system is 
enthalpically favourable.16, 18-19 Furthermore in the case of cis-[Ru(azpy)2(9-
EtG)(H2O)]2+, where azpy is 2-phenylazopyridine, an intramolecular hydrogen bond
between the carbonyl oxygen of 9-EtG and H2O stabilized the conformation.20 In order
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to confirm the presence of atropisomers, variable temperature 1H-NMR and NOESY
studies would need to be performed to investigate the rotation of the 9-EtG ligand.
5.4.3. Photoactivity against E. coli and B. subtilis
The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was incubated with E. coli and B. subtilis
in the dark for 1 h at 298 K and subsequently photoirradiated with the 96-array blue
LED (λirr = 465 nm, 20 mW cm-2) for 2 h 20 min at 298 K. In the case of E. coli no
activity was found in the dark or once photoirradiated at all complex concentrations
(10 µM – 100 µM), see Figure 5.7. The monodentate ligand of 4 is isoniazid (INH)
and at a concentration of 400 µM has no activity. When complex 4 was incubated with
B. subtilis activity was observed only at 200 µM and 100 µM when photoirradiated,
see Figure 5.7. Interestingly against B. subtilis, isoniazid (400 µM) has no effect. The
activity of 4 in B. subtilis could be due to a) the activity of the Ru(II) photoproducts
or b) the complex (4) may aid isoniazid to become active (potentially by enhanced
uptake), or both may have an effect.
The reason for the difference in activity of 4 against E. coli and B. subtilis is most
likely due to the differences in the bacterial cell walls. Gram-positive bacteria (i.e. B.
subtilis) are generally permeable to a variety of antibiotics due to a porous
peptidoglycan layer in its cell wall.21 Furthermore, the presence of negatively-charged
teichoic acids in the cell wall may facilitate the uptake of positively charged antibiotics
into the cell envelope.22 Gram-negative bacteria (i.e. E. coli) have a more complex cell
envelope consisting of an outer membrane as well as a peptidoglycan layer. The outer
membrane is composed of lipopolysaccharides and phospholipids, and molecular
diffusion across this barrier is very hindered.22 Porins offer another pathway for an
antimicrobial compound to gain entry through the outer membrane, however they only
permit molecules with a mass of <600 Da.22 Interestingly polycationic species are very
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effective at killing gram-negative bacteria as they can alter the outer membrane.9, 23
Therefore it is hypothesised that cis-[Ru(bpy)2(INH)2][PF6]2 (4) is not active in E. coli
due to reduced uptake, however uptake experiments need to be performed to confirm
this.
5.4.4. Photoactivity against M. smegmatis
5.4.4.1. Effect of blue light alone on survival of M. smegmatis
Prior to incubation of the photoactive complexes with M. smegmatis, an assessment
of the effect of light on the growth of the bacteria was performed. When the bacteria
were photoirradiated using the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) at 298
K, the bacterial survival increased with increasing photoirradiation time (e.g. bacterial
survival was 43% after 1 min and 94% after 2 h), see Figure 5.8. This was very unusual
as in the literature there are many examples of blue light (with a wavelength of 400
nm - 470 nm and powers ranging from 20 mW/cm2 – 100 mW/cm2) having a
bactericidal effect against bacteria such as methicillin-resistant Staphylococcus aureus
(MRSA), Propionibacterium acnes (the causative agent of acnes), Pseudomonas
aeruginosa, Helicobacter pylori and Streptococcus mutans (oral bacteria) both in vitro
and in vivo.24-32 In all of the aforementioned cases, increasing the time of
photoirradiation caused a decrease in bacterial survival, contrary to the results
obtained in this work for M. smegmatis. Interestingly, in one instance in the literature
when M. smegmatis was photoirradiated with high doses of 405 nm blue light, the
bacteria were not effectively killed (the kill extent decreased from 97% for 150 J/cm2
light dose to 61% for 180 J/cm2 light dose).33 The reason for this was unknown. This
is more consistent with the results found in this work. It is hypothesised that low doses
of blue light in M. smegmatis are bactericidal, while at higher doses of blue light
photoreactivation occurs whereby a repair system is utilised. Blue light (> 400 nm)
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may be harmful to bacteria due to the production of reactive oxygen species from
endogenous photosensitisers, such as porphyrin containing cytochrome.34 However
when Mycobacteria, including mycobacterium smegmatis and mycobacterium
tuberculosis, have been exposed to UV-irradiation and subsequently photoirradiated
with white light, the bacteria photoreactivate and the growth of bacteria is restored
(the mechanism may involve a photoreactivating enzyme, however the identity of this
is unknown).35-39 The degree of photoreactivation increases with increasing dose of
white light, which correlates with the results obtained in this work where increasing
the dose of blue light promotes a higher survival.
5.4.4.2. Photoactivity of complexes against M. smegmatis
The complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5) and
cis-[Ru(phen)2(INH)2][PF6]2 (6) were tested against M. smegmatis in the dark and
photoirradiated with the 96-array blue LED (λirr = 465 nm, 20 mW cm-2) for 1 min, 30
min, 1 h and 2 h. In the dark, complexes 4 and 6 were most active. As the concentration
of the complexes increased, the survival of bacteria decreased, owing to the dark
toxicity of the complexes, see Figure 5.9. For both complexes at a concentration of 50
µM the survival of the bacteria was ~ 40% while at 10 µM was ~ 90%. Complex 5
showed no dark toxicity at all concentrations ranging from 10 µM – 50 µM. The reason
for this dark toxicity could be due to the presence of an active ligand, which in the
case of 4 and 6 is isoniazid (INH). The hydrazide group of isoniazid is activated by an
enzyme called KatG, see Chapter 1 for an in depth description of isoniazid activation.
Since the hydrazide portion of isoniazid is still exposed once INH is bound to
ruthenium, it may still be activated by the enzyme to a small extent.
Once complexes 4 and 6 were photoirradiated with blue light, the activity of the
complexes increased dramatically. For complexes 4 and 6 at concentrations of 10 µM
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– 50 µM, the survival of the bacteria was < 4% and < 2% respectively when
photoirradiated for 1 min, 30 min, 1 h and 2 h, see Figure 5.9. This is comparable to
the survival (< 2%) when the bacteria were exposed to the minimum inhibitory
concentration (MIC) of isoniazid (22 µM). The MIC for complexes 4 and 6 when
photoirradiated for 1 min was found to be 4 µM (survival in dark was ~ 80%) and 8
µM (survival in dark was ~ 100%), respectively, see Figure 5.10. This dramatic
increase in activity from dark exposure to light exposure suggests that in vitro
isoniazid can be released from the ruthenium(II) centre by at least 1 min blue light
photoirradiation, and that isoniazid retains its activity. Interestingly the MIC for 4 and
6 after 1 min photoirradiation is lower than that for isoniazid; 5.5x lower in the case
of 4 and 2.75x lower in the case of 6. This could be due to, a) the synergism between
the damaging 1 min blue photoirradiation and the released isoniazid ligand, b) the
synergism between the active Ru(II) photoproducts and the released isoniazid ligand,
c) the increased uptake of the isoniazid ligand into the bacteria as a result of the metal
complex, or a mixture of (a), (b) and (c).
The survival of bacteria for all complex concentrations of 5 and all time points of
photoirradiation was > 30%, thus complex 5 is much less active than complexes 4 and
6 with an MIC > 50 µM. This is due to the reduced activity of the monodentate ligand
nicotinamide (NA); at a concentration of 100 µM a survival of 66% was observed. For
5 at a complex concentration 50 µM, after 2 h photoirradiation the survival of bacteria
was found to be 45%, which is 21% lower than the survival for the maximum amount
of ligand than can be released (i.e. 100 µM). This supports the hypothesis that the
Ru(II) centre is contributing to the activity (either by increasing the uptake of ligand
or by production of active photoproducts), as at this time point of photoirradiation the
light alone does not affect the survival of bacteria.
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Complexes 4 and 6 were photoirradiated in the presence of M. smegmatis using the
32-array multi-coloured LED (λirr = 465 nm, 520 nm, 589 nm and 625 nm, 5 mW cm-
2) for 30 min to investigate wavelength dependence on the activity. Interestingly for
this light source, all wavelengths did not harm the bacteria; survival was > 85% in all
cases, see Figure 5.11. This reduced antibacterial effect is due to the reduction in
power of the light source. For complex 4 the antibacterial activity with different
wavelengths decreases in the order of blue > green > yellow ≈ red, and for complex 6
blue ≈ green > yellow > red. This general trend correlates well with results in Chapter 
4, where for complexes 4 and 6 photoactivity decreases in the order blue > green >
yellow > red. At longer wavelengths of photoirradiation, the photoactivity of the
complex is reduced, thus the antibacterial activity of the complex decreases.
5.4.4.3. BaclightTM assay
The Mycobacterium cell wall contains an array of mycolic acids and glycolipids that
causes the membrane to have a low fluidity, which makes it difficult for antibiotics to
diffuse through the membrane.22 It is proposed that isoniazid enters the cell by passive
diffusion.40 However a drug does not necessarily need to diffuse through the cell wall
and enter to the bacterium to cause damage. For example, antibacterial agents such as
vancomycin bind to targets in the cell wall, and daptomycin forms harmful pores in
the membrane.41 The BaclightTM assay can be used to assess if an antibacterial agent
is causing membrane damage by forming pores. Isoniazid is selective and inhibits an
enzyme (InhA) that is responsible for cell wall mycolic acid synthesis, as a result it
can be used as a positive control in BaclightTM assay as it affects a specific pathway,
and does not permeabilize the membrane by forming pores.42 As described in Section
5.2.6., the ratio between green and red fluorescence (F530 nm/F630 nm) can be used to
investigate the membrane integrity. By constructing an M. smegmatis calibration
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graph, bacteria with no membrane damage exhibited a ratio of ~ 1.2, while bacteria
with damaged membranes exhibited a value of ~ 0.5, see Figure 5.14. For 10xMIC
concentration of isoniazid (220 µM) the F530 nm/F630 nm ratio was 1.23, consistent with
no membrane damage. For complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) at both MIC (4
µM) and 4xMIC (16 µM) in the dark and once photoirradiated with 96-array blue LED
(λirr = 465 nm, 20 mW cm-2) for 1 min, the F530 nm/F630 nm ratio was ≥ 1. This suggests 
for complex 4, no/very little membrane damage occurs. For complex cis-
[Ru(phen)2(INH)2][PF6]2 (6) at both MIC (8 µM) and 4xMIC (32 µM) in the dark and
once photoirradiated with 96-array blue LED for 1 min, the F530 nm/F630 nm ratio was ≤ 
1. Therefore complex 6 appears to damage the membrane by creating pores. Increasing
the complex concentration resulted in more damage, i.e. lower F530 nm/F630 nm ratio. It
is hypothesised that complex 6 enters the cell wall and forms pores because of its
increased hydrophobicity (comparing complex 4 which has 2,2'-bipyridine and
complex 6 which has 1,10-phenanthroline as the chelating ligand). Interestingly this
membrane damage does not affect the MIC obtained for complex 6 when compared to
complex 4, as both complexes observe very similar MIC’s.
5.5. Summary
The photobiological properties of complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4), cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) were explored. The
complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) did not bind to L-cysteine after formation of
the photoproduct cis-[Ru(bpy)2(INH)H2O]2+ by photoirradiating the sample with blue
light, however binding occurred with 9-ethyguanine (9-EtG) to form the photoadduct
cis-[Ru(bpy)2(INH)(9-EtG)]2+. The extent of binding was small (~16 %), however the
binding was evident from 1H-NMR and HR-MS data. Interestingly for cis-
[Ru(bpy)2(INH)(9-EtG)]2+, two atropisomers were detected in solution. Due to the
Chapter 5
____________________________________________________________________
199
bulky nature of 9-EtG there is a high energy rotation barrier for the 9-EtG ligand. One
atropisomer formed instantly (kinetic atropisomer) and the other formed over time
(thermodynamic atropisomer) as the complex was incubated in the dark for 24 h at
298 K. The complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) was inactive against E. coli,
however it showed some activity once photoirradiated with blue light for 2 h 20 min
against B. subtilis at concentrations of 100 µM and 200 µM. The complexes cis-
[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) were found to be
active against M. smegmatis, with MIC values of 4 µM and 8 µM respectively after 1
min photoirradiation with blue light. This was a 5.5 x and 2.75x increase in potency
(for 4 and 6 respectively) when compared to the ligand, isoniazid, alone which has an
MIC of 22 µM. The activity of the 4 and 6 was significantly reduced in the dark,
where survival of the bacteria is > 80% at the MIC value, showing that the active
ligand (isoniazid) had successfully been released in vitro after photoirradiation with
blue light. Blue light (463 nm) was the optimum wavelength for maximum activity for
both 4 and 6, while the complexes were not active once photoirradiated with red light.
The complex cis-[Ru(phen)2(INH)2][PF6]2 (6) forms pores in the cell wall of M.
smegmatis, while cis-[Ru(bpy)2(INH)2][PF6]2 (4) does not, as detected by the
BacLightTM assay. This may be due to the increased hydrophobicity of 6 when
compared to 4.
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6.1. Introduction
In the clinic, the optimum wavelength of light used to activate a photoactive
therapeutic agent is known as the phototherapeutic window (between 600 nm – 1000
nm), as discussed in Chapter 1. Thus a photoactive therapeutic agent should have a
strong absorption band in this region. The Ru(II) polypyridyl complexes based on cis-
[Ru(N-N')2(L)2]2+, where N-N' is 2,2'-bipyridine or 1,10-phenanthroline and L is
isoniazid or nicotinamide, studied in previous chapters (complexes 1 – 7) were
activated by blue or green light (465 nm – 520 nm), just outside the phototherapeutic
window. One methodology to extend the photoactivation of Ru(II) polypyridyl
complexes into the phototherapeutic window is by two-photon activation. Two-photon
activation occurs when a compound absorbs two photons simultaneously to achieve a
higher energy transition. In order to achieve this, a femtosecond pulsed laser light
source needs to be utilised in order to achieve a high density and flux of photons.
Efficient two-photon chromophores generally have extended π-conjugated systems 
with opposing donor and acceptor groups.1-2 The π-conjugated and electron donor 
ligand MOPEP, 4-[2-(4-methoxyphenyl)ethynyl]pyridine, was added to a square
planar platinum(II) complex, cis-[Pt(Cl)2(MOPEP)2], which rendered the complex
two-photon active once photoirradiated with 600 nm laser light.3 Interestingly
complexes such as cis-[Ru(bpy)2(4AP)2]2+, where bpy is 2,2'-bipyridine and 4AP is 4-
aminopyridine, have been found to release a ligand of 4AP in one-photon (with ≥ 480 
nm light) and two-photon regimes (with 800 nm laser light).4-5 In comparison, the
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addition of highly conjugated fluorene-substituted 1,10-phenanthroline ligands
(FPhen) to give [Ru(FPhen)3]2+ highly enhanced the two-photon activation
efficiency.6
This Chapter focuses on the synthesis of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9), see
Figure 6.1, and investigating its two-photon activity.
Figure 6.1. Structure of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9).
Comparisons with the control compound cis-[Ru(bpy)2(py)2][PF6]2 (10) were made.
Due to lack of solubility in aqueous solution, experiments were conducted in
acetonitrile. Additionally the two photon activation of cis-[Ru(bpy)2(INH)2][PF6]2 (4)
in aqueous solution was explored. The release of ligands was followed by UV-visible
spectroscopy and transient absorption spectroscopy using a femtosecond pulsed laser
and a non-laser light source. The DNA binding properties of cis-
[Ru(bpy)2(MOPEP)2][PF6]2 (9) were also investigated since MOPEP’s extended
aromatic system was expected to promote DNA intercalation.
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6.2. Experimental
6.2.1. Materials
The synthesis of cis-[Ru(bpy)2(INH)2][PF6]2 (4) can be found in Chapter 3. The
synthesis of the starting material [Ru(bpy)2(Cl)2], where bpy is 2,2'-bipyridine, can be
found in Chapter 2. 1-Ethynyl-4-meoxybenzne, 4-bromopyridine, PdCl2(PPh3)2,
tetrabutylammonium fluoride hydrate, NH4PF6, Trizma® base, NaCl, pyridine and
acetonitrile were purchased from Sigma Adlrich. UltraPureTM Calf thymus (CT) DNA
was purchased from Life Technologies. Description of the photoirradiation setups can
be found in Chapter 2.
6.2.2. Preparation of MOPEP (8)
The synthesis of MOPEP (4-[2-(4-methoxyphenyl)ethynyl]pyridine) was adapted
from previously published methods.3, 7 1-Ethynyl-4-meoxybenzne (310 µL, 2.4
mmol), 4-bromopyridine (388 mg, 2 mmol), PdCl2(PPh3)2 (42 mg, 0.06 mmol) and
tetrabutylammonium fluoride hydrate (1.57 g, 6 mmol) were stirred under N2 at 353
K for 19 h. After cooling to room temperature (298 K), water (60 mL) was added and
the solution was extracted with diethyl ether. The diethyl ether layer was washed with
brine, and diethyl ether was removed under reduced pressure. The resulting orange
powder was recrystallized from petroleum ether (bp 40-60 oC) to give a pale yellow
powder. Yield 22% (92 mg, 0.4 mmol). Elemental analysis calculated for C14H11NO
%C: 80.36, %H: 5.30, %N: 6.69; found %C: 79.48, %H: 5.27, %N: 5.90. ESI-MS
calculated for C14H12NO [M+H]+ m/z 210.1, found m/z 210.0. 1H-NMR (chloroform-
d3, 400 MHz) δH: 3.9 (3H, s), 6.9 (2H, d, J = 8.8 Hz), 7.5 (4H, m), 8.6 (2H, d, J = 6.2
Hz).
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6.2.3. Preparation of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9)
Cis-[Ru(bpy)2(Cl)2] (18.4 mg, 0.04 mmol) and MOPEP (8) (40 mg, 0.2 mmol) were
added to 8 mL of 1:3 water:ethanol mixture and the solution was refluxed under
nitrogen while stirring for 20 h. The reaction vessel was covered in foil to avoid light
exposure. After cooling to room temperature (298 K), the solution was filtered and
NH4PF6 (32.2 mg, 0.2 mmol) was added to produce a red powder. The powder was
dissolved in methanol and the red product was precipitated by addition of diethyl ether.
Yield 32% (14 mg, 0.01 mmol). Elemental analysis calculated for
C48H38F12N6O2P2Ru.2MeOH %C: 50.64, %H: 3.91, %N: 7.09; found %C: 50.21, %H:
3.40, %N: 6.86. ESI-MS calculated for C48H38N6O2Ru [M]2+ m/z 416.1, found m/z
416.0. 1H-NMR (acetone-d6, 400MHz) δH: 3.9 (6H, s), 7.0 (4H, d, J = 8.9 Hz), 7.5
(4H, d, J = 6.6 Hz), 7.5 (4H, d, J = 8.9 Hz), 7.6 (2H, ddd, J = 7.6, 5.4 and 1.1 Hz), 8.0
(2H, ddd, J = 7.6, 5.6 and 1.1 Hz), 8.1 (2H, td, J = 7.9 and 1.3 Hz), 8.3 (2H, d, J = 5.3
Hz), 8.3 (2H, td, J = 7.9 and 1.1 Hz), 8.6 (2H, d, J = 8.2 Hz), 8.7 (6H, m), 9.4 (2H, d,
J = 5.4 Hz).
6.2.4. Preparation of cis-[Ru(bpy)2(py)2][PF6]2 (10)
Water (10 mL) was degassed by bubbling nitrogen through the solution for 15 min.
Cis-[Ru(bpy)2(Cl)2] (50 mg, 0.1 mmol) was added and solution heated at 353 K under
nitrogen while stirring for 15 min. The reaction vessel was covered in foil to avoid
light exposure. Pyridine (100 µL, 1 mmol) was added and solution heated at 353 K for
5 h. After cooling to room temperature (298 K), the solution was filtered and NH4PF6
(84 mg, 0.5 mmol) was added to give an orange precipitate. The precipitate was
collected by filtration and washed with water and diethyl ether. Yield 46% (40 mg,
0.05 mmol). Elemental analysis calculated for C30H26F12N6P2Ru.2H2O %C: 40.14,
%H: 3.37, %N: 9.36; found %C: 39.23, %H: 2.78, %N: 8.65. ESI-MS calculated for
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C30H26N6Ru [M]2+ m/z 286.1, found 286.0. 1H-NMR (acetone-d6, 400 MHz) δH: 7.45
(4H, m), 7.54 (2H, ddd, J = 7.69, 5.62 and 1.27 Hz), 7.96 (4H, m), 8.08 (2H, td, J =
7.85 and 1.43 Hz), 8.28 (4H, m), 8.60 (2H, d, J = 8.17 Hz), 8.67 (6H, m), 9.33 (2H, d,
J = 5.58 Hz).
6.2.5. Photoirradiation using non-laser light source
MOPEP (8), cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) and cis-[Ru(bpy)2(py)2][PF6]2 (10)
were dissolved in acetonitrile to give a concentration of either 40 µM or 10 µM. The
solutions (600 µL) were placed into a 1 cm path length quartz cuvette and
photoirradiated using a blue LED (λirr = 463 nm, 50 mW cm-2) and the KiloArc light
source (λirr = 600 nm and 800 nm) at 298 K for various times of photoirradiation. The
UV-visible spectrum of each sample was recorded on a Cary 300-Scan
spectrophotometer. The absorbance over the range 200 – 800 nm was recorded at 298
K. The data were processed using OriginPro 9.1 and, where applicable, plots of change
in absorbance versus time were fitted to the exponential equation A = A0 + CeRt (where
A is absorbance, t is time and C, A0 and R are calculated parameters) to give the half-
life of formation (t1/2, s).
6.2.6. Photoirradiation using laser light source
The laser experiments were performed in collaboration with Dr Simon E. Greenough
from the Chemistry Department at University of Warwick.
An acetonitrile solution (178 µM) of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) was
photoirradiated using the laser set-up described in Chapter 2. The average absorbance
at 373 nm - 378 nm was monitored at various time points of photoirradiation (up to 30
min), using different powers of 800 nm and 600 nm laser light (0.5 mW, 0.6 mW, 0.7
mW, 0.8 mM, 0.9 mW and 1 mW). Plots of ln(Abs) versus time were made and fitted
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to a linear regression to obtain a pseudo-first order rate constant (kobs) for each power
of laser light. For cis-[Ru(bpy)2(INH)2][PF6]2 (4), an aqueous solution (690 µM) was
photoirradiated using the transient laser-set up described in Chapter 2. The integrated
area (between 350 nm – 675 nm) at a pump-probe (probe λirr = 800 nm) delay of 100
ps was recorded at each power of laser light (12 mW, 15 mW, 18 mW, 21 mW, 24
mW). log-log plots were constructed of either log(kobs) or log(integrated area) versus
log(power), where a slope of 1 indicates a one-photon process, and a slope of 2
indicates a two-photon process. This is due to the quadratic relationship between two-
photon activation (TPA) and the excitation power (I) where TPA ∝ I2.8
6.2.7. Interaction with DNA
Calf thymus (CT) DNA (50 µM, with respect to nucleotides), cis-
[Ru(bpy)2(MOPEP)2][PF6]2 (9) (5 µM, complex initially dissolved in 5% v/v DMSO
and diluted accordingly) and NaCl (50 mM) were dissolved in Tris buffer (5 mM).
The Tris buffer was prepared from Trizma® base diluted with dd.H2O and pH adjusted
using HCl to give a final pH of 7.4. The control experiment contained no complex 9.
Both the sample (CT DNA and complex 9) and the control sample (CT-DNA only)
were incubated in the dark at 298 K for 1 h. Thermal denaturation of CT-DNA in the
presence or absence of complex 9 was investigated by recording the change in
absorbance at 260 nm while increasing the temperature from 298 K to 371 K. The data
were processed using OriginPro 9.1, and for each sample plots of absorbance at 260
nm versus temperature were fitted to a Boltzmann sigmoidal equation to afford the
melting temperature (Tm) at the inflection point of the curve.
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6.3. Results
6.3.1. Photoirradiation using non-laser light source
The UV-visible spectra of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) and cis-
[Ru(bpy)2(py)2][PF6]2 (10) in acetonitrile are shown in Figure 6.2 with extinction
coefficients listed in Table 6.1.
Figure 6.2. UV-visible spectrum of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) (10 µM) and
cis-[Ru(bpy)2(py)2][PF6]2 (10) (40 µM) in acetonitrile in the dark at 298 K.
Table 6.1. Extinction coefficients for MOPEP (8), cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9)
and cis-[Ru(bpy)2(py)2][PF6]2 (10) in acetonitrile in the dark at 298 K.
Wavelength (nm) Extinction coefficient (M-1 cm-1)
8
298 30000
310 30000
354 1000
9
291 60000
327 40000
380 30000
424 20000
10
340 10000
425 6000
455 7000
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Interestingly for 9 there was a very broad band at 380 nm with a shoulder at 424 nm,
whereas for 10 there is a relatively narrower band at 425 nm. At < 350 nm the spectra
are similar with respect to the position of the bands (e.g. band at 327 nm for 9 and 340
nm for 10). The major difference between 9 and 10 is their extinction coefficients. In
the case of MOPEP (8), there was a band at ~ 300 nm with an extinction coefficient
of 30000 M-1 cm-1. Similarly for cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9), all bands had
extinction coefficients in the range of 104 M-1 cm-1. In the case of cis-
[Ru(bpy)2(py)2][PF6]2 (10), all bands had extinction coefficients in the range of 103 M-
1 cm-1, which is 10x smaller than for 8 or 9.
Changes in the absorption spectra of MOPEP (8) and cis-[Ru(bpy)2(MOPEP)2][PF6]2
(9) were investigated in acetonitrile (ACN) using a blue LED (λirr = 463 nm, 50 mW
cm-2) for various times at 298 K, see Figure 6.3.
Figure 6.3. UV-visible spectrum of MOPEP (8) (40 µM) and cis-
[Ru(bpy)2(MOPEP)2][PF6]2 (9) (10 µM) in acetonitrile photoirradiated using a blue
LED (λirr = 463 nm, 50 mW cm-2) for various times at 298 K.
MOPEP (8) was stable when photoirradiated for 3 h with no changes observed in the
UV-visible spectrum. For cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) there were dramatic
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changes in the UV-visible spectrum upon photoirradiation. The bands at 380 nm and
327 nm (including the shoulder at 424 nm) decreased, while the band at 291 nm
increased. Interestingly a shoulder at 310 nm constantly increased, attributable to the
continued photorelease of the MOPEP ligand and the absorption of free MOPEP in
solution. As a result there was an isosbestic point at 318 nm. The increase in the
absorbance at 310 nm was followed at various points of photoirradiation, see Figure
6.4.
Figure 6.4. Kinetic traces for the increase in absorbance of the shoulder at 310 nm
after photoirradiation of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) in acetonitrile using a blue
LED (λirr = 463 nm, 50 mW cm-2) for various times at 298 K.
After 30 s photoirradiation the first MOPEP ligand was released, producing the
photoproduct cis-[Ru(bpy)2(MOPEP)(ACN)]2+. This was evident by the change in
absorbance at 310 nm reaching its first plateau, and when fitted to a single exponential
function gave half-life for formation of photoproduct t1/2 = 3.6 s. Further
photoirradiation for 25 min released the second MOPEP ligand, producing the
photoproduct cis-[Ru(bpy)2(ACN)2]2+. The change in absorbance at 310 nm reached a
second plateau, and when fitted to a single exponential function gave t1/2 = 192.7 s.
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Both cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) and cis-[Ru(bpy)2(py)2][PF6]2 (10) were
photoirradiated in acetonitrile using the KiloArc light source (λirr = 600 nm and 800
nm) for various times at 298 K, see Figure 6.5.
Figure 6.5. Kinetic traces for the decrease in absorption at 424 nm and 455 nm after
photoirradiation of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) (top) and cis-
[Ru(bpy)2(py)2][PF6]2 (10) (bottom) in acetonitrile (40 µM) using the KiloArc light
source (λirr = 600 nm and 800 nm) for various times at 298 K..
For both 9 and 10, once photoirradiated with 600 nm light the absorbance band at 424
nm and 455 nm respectively, decreased mono-exponentially over the time frame 0 –
9 h. Interestingly cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) was slightly active when
photoirradiated using 800 nm light, as was evident from the decrease in the absorption
band at 424 nm. Conversely in the case of cis-[Ru(bpy)2(py)2][PF6]2 (10), no activity
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was observed at 800 nm photoirradiation as there were no changes in the absorbance
band at 455 nm.
6.3.2. Photoirradiation using laser light source
Changes in the absorption spectrum of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) were
investigated in acetonitrile (ACN) using a laser light source (λirr = 600 nm and 800
nm) for various times of photoirradiation and powers of the laser light (0.5 mW – 1
mW) at 298 K. Changes in the absorption spectrum were monitored and fitted to a
pseudo-first order rate equation to obtain the pseudo-first order rate constant kobs. Log-
log plots were made of log(kobs) versus log(power) to investigate if a one-photon
(resulting in a slope of 1) or two-photon (resulting in a slope of 2) process was
occurring at that specific wavelength of photoirradiation, see Figure 6.6.
Figure 6.6. Log(kobs)-log(power) plots for cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9)
photoirradiated in acetonitrile using a laser light source at 600 nm (left) and 800 nm
(right) at 298 K.
At both wavelengths of photoirradiation (600 nm and 800 nm), the slope of the
log(kobs) versus log(power) plots indicated that photorelease was a one-photon process
(slope = 1.0 ± 0.1). The same analysis was carried out for cis-[Ru(bpy)2(INH)2][PF6]2
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(4) in aqueous solution using the transient absorption spectroscopy approach, see
Figure 6.7. After photoirradiation (800 nm) with 100 ps pump-probe delay, there is an
absorption of the 3MLCT state at 358 nm, a ground state bleach feature at ~ 420 nm
and an absorption due to the penta-coordinate intermediate at > 550 nm. A more in-
depth discussion of such features is given in Chapter 4. The integrated area between
350 nm – 675 nm was recorded at each power of laser light (12 mW – 24 mW), and
log-log plots were constructed of log(integrated area) versus log(power). Interestingly
this analysis indicated that the photorelease is a two-photon process (slope = 1.90 ±
0.09).
Figure 6.7. Dependence of the transient absorption spectrum of cis-
[Ru(bpy)2(INH)2][PF6]2 (4) in aqueous solution on the power of a laser light source at
800 nm (left), and plot of log(integrated area)-log(power) (right).
6.3.3. Interaction with DNA
Double stranded DNA has an absorption band at 260 nm. When heated, the double-
stranded DNA is denatured, and as a result the absorption band at 260 nm increases
due to the formation of single-stranded DNA. This increase in absorbance can be
plotted versus temperature to produce a melting curve, see Figure 6.8. When fitted to
a Boltzmann sigmoidal equation, the inflection point is known as the melting
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temperature (Tm), the point at which 50% of the DNA is denatured into single strands.
The melting temperature of CT-DNA was determined in the absence and presence of
cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) (1:10 complex:DNA ratio) after 1 h dark
incubation at 298 K, see Table 6.2. Interestingly there was only a 0.5 K increase in
melting temperature upon addition of complex 9 (from 352.5 K to 353 K).
Figure 6.8. Melting curve for CT-DNA in 5 mM Tris buffer and 50 mM NaCl, fitted
to a Boltzman sigmoidal equation.
Table 6.2. Melting temperature (Tm) of CT-DNA in the absence and presence of cis-
[Ru(bpy)2(MOPEP)2][PF6]2 (9) when incubated in the dark for 1 h at 298 K.
Melting temperature (K)
CT-DNA 352.5 ± 0.2
CT-DNA and complex 9 353 ± 1
6.4. Discussion
6.4.1. Two-photon activation
The complex cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) was synthesised and exhibited
efficient photorelease upon photoirradiation using blue light (λirr = 463 nm, 50 mW
cm-2) in acetonitrile at 298 K. When photoirradiated at a concentration of 10 µM, the
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first MOPEP ligand was released with t1/2 = 3.6 s and the second MOPEP ligand was
released with t1/2 = 192.7 s. The previously synthesised complex cis-
[Pt(Cl)2(MOPEP)2] is active with UVA light (330 – 380 nm) to release the MOPEP
ligands, however MOPEP itself photodecomposes after exposure to UVA light.3
Notably the MOPEP ligand alone did not degrade after photoirradiation with blue light
(λirr = 463 nm, 50 mW cm-2) for 3 h.
Both cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) and cis-[Ru(bpy)2(py)2][PF6]2 (10) were
photoactive when photoirradiated with 600 nm non-laser light (over a longer time
period of 9 h) in acetonitrile, however only cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) was
active with 800 nm non-laser light. This confirms that when photoirradiated with 800
nm non-laser light, the photoactivation of 9 is a one-photon process, as two-photon
activation cannot be achieved using a non-laser light source. Furthermore when cis-
[Ru(bpy)2(MOPEP)2][PF6]2 (9) was photoirradiated with a laser light source at 600
nm and 800 nm in acetonitrile, the log(kobs) vs log(power) plots confirmed that one-
photon activation was occurring at these wavelengths. The reason for this is apparent
from Figure 6.9.
Figure 6.9. UV-visible absorption spectrum of cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9)
and cis-[Ru(bpy)2(py)2][PF6]2 (10) in acetonitrile at 298 K.
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In the case of cis-[Ru(bpy)2(py)2][PF6]2 (10) there is no absorbance at 800 nm,
however for cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) there is a shoulder that extends from
600 nm to 800 nm (with an extinction coefficient of ~ 100 M-1 cm-1 at 700 nm). This
explains why 9 is one-photon active at 800 nm and 10 is not, as photoirradiating a
complex into its one-photon absorption band will induce a one-photon process.
Conversely when cis-[Ru(bpy)2(INH)2][PF6]2 (4) was photoirradiated with a laser
light source at 800 nm in aqueous solution, the log(integrated area) vs log(power)
showed that two-photon activation was occurring at this wavelength. This is a similar
behaviour to the complex cis-[Ru(bpy)2(4AP)2]2+, where 4AP is 4-aminopyridine, that
is two-photon active with 800 nm laser excitation. Interestingly in aqueous solution
cis-[Ru(bpy)2(INH)2][PF6]2 (4) does not have a measurable absorbance at 800 nm, see
Figure 6.10, and so does not observe one-photon activation at this wavelength. It was
found in Chapter 4 that complex 4 is not photoactive with wavelengths > 610 nm with
a non-laser light source.
Figure 6.10. UV-visible absorption spectrum of cis-[Ru(bpy)2(INH)2][PF6]2 (4) in
aqueous solution at 298 K.
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The reason for the shoulder at 600 nm – 800 nm for cis-[Ru(bpy)2(MOPEP)2][PF6]2
(9) could be due to the stronger electron-donating ability of the MOPEP ligand (c.f.
pyridine or isoniazid) which may produce a lower energy 1MLLCT(Ru/MOPEP-bpy)
transition (and thus extend the shoulder of the band). For example, in the complex cis-
[Ru(bpy)2(4AP)2]2+, where 4AP is 4-aminopyridine, the lowest singlet excited state
was 1MLLCT(Ru/4AP-bpy) in character, potentially a result of the electron-donating
amino functionality.9 Additionally the extended aromatic nature of the MOPEP ligand
may enhance the extinction coefficient of this absorption band, allowing
photoactivation to occur in the shoulder of the band at longer wavelengths.
For a further understanding of why cis-[Ru(bpy)2(INH)2][PF6]2 (4) is two-photon
active at 800 nm and cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) is one photon at 800 nm,
computational approaches would need to be adopted to elucidate two-photon
activation cross sections.3
6.4.2. Interaction with DNA
For complexes of the type cis-[Ru(N-N')2(H2O)2]2+ and [Ru(N-N')3]2+, where N-N' is a
bipyridyl based ligand, both covalent and intercalative binding to DNA increases the
melting temperature (Tm) by 1 – 14 degrees.10-13 However the Tm of calf thymus DNA
(CT-DNA) increased only by 0.5 K in the presence of cis-[Ru(bpy)2(MOPEP)2][PF6]2
(9) (from 352.5 K to 353 K), suggesting there is no interaction between 9 and CT-
DNA. Even though the MOPEP ligand is an extended π-conjugated planar ligand, the 
monodentate ligands in cis-[Ru(bpy)2(L)2]2+, where L is a pyridine based ligand, rotate
freely about the Ru-N bond at 298 K and higher temperatures, depending on the bulky
nature of the ligand involved. A more detailed discussion of rotation in such
complexes is given in Chapter 3. This rotation may hinder any interaction with DNA,
and may explain the result above. Metal complexes that tend to intercalate into DNA
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have extended π-conjugated planar ligands that are rigid (e.g. bidentate/tridentate 
ligands) and contain fused aromatic rings.14
6.5. Summary
The complex cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) was synthesised and its photoactivity
explored in acetonitrile using both a non-laser and laser light source. Both complex 9
and the control complex cis-[Ru(bpy)2(py)2][PF6]2 (10), where py is pyridine, were
photoactive in a one-photon regime by photoirradiating with a non-laser light source
at 600 nm. However only complex 9 was photoactive in a one-photon regime when
photoirradiated with a non-laser light source at 800 nm. Interestingly this one-photon
behaviour was confirmed when photoirradiated using a laser light source. This
behaviour is due to an extended absorption band shoulder observed for complex 9
between 600 nm and 800 nm, which results in an extinction coefficient of ~ 100 M-1
cm-1 at 700 nm. Interestingly cis-[Ru(bpy)2(INH)2][PF6]2 (4) was two-photon active
once photoirradiated with a laser light source at 800 nm in aqueous solution.
The results obtained in this chapter show that complexes of the type cis-
[Ru(bpy)2(L)2]2+, where L is a pyridine based ligand, can be photoactive in either a
one-photon or two-photon regime when photoirradiated with laser light at 800 nm,
depending on the properties of the ligand L.
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Chapter 7
Conclusions and future work
7.1. Conclusions
This thesis is concerned with the synthesis, design, photochemical and photobiological
properties of potential antibacterial ruthenium(II) polypyridyl complexes.
In Chapter 3, two sets of novel antibacterial compounds were synthesised based on
cis-[Ru(N-N')2(L)2][PF6]2 and cis-[Ru(N-N')(L)X][PF6], where N-N' is 2,2'-bipyridine
(bpy) or 1,10-phenanthroline (phen), L is isoniazid (INH) or nicotinamide (NA) (anti-
tuberculosis compounds) and X is either Cl or I. Their dark solution chemistry was
explored utilizing UV-visible spectroscopy and 1H-NMR. Complexes cis-
[Ru(bpy)2(INH)2][PF6]2 (4), cis-[Ru(bpy)2(NA)2][PF6]2 (5), cis-
[Ru(phen)2(INH)2][PF6]2 (6) and cis-[Ru(phen)2(NA)2][PF6]2 (7) were stable in the
dark in aqueous solution, however cis-[Ru(bpy)2(NA)Cl][PF6] (1) hydrolysed to form
the aqua species cis-[Ru(bpy)2(NA)(H2O)]2+. Interestingly the presence of 5% DMF,
5% DMSO or 5% acetone resulted in the binding of the organic species, complicating
the hydrolysis process. By 1H-NMR, the rotation of the NA ligand in cis-
[Ru(bpy)2(NA)Cl][PF6] (1) and cis-[Ru(bpy)2(NA)I][PF6] (2) was hindered on the
NMR timescale (500 MHz) at 298 K, with two atropisomers observable at 185 K.
Further investigations using Density Functional Theory (DFT) showed that the
hindered rotation is due to hydrogen bonding between a NA proton and the halide.
This may have implications if a biomolecule adds to the complex cis-
[Ru(bpy)2(NA)(H2O)]2+, as the hindered rotation may affect the binding.
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In Chapter 4, the photochemical and photophysical properties of 1 and 4 – 7 were
explored by UV-visible spectroscopy, liquid chromatography (LC), time-dependent
DFT (TD-DFT) and transient-absorption spectroscopy. The production of cis-[Ru(N-
N')2(L)(H2O)]2+ after photoirradiation of 4 – 7 using a blue LED (λirr = 463 nm, 50
mW cm-2) in aqueous solution at 298 K was monitored by UV-visible spectroscopy.
Complexes containing 1,10-phenanthroline (phen) were more photoactive than
complexes containing 2,2'-bipyridine (bpy) (i.e. cis-[Ru(phen)2(NA)2][PF6]2 (7) > cis-
[Ru(bpy)2(NA)2][PF6]2 (5) and cis-[Ru(phen)2(INH)2][PF6]2 (6) > cis-
[Ru(bpy)2(INH)2][PF6]2 (4)) while complexes containing nicotinamide (NA) were
more photoactive than complexes containing isoniazid (INH) (i.e. cis-
[Ru(bpy)2(NA)2][PF6]2 (5) > cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-
[Ru(phen)2(NA)2][PF6]2 (7) > cis-[Ru(phen)2(INH)2][PF6]2 (6)). By utilizing TD-DFT,
the following qualitative assessments were made; a) phen containing complexes
observed a higher number of 1MLCT states, possibly contributing to their increased
photoactivity and b) the improved π-accepting properties of NA when compared to 
INH causes the dissociative 3MC state to lower in energy in NA-containing complexes,
thus increasing their photoactivity. Liquid chromatography-mass spectrometry (LC-
MS) analysis showed that the photoproduction of cis-[Ru(bpy)2(H2O)2]2+ from 4 was
complicated by the photoisomerisation to trans-[Ru(bpy)2(H2O)2]2+ and the resulting
oxidation to trans-[Ru(bpy)2(H2O)(OH)]2+. Furthermore the production of trans-
[Ru(bpy)2(H2O)2]2+ was affected by the power of the light source.
In Chapter 5, the photobiological properties of 4 – 6 were explored by assessing their
binding ability to L-cysteine and 9-ethylguanine, and investigating their activity in
vitro against E. coli, B. subtilis and the M. tuberculosis model M. smegmatis. By 1H-
NMR, photoirradiating the complex cis-[Ru(bpy)2(INH)2][PF6]2 (4) in the presence of
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L-cysteine (in order to produce cis-[Ru(bpy)2(INH)(H2O)]2+) showed no binding,
however in the presence of 9-ethylguanine (9-EtG) binding occurred to produce cis-
[Ru(bpy)2(INH)(9-EtG)]2+. Interestingly, due to the bulky nature of 9-ethylguanine,
different atropisomers were observable over a 24 h period at 298 K. Complex 4 was
inactive against E. coli and only active in B. subtilis at concentrations ranging from
100 – 200 μM once photoactivated with blue light. When tested against M. smegmatis,
complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-[Ru(phen)2(INH)2][PF6]2 (6) were
both inactive in the dark with a bacterial survival of > 80 % at concentrations <10 μM. 
Once photoirradiated for 1 min with blue light, complexes 4 and 6 gave a minimum
inhibitory concentration (MIC) of 4 μM and 8 μM, respectively, which is at least 3x 
the potency of the ligand alone (MIC of isoniazid is 22 μM). Interestingly the activity 
can be extended to green light. This proof-of-concept has shown that the isoniazid
ligand can be successfully photoreleased from a ruthenium(II) complex in vitro and
retain its activity. The complex cis-[Ru(phen)2(INH)2][PF6]2 (6) was found to produce
pores in the cell wall of M. smegmatis as was evident from the BacLightTM assay,
while cis-[Ru(bpy)2(INH)2][PF6]2 (4) does not, however this does not seem to affect
the activity.
In Chapter 6, the complex cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9), where MOPEP is 4-[2-
(4-methoxyphenyl)ethynyl]pyridine (MOPEP), was synthesised in an attempt to try
and efficiently extend the photoactivation of the complex into the red region (>600
nm) by two-photon activation. Surprisingly the complex was found to be one-photon
active with 600 nm and 800 nm light. This was due to the MOPEP ligand extending
the absorption band shoulder of complex 9 to give an extinction coefficient of ~ 100
M-1 cm-1 at 700 nm.
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7.2. Future work
This section highlights future research areas based on the complexes synthesised in
this thesis either by modification of the chelating scaffold (Section 7.2.1. and 7.2.2.)
or investigating the potential modes of action of ruthenium(II) polypyridyl complexes
in bacteria (Section 7.2.3. and 7.2.4.).
7.2.1. Addition of an antibacterial scaffold
The work carried out here has shown that complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4)
and cis-[Ru(phen)2(INH)2][PF6]2 (6), where bpy is 2,2'-bipyridine, phen is 1,10-
phenanthroline and INH is isoniazid, photoreleased INH using blue/green light and
are active against Mycobacterium smegmatis after photoirradiation. Modification of
the chelating ligand (bpy) may enhance further the activity of the complex.
The addition of a ferrocene substituent to chloroquine (currently used to treat malaria)
affords a complex, Ferroquine, which is 22 times more potent than chloroquine itself
against Plasmodium falciparum (causative agent of malaria).1 Thus addition an
existing drug to the scaffold of a metal complex can afford a complex with improved
activity. Ascididemin (ASC) is a natural product found be a “hit” in a screen of
compounds against Mycobacterium aurum A+ (a Mycobacterium tuberculosis
model).2 Although it is a natural product it can be synthesised in 3 steps.3 ASC has a
structure based on 1,10-phenanthroline, and therefore has a suitable structure to
chelate to a metal. Synthesis of the complex cis-[Ru(ASC)2(INH)2]2+, where INH is
isoniazid, may therefore afford a complex that has a triple action; 1) ASC scaffold
may still have its pharmacophore exposed and thus retain its activity, 2) INH can be
released by photoactivation and 3) the Ru(II) aqua species obtained after
photoactivation may covalently bind to DNA and intercalate into DNA due to the
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extended aromatic system of ASC. Interestingly attachment of ASC may afford three
isomers, see Figure 7.1, due to the asymmetric nature of ASC. Such isomers have been
explored in complexes of the type [Ru(azpy)2(Cl)2], where azpy is 2-
phenylazopyridine.4
Figure 7.1. Structure of ascididemin (ASC) and potential isomers (only Λ enantiomers 
are shown) after coordination of ASC to ruthenium(II) to afford the complex cis-
[Ru(ASC)2(L)2]2+, where L is a pyridine based ligand.
7.2.2. Addition of red-light shifting moieties to the chelating scaffold
In Chapter 6 the addition of MOPEP, 4-[2-(4-methoxyphenyl)ethynyl]pyridine, as a
monodentate ligand to give cis-[Ru(bpy)2(MOPEP)2][PF6]2 (9) rendered the complex
photoactive with 600 nm – 800 nm light. However this complex is limited by the fact
that an existing biologically active ligand cannot be released from the structure by
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light. Therefore substituents that shift the wavelength of activation could be attached
to the chelating scaffold to allow the attachment and photorelease of biologically
active ligands, see Figure 7.2. In the case of MOPEP this can be achieved synthetically
by the same method as in Chapter 6, but with 4,4'-Dibromo-2,2'-bipyridine as the
starting material.
Another methodology could be the attachment of a fluorophore that absorbs at >600
nm. For example, the rhodamine B fluorophore was added to the chelating ligand of a
Ru(II) complex so that low energy light (570 nm) can be efficiently harvested by the
fluorophore and transferred to the Ru(II) complex via energy transfer.5 BODIPY dyes
(4,4-difluoro-4-bora-3a,4a-diaza-s-indacene) absorb at >500 nm and possess a high
quantum yield of fluorescence.6 The complex [(η6-p-cymene)Ru(bpy)(BODIPY-
py)]2+, where BODIPY-py is BODIPY attached to pyridine, has been reported to
photorelease BODIPY-py upon exposure to >500 nm light.7 It is proposed that
BODIPY could be attached to the 2,2'-bipyridine ligand by a previously published
one-pot method using 2,2′-bipyridine-4,4′-dicarboxaldehyde.8
Figure 7.2. Structure of the proposed red-light shifting antennae (BODIPY and
MOPEP) to be attached to the 2,2'-bipyridine scaffold.
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7.2.3. Further biological testing
In Chapter 5 complexes cis-[Ru(bpy)2(INH)2][PF6]2 (4) and cis-
[Ru(phen)2(INH)2][PF6]2 (6) where tested against M. smegmatis and were active with
blue light. However the minimum inhibitory concentration (MIC) with green light
should be assessed, along with finding the minimum time of photoirradiation to yield
an appreciable MIC value (less than that for isoniazid). Additionally further studies
need to elucidate which photoproduct is active. This may be accomplished by dosing
the bacteria with pre-synthesised photoproducts, e.g. cis-[Ru(bpy)2(H2O)2]2+.
However care needs to be taken as they may have different uptake mechanisms than
the original complex and so may not be representative. Cell uptake experiments may
help in this case, and would help to understand how much of the complex is taken up
and if this needs to be improved by changing ligands around the metal. For example
the attachment of an antibacterial peptide to the chelating ligand scaffold may enhance
uptake and additionally provide another mechanism of action.9
Interestingly one avenue that could be explored is the potential binding of cis-
[Ru(bpy)2(H2O)2]2+ to hydrogenases. The complex [Ru(bpy)2(NH2phen)]2+, where
NH2phen is 5-amino-1,10-phenanthroline, has been bound covalently to carboxylates
on the surface of an hydrogenase from T. roseopersicina and was found to produce
hydrogen by photoirradiation via the transfer of electrons from the Ru(II) complex to
the hydrogenase.10 However hydrogen production by a hydrogenase in
Mycobacterium smegmatis has been linked to the long term survival of the bacterium
in hypoxic conditions.11 It would be interesting to investigate whether cis-
[Ru(bpy)2(H2O)2]2+ can bind to hydrogenase, and whether this would have a positive
(i.e. disrupting the efficient functioning of hydrogenase) or negative effect (i.e. by
aiding the production of H2) on the growth of Mycobacteria.
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7.2.4. Affecting the NADH/NAD+ ratio by photoactive ruthenium(II) complexes
As mentioned previously in Chapter 1, the target of isoniazid is an enzyme called
InhA, and isoniazid inhibits InhA by forming an adduct with NAD+ (INH-NAD) that
can competitively bind in place of NADH. Interestingly mutations in NADH
hydrogenase (Ndh) in Mycobacterium smegmatis conferred resistance to isoniazid by
increasing the intracellular ratio of NADH/NAD+, where excess NADH levels
competitively inhibit the binding of INH-NAD adduct to InhA, see Figure 7.3.12-13 For
a detailed description of the mechanism of action of isoniazid see Chapter 1.
Figure 7.3. Diagram to depict the usual action of the INH-NAD adduct inhibiting the
InhA enzyme (top) with the competitive binding of NADH when levels of NADH are
increased restoring the activity of InhA (bottom).
Ruthenium(II) arene complexes, such as [(η6-hmb)Ru(bpm)Cl]+ where hmb is
hexamethylbenzene and bpm is 2,2'-bipyrimidine, aquate in aqueous solution to form
the aqua complex [(η6-hmb)Ru(bpm)(H2O)]2+ and can convert NADH to NAD+ via
metal-hydride formation.14 Interestingly the pyridine (py) analogues, such as [(η6-
hmb)Ru(bpm)(py)]2+, are photoactive with visible light and release py to form the aqua
Chapter 7
____________________________________________________________________
231
complex.15 This methodology was used to oxidise NADH to NAD+ by
photoirradiating [(η6-hmb)Ru(bpm)(py)]2+ with UVA light (300 – 400 nm), however
photodegredation of NADH by UVA light was potentially contributing to the
conversion.16 It is proposed that the synthesis of [(η6-hmb)Ru(bpm)(INH)]2+ may help
to circumvent the issue of isoniazid resistance by initial photorelease of INH using
visible light and formation of [(η6-hmb)Ru(bpm)(H2O)]2+, followed by oxidation of
NADH to NAD+ to circumvent isoniazid resistance if Ndh mutations are causing an
excess of NADH. However one issue with this methodology is that Ru(II) arene
complexes are most active with harmful UVA light, while visible light reactions
require long irradiation times (in some cases up to 12 h).15 Therefore another set of
complexes could be synthesised based on [Ru(bpy)(terpy)(py)]2+ (where terpy is
2,2':6',2"-terpyridine), as it was shown that upon photoirradiation with >500 nm light
the complex can release py, form the aqua complex [Ru(bpy)(terpy)(H2O)]2+ and
subsequently reduce a NAD model (1-benzyl-3-carbamoyl-pyridinium cation) by the
formation of a metal-hydride species.17 Both methodologies are shown in Figure 7.4A
with the proposed mechanism of NADH oxidation in Figure 7.4B.
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Figure 7.4. Structures of potential photoactive ruthenium(II) NADH oxidising agents
(A) and proposed mechanism of action of such complexes (B)14.
7.5. References
1. Biot, C.; Glorian, G.; Maciejewski, L. A.; Brocard, J. S.; Domarle, O.;
Blampain, G.; Millet, P.; Georges, A. J.; Abessolo, H.; Dive, D.; Lebibi, J. J. Med.
Chem., 1997, 40 (23), 3715-3718.
2. Chung, G. A.; Aktar, Z.; Jackson, S.; Duncan, K. Antimicrob. Agents
Chemother., 1995, 39 (10), 2235-8.
3. Yin, H.; Shan, N.; Wang, S.; Yao, Z.-J. J. Org. Chem., 2014, 79 (20), 9748-
9753.
4. Krause, R. A.; Krause, K. Inorg. Chem., 1980, 19 (9), 2600-2603.
5. Bahreman, A.; Cuello-Garibo, J.-A.; Bonnet, S. Dalton Trans., 2014, 43 (11),
4494-4505.
6. Loudet, A.; Burgess, K. Chem. Rev., 2007, 107 (11), 4891-4932.
Chapter 7
____________________________________________________________________
233
7. Zhou, Q.-X.; Lei, W.-H.; Hou, Y.-J.; Chen, Y.-J.; Li, C.; Zhang, B.-W.; Wang,
X.-S. Dalton Trans., 2013, 42 (8), 2786-2791.
8. Bartelmess, J.; Weare, W. W. Dyes Pigments, 2013, 97 (1), 1-8.
9. Bahar, A. A.; Ren, D. Pharmaceuticals, 2013, 6 (12), 1543-1575.
10. Zadvornyy, O. A.; Lucon, J. E.; Gerlach, R.; Zorin, N. A.; Douglas, T.; Elgren,
T. E.; Peters, J. W. J. Inorg. Biochem., 2012, 106 (1), 151-155.
11. Berney, M.; Greening, C.; Conrad, R.; Jacobs, W. R.; Cook, G. M. Proc. Natl.
Acad. Sci., 2014, 111 (31), 11479-11484.
12. Vilchèze, C.; Weisbrod, T. R.; Chen, B.; Kremer, L.; Hazbón, M. H.; Wang,
F.; Alland, D.; Sacchettini, J. C.; Jacobs, W. R. Antimicrob. Agents Chemother., 2005,
49 (2), 708-720.
13. Miesel, L.; Weisbrod, T. R.; Marcinkeviciene, J. A.; Bittman, R.; Jacobs, W.
R. J. Bacteriol., 1998, 180 (9), 2459-2467.
14. Betanzos-Lara, S.; Liu, Z.; Habtemariam, A.; Pizarro, A. M.; Qamar, B.;
Sadler, P. J. Angew. Chem. Int. Ed., 2012, 51 (16), 3897-3900.
15. Betanzos-Lara, S.; Salassa, L.; Habtemariam, A.; Novakova, O.; Pizarro, A.
M.; Clarkson, G. J.; Liskova, B.; Brabec, V.; Sadler, P. J. Organometallics, 2012, 31
(9), 3466-3479.
16. Betanzos-Lara, S. Design, Synthesis and Activation of Ruthenium Arene
Anticancer Complexes. PhD Thesis, University of Warwick, 2010.
17. Ishitani, O.; Inoue, N.; Koike, K.; Ibusuki, T. J. Chem. Soc., Chem. Commun.,
1994, (4), 367-368.
